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ABSTRACT 
Background: Sub-Sahara Africa is experiencing an epidemiological transition with an 
increasing burden of non-communicable diseases (NCDs) including obesity, hypertension, 
insulin resistance (IR) and dyslipidaemia. These NCD are collectively labelled the metabolic 
syndrome (MetS). The MetS is characterised by dyslipidaemia, and in particular, distorted fatty 
acid (FA) metabolism. Additionally, the MetS and its components are also associated with 
different FA classes. Furthermore, several lifestyle-cancers have also been associated with the 
MetS and its components. 
 
Aim: To determine the association and interaction between the MetS and cancer risk and the 
likely influence of FAs on body composition in a female population residing in the Western Cape, 
South Africa. 
 
Methods: Female farm workers in the Cape Winelands region (n=80) aged 20-60 years were 
randomly selected and categorised as having the MetS (n=34 MetS and n=46 non-MetS) using 
the International Diabetes Federation (IDF) criteria. All participants were additionally classified 
according to their body mass index (BMI). Blood pressure was measured, followed by blood 
sampling to determine blood glucose and insulin levels, as well as a full lipid profile. Selected 
red blood cell (RBC) membrane FAs and FA ratios were analysed, and enzyme-linked 
immunosorbent assays (ELISAs) were used to quantify serum insulin-like growth factor-1 (IGF-
1) and leptin concentrations. Anthropometric measurements and bioelectric impedance analyses 
(BIA) were also performed. 
 
Results: The prevalence of the MetS was 42.5 % with abdominal obesity (100.0 % for the MetS, 
and 39.1 % for the non-MetS), hypertension (82.4 % for the MetS, and 47.8 % for the non-
MetS), and low high-density lipoprotein cholesterol (HDL-c) (76.5 % for the MetS, and 34.8 % for 
the non-MetS) being the most prevalent MetS risk factors. Several statistically significant 
differences were observed between the MetS and non-MetS groups for blood parameters, 
including insulin and HDL-c levels (p<0.001), and glucose, IGF-1, and leptin levels (p<0.05). The 
MetS group also presented with significantly higher anthropometric measurements, including 
BMI (p<0.05), waist circumference (WC), waist-to-hip ratio (W:H), and the sagittal abdominal 
diameter (SAD) (all p<0.001). Furthermore, BIA (including visceral adipose tissue (VAT) area, 
percentage VAT (VAT %) and -subcutaneous adipose tissue (SAT %), and VAT to SAT ratio 
(VAT:SAT) (p<0.001 for all) also differed between the MetS and non-MetS groups. No 
significant differences were noted for any of the individual FAs or FA ratios. Categorisation 
according to metabolic status and BMI was shown to influence several metabolic-associated 
blood parameters, anthropometric measurements, BIA. However, metabolic status and BMI did 
not influence individual FA levels or FA ratios. The obese MetS group presented with 
significantly higher IGF-1 levels compared to their normal weight non-MetS counterparts. 
Correlation analyses indicated several significant associations between anthropometric 
measurements, BIA, FAs and metabolic-associated blood parameters. 
 
Conclusion: The results from this study suggest that metabolic status alone, and the combined 
effect of metabolic status and BMI, may predict alterations in metabolic-associated blood 
parameters, anthropometric measurements, and BIA in women, possibly linking obesity and the 
MetS to an increased risk of developing lifestyle-associated cancer. 
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OPSOMMING 
Agtergrond: Tans ondervind Sub-Sahara Afrika ‘n epidemiologiese oorgang met toenemende 
las van nie-oordraagbare siektes (NOS’s) insluitend vetsug, hipertensie, 
insulienweerstandigheid (IW) en dislipidemie. Hierdie NOS word gesamelik na die metaboliese 
sindroom (MetS) verwys. Die MetS word gekenmerk deur dislipidemie, en veral ‘n verwronge 
vetsuur (VS)-metabolisme. Addisioneel word die MetS en komponente daarvan ook met die 
verskillende VS klasse geassosieer. Verskeie leefstylkankers word voorts ook met die MetS sy 
en komponente geassosieer.  
  
Doel: Om die verband en interaksie tussen die MetS en risiko vir kankerontwikkeling te bepaal, 
en die moontlike invloed van VSe op liggaamsamestelling in ‘n vroulike populasie wat woonagtig 
is in die Wes-Kaap, Suid-Afrika.  
 
Metodes: Vroulike plaaswerkers van die Kaapwynland distrik (n=80) tussen die ouderdomme 
20-60 jaar, is ewekansig gekies en geklassifiseer met die MetS (n=34 MetS, en n=46 non-MetS) 
deur van die Internasionale Diabetes Federasie (IDF) kriteria gebruik te maak. Alle deelnemers 
is addisioneel volgens hulle liggaamsmassa indeks (LMI) geklassifiseer. Bloeddruk is bepaal, 
gevolg deur ‘n bloedmonster om bloedglukose, insulienkonsentrasie, en ‘n volledige lipiedprofiel 
te bepaal. Geselekteerde rooibloedselmembraan VSe en VS verhoudings is bepaal, terwyl daar 
van ‘n ensiemgekoppelde immunosorberende toets (ELISA) gebruik gemaak is om serum 
insulienagtige groeifaktor-1 (IGF-1) en leptienkonsentrasies te bepaal. Antropometriese metings 
en bio-elektrieses impedansie analises (BEI) is ook uitgevoer.  
 
Resultate: Die voorkoms van die MetS was 42.5 %, waarvan abdominale vetsug (100.0 % vir 
die MetS, en 39.1 % vir die nie-MetS), hipertensie (82.4 % vir die MetS, en 47.8 % vir die nie-
MetS), en lae hoë-digtheidlipoproteïencholesterol (HDL-c) (76.5 % vir die MetS, en 34.8 % vir 
die nie-MetS) die mees algemene MetS risikofaktore was. Verskeie statistiesbetekenisvolle 
verskille is tussen die MetS en die nie-MetS groepe vir bloedparameters, insluitend insulien en 
HDL-c vlakke (p<0.001), glukose, IGF-1, en leptien vlakke (p<0.05) waargeneem. Die MetS 
groep het ook betekensivolle hoër antropometriese metings opgelewer, insluitend LMI (p<0.05), 
middelomtrek (MO), middel-heup verhouding (M:H) en sagitale abdominale deursnit (SAD) 
(almal p<0.001). Verder is betekenisvolle verskille in BEI (insluitend viserale vetweefsel (VVW) 
area, persentasie VVW (VVW %), subkutane vetweefsel (SVW %), en VVW:SVW verhouding 
(p<0.001 vir almal) tussen die MetS en nie-MetS groepe waargeneem. Geen betekensvolle 
verskil vir die individuele VSe of VS verhoudings is gevind nie. Klassifisering volgens die 
metaboliese status en LMI, het verskeie metabolies-geassosieerde parameters, 
antropometriese metings, en BEI voorspel. Die metaboliese status en LMI het nie die individuele 
VSe of VS verhoudings beïnvloed nie. Die vetsugtige MetS groep het verhoogde IGF-1 vlakke 
teenoor normale gewig, nie-MetS individue gelewer. Verskeie antropometriese metings, BEI, 
VSe en metabolies-gessosiëerde bloedmetings het korrelasies getoon.  
 
Gevolgtrekking: Die resultate van hierdie studie stel voor dat die metaboliese status, en die 
gekombineerde effek van die metaboliese status en die LMI verandering in die metabolies-
geassosieerde bloedparameters, antropometriese metings en BEI, in vroue kan voorspel. Dit 
kan moontlik verdere vetsugtigheid in die MetS met ‘n verhoogde risiko vir die ontwikkeling van 
lewenstyl-geassosieerde kanker verbind.  
 
Sleutelwoorde: 
Metaboliese sindroom, vetsuurprofiel, liggaamsamestelling, leptien, kankerrisiko 
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CHAPTER 1: INTRODUCTION AND 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Recently, considerable focus was placed on non-communicable diseases (NCDs) as the leading 
cause of death worldwide, with an estimated 73.0 % of deaths attributed to this in low- and 
middle income countries (WHO, 2014a). Metabolic diseases form part of these NCDs, and are 
also increasing globally, resulting in the emergence of cardiovascular disease (CVD), type 2 
diabetes mellitus (T2DM), and lifestyle-associated cancers (WHO, 2013). It has further been 
shown that a health transition is currently taking place in sub-Saharan Africa (SSA), which 
escalates disease burden even more (Young et al., 2009; WHO, 2010a). A recent study 
ascribed the association of the increased prevalence of obesity, T2DM, CVD, and lifestyle-
associated cancers in SSA with mortality (approximately 25.0 %), due to urbanisation (Steyn et 
al., 2012; WHO, 2014a). Several factors may be dominant in this circumstance, including 
environmental, genetic, and lifestyle factors (Steyn et al., 2012). These factors are interrelated, 
leading to a combination of metabolic-associated changes, such as abdominal obesity, 
hypertension, hyperglycaemia, insulin resistance (IR), and dyslipidaemia, collectively known as 
the metabolic syndrome (MetS) (Figure 1.1) (WHO, 2005; Alberti et al., 2009; Jeon et al., 2011; 
Erasmus et al., 2012; Klug et al., 2012; Camargo et al., 2014; WCRFI, 2014).  
 
Figure 1.1: Common causes and risk factors of chronic non-communicable diseases. 
(Adapted from: WHO, 2005; Park et al., 2012; Peer et al., 2013; Pradeilles et al., 2015). 
 
MetS 
Underlying socio-
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Modifiable risk factors:  
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- Alcohol consumption 
Unmodifiable risk 
factors:  
- Genetic factors 
- Age 
Intermediate risk 
factors:  
- Hypertension 
- Hyperglycaemia and IR 
- Dyslipidaemia  
- Overweight or obesity 
- Inflammation 
Common chronic 
diseases:  
- CVD 
- Stroke 
- T2DM 
- Lifestyle-associated cancers 
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The MetS is associated with alterations in lipid metabolism, specifically dysregulation of fatty 
acid (FA) metabolism (Kabagambe et al., 2008; Patel et al., 2010; Novgordtseva et al., 2011; 
Shab-Bidar et al., 2014). This has led to the assumption that visceral adiposity and metabolic 
derangements were linked to significant correlations between blood FA concentrations in 
individuals with the MetS and healthy controls (Kabagambe et al., 2008; Novgorodtseva et al., 
2011; Zhang et al., 2012a; Zong et al., 2013; Žák et al., 2014). Moreover, individuals with the 
MetS showed significantly higher plasma saturated FA (SFA) and monounsaturated FA (MUFA) 
levels, and lower polyunsaturated FA (PUFA) levels compared to healthier controls (Kawashima 
et al., 2009; Žák et al., 2014). 
 
The MetS is also associated with an increased risk of several lifestyle-associated cancers, 
including thyroid, oesophageal, colorectal, postmenopausal breast, urinary bladder, and cancer 
of the central nervous system (CNS) (Kuchiba et al., 2012; Leiba et al., 2012; Reeves et al., 
2012; Kawai et al., 2013; Wiedman et al., 2013; Li et al., 2014; Lindkvist et al., 2014; Roswall et 
al., 2014; Almquist et al., 2015). Studies highlighted elevated body mass index (BMI), the use of 
alcohol and/or tobacco, physical inactivity, and reduced intake of fruits and vegetables as some 
of the lifestyle factors that may be responsible for the increased risk of developing NCDs 
(Lindkvist et al., 2014; Almquist et al., 2015; Miglani et al., 2015; WHO, 2015a). 
 
This chapter provides background on the burden of the MetS, the different definitions and 
classifications used, with a specific focus on the South African setting. Furthermore, this chapter 
will explore the effects of the MetS and its association with different FAs, and cancer risk. This 
chapter concludes with the significance, aim, and objectives of the study. 
 
1.2 THE METABOLIC SYNDROME (MetS) 
1.2.1 Introduction 
The MetS is a cluster of risk factors that are mostly associated with abdominal obesity or 
IR/diabetes (Alberti et al., 2006; IDF, 2006). Although various definitions exist to diagnose the 
MetS, there is currently no standardised internationally accepted version of classifying specific 
populations. This confounds the comparison of different studies worldwide, since the prevalence 
of the MetS is dependent on the definition being used.  
 
1.2.2 Definitions and classifications of the metabolic syndrome 
The World Health Organisation (WHO) formulated the initial MetS definition in 1998. Here, IR 
was considered essential for the diagnosis of the MetS, along with any two additional risk 
factors, including obesity, hypertension, elevated triglycerides (TGs), reduced high density 
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lipoprotein cholesterol (HDL-c), or microalbuminuria (WHO, 1999; Alberti et al., 2009). This 
definition was also the first to include microalbuminuria as a MetS risk factor (WHO, 1999). 
 
The National Cholesterol Education Program Adult Treatment Panel III (ATP III) formulated a 
definition of the MetS stating that neither IR nor any other single risk factor was essential, 
although the presence of any three of the known MetS risk factors (obesity, hypertension, 
hyperglycaemia or dyslipidaemia) was needed (NCEP, 2001). The International Diabetes 
Federation (IDF) uses abdominal obesity, and any two risk factors to define the MetS (IDF, 
2006). This definition also made use of similar cut-off values proposed by the ATP III definition 
(NCEP, 2001). Although obesity is associated with several metabolic risk factors (including 
hypertension, IR, hyperglycaemia, and dyslipidaemia), only the IDF requires abdominal obesity 
as essential for MetS diagnosis (IDF, 2006). Furthermore, this definition also specifically defined 
different cut-off values for abdominal obesity in different ethnic groups (summarised in Table 
1.1) (IDF, 2006).  
 
Table 1.1: Waist circumference cut-off values for different ethnic groups according to the IDF. 
COUNTRY/ETHNIC GROUP WC CUT-OFF VALUES 
 Males Females 
Europeans * ≥94.00 cm ≥80.00 cm 
South Asians ** ≥90.00 cm ≥80.00 cm 
Chinese ≥90.00 cm ≥80.00 cm 
Japanese *** ≥90.00 cm ≥80.00 cm 
Ethnic South and Central Americans Use South Asian recommendations until more specific data are available 
Sub-Saharan Africa Use European data until more specific data are available 
Eastern Mediterranean and Middle East populations Use European data until more specific data are available 
*  In future epidemiologic studies of populations of European origin, prevalence should be given using both European and North  
 American cut-points to allow better comparisons. 
** Based on a Chinese, Malay and Asian-Indian population. 
*** Originally different values were proposed for Japanese people, but new data support the use of the values shown above. 
(IDF, 2006). 
 
In an attempt to resolve the use of different definitions of the MetS, the IDF and the American 
Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), suggested that 
abdominal obesity should be omitted as an essential risk factor for MetS diagnosis (Alberti et al., 
2009). Instead, the resultant Joint Interim Statement (JIS) deemed the use of any three of the 
five risk factors as sufficient. The JIS definition is therefore almost similar to that of the IDF, 
except that abdominal obesity is not an essential risk factor (IDF, 2006; Alberti et al., 2009). The 
different MetS definitions are summarised in Table 1.2. 
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Table 1.2: Different clinical definitions of the metabolic syndrome.  
 WHO ATP III IDF JIS* 
Reference (WHO, 1999) (NCEP, 2001) (IDF, 2006) 
(Alberti et al., 
2009) 
Criteria 
IR diagnosed as T2DM, 
Impaired glucose 
regulation or  
≥2 factors of the following: 
≥3 of the following: 
Increased WC 
according to ethnic 
group** and ≥2 of 
the following: 
≥3 of the following: 
Abdominal obesity 
W:H ≥0.90 (men) 
≥0.85 (women) or 
BMI≥30.00 kg/m
2
 
Men: WC ≥102.00 
cm 
Women: ≥88.00 cm 
Men: WC ≥94.00 cm 
Women: ≥80.00 
cm** 
Men: WC ≥90.00 
cm 
Women: ≥80.00 cm 
Impaired glucose 
regulation 
Fasting plasma glucose 
≥6.10 mmol/L 
2hr post-glucose load 
≥7.80 mmol/L 
Fasting plasma 
≥6.10 mmol/L 
Fasting plasma 
≥5.60 mmol/L 
Or T2DM diagnosis 
Fasting plasma 
≥5.60 mmol/L 
Or treatment for 
elevated glucose 
Hyperinsulinaemia ≥1.70 mmol/L 
TG  ≥1.70 mmol/L ≥1.70 mmol/L ≥1.70 mmol/L 
≥1.70 mmol/L 
Or treatment for 
elevated TG 
HDL-c 
Men: <0.90 mmol/L 
Women: <1.00 mmol/L 
Or treatment for reduced 
HDL-c levels 
Men: <1.03 mmol/L 
Women: <1.29 
mmol/L 
Men: <1.03 mmol/L 
Women: <1.29 
mmol/L 
Or treatment for 
reduced HDL-c 
Men: <1.03 mmol/L 
Women: <1.29 
mmol/L 
Or treatment for 
reduced HDL-c 
Hypertension 
BP ≥140.00/≥90.00 
mmHg 
Or treatment for 
hypertension 
BP ≥130.00/≥85.00 
mmHg 
Or treatment for 
hypertension 
BP ≥130.00/≥85.00 
mmHg 
Or treatment for 
hypertension 
BP ≥130.00/≥85.00 
mmHg 
Or treatment for 
hypertension 
Microalbuminuria  
Urinary albumin excretion 
rate ≥20.00 µg/min 
Albumin/Creatinine ratio 
≥30.00 mg/g 
- - - 
* Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung 
and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society and International 
Association for the study of obesity. 
** Different cut-off values for different ethnic groups, including Europids, South Asians, Chinese, and Sub-Saharan Africans. The 
latter group uses the European cut-off values until specific data become available. 
 
Public health studies originating from South Africa mainly used the IDF’s definition (Jennings et 
al., 2009; Erasmus et al., 2012). As illustrated in Table 1.2, the IDF definition includes abdominal 
obesity (as measured by waist circumference (WC)) in combination with any two other MetS-
specific criteria (IDF, 2006). It is therefore expected that the prevalence of the MetS will differ 
between developed and developing countries, since different MetS definitions use different 
criteria and cut-off values. 
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1.2.3 Prevalence of the metabolic syndrome 
1.2.3.1 Global vs local 
The estimated global MetS prevalence ranged between 20.0-25.0 % according to the IDF in 
2006 (IDF, 2006). African studies reported this prevalence to vary as a function of geographical 
location and ethnicity. For example, the MetS prevalence in Nigeria and Ghana vary between 
12.1 % and 35.9 % respectively (Adegoke et al., 2010; Gyakobo et al., 2012), whereas a 
relatively recent South African study reported a much higher prevalence of 42.1 % (Crowther & 
Norris, 2012). 
 
Various studies have shown the prevalence of the MetS to be more associated with women 
(Garrido et al., 2009; Motala et al., 2011; Erasmus et al., 2012; Gyakobo et al., 2012). Motala et 
al. (2011) reported an overall prevalence of 23.3 % amongst a population in Kwa-Zulu Natal, 
with women displaying more than double the prevalence (26.3 % vs 11.6 %, IDF definition). 
More recently, a South African study amongst a coloured population in the greater Cape Town 
region, reported that 30.6 % of men and almost 70.0 % of women older than 31 years, were 
classified as having the MetS (Erasmus et al., 2012). In contrast, Hoebel et al. (2013) noted a 
much higher MetS prevalence amongst Black and Caucasian men (59.0-77.0 % in men vs 22.0-
69.0 % in women) between the ages of 25 and 65 years from an urban environment. The latter 
study concluded that the higher MetS prevalence in men was due to the level of urbanisation 
and associated lifestyle choices such as increased alcohol intake and tobacco use, unhealthy 
dietary habits, and physical inactivity (Hoebel et al., 2013). Furthermore, gender and ethnic 
disparities in lipid and glucose metabolism may contribute to variations in the prevalence of the 
MetS and its individual risk components (Hoebel et al., 2013; Rochlani et al., 2015).  
 
1.2.3.2 Prevalence of the individual components of the metabolic syndrome 
Several studies reported contrasting results regarding the most and least prevalent individual 
MetS risk factor for different populations. Garrido et al. (2009) observed low HDL-c levels as the 
most prevalent MetS risk factor, although several more recent studies established that 
abdominal obesity was more prevalent (Hoebel et al., 2011; Gyakobo et al., 2012; Peer et al., 
2015; Salonen et al., 2015; Strand et al., 2015). According to Hoebel et al. (2011) elevated 
fasting blood glucose (FBG), low HDL-c levels, and hypertension were the second, third and 
fourth most common individual MetS risk factor respectively, while a very low prevalence of 
elevated TG levels was noted. Similarly, Gyakobo et al. (2012), Peer et al. (2015) and Salonen 
et al. (2015) also found low HDL-c and hypertension to be the second and third most prevalent 
individual MetS risk factor, respectively. Strand et al. (2015) reported that hypertension was the 
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second most prevalent MetS component, followed by low HDL-c and high TG levels, while very 
few participants presented with elevated FBG levels. Although most studies have shown 
consensus regarding the prevalence of the individual components of the MetS, the order in 
which these factors appear largely depends on the population being studied, as well as the 
definition used.  
 
Abdominal obesity 
Obesity is regarded as a state of excessive fat accumulation to such an extent that general 
health is impaired (WHO, 2015b). The global prevalence of adult overweight or obesity was 
estimated to be approximately 2.1 billion (Ng et al., 2014), which is particularly alarming, since it 
is also estimated that the rising obesity rates in children will contribute to the increase in global 
obesity prevalence during adulthood (Abrahams et al., 2011; Steyn et al., 2012). 
 
Globally, the prevalence of adult overweight and obesity increased by nearly 30.0 % in three 
decades, independent of gender or ethnicity (Ng et al., 2014). In contrast to the data from 
developed countries, female obesity is on the rise in many low- and middle income countries 
(Garrido et al., 2009; Alkerwi et al., 2011; Crowther & Norris, 2012; Erasmus et al., 2012; Peer 
et al., 2013; Senekal et al., 2015). Garrido et al. (2009) reported that 27.3 % and 28.7 % of the 
Batswanas were overweight and obese, which are significantly lower than the nearly 64.0 % of 
sub-Saharan African women that were overweight in 2014 (Ng et al., 2014). Furthermore, this 
study showed that specifically in South African women, the prevalence of being overweight was 
much higher than the prevalence of obesity (69.3 % vs 42.0 %) (Ng et al., 2014).  
 
With specific reference to using WC as the anthropometric measure of abdominal obesity, 
Motala et al. (2011) found that 96.9 % of women presented with abdominal obesity. The 
prevalence of abdominal obesity (WC≥80 cm) reported here, was higher than that reported in 
other African countries, including Botswana (42.0 %), and Ghana (55.3 %) (Garrido et al., 2009; 
Gyakobo et al., 2012). Particularly in South Africa, more Caucasian women presented with 
abdominal obesity compared to Black women (77.9 % vs 75.6 %) (Hoebel et al., 2011; Crowther 
& Norris, 2012). 
 
Studies have also indicated that measures of obesity differ between MetS and non-MetS 
groups. Here, MetS participants presented with significantly higher BMIs and WCs compared to 
their non-MetS counterparts (Nigam et al., 2009; Bremer et al.; 2011; Esteghamati et al., 2011; 
Atanassova et al., 2014). Studies have also shown that obesity is strongly associated with 
hypertension (Wildman et al., 2008; Jeon et al., 2011; Peer et al., 2013; Abu-Farha et al., 2014; 
Helelo et al., 2014), since the relationship between obesity and microvascular dysfunction and 
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abnormal vascular tone increases vasoconstriction, and leads to elevated BP (de Boer et al., 
2011; Peer et al., 2013, Helelo et al., 2014; Kaur, 2014).  
 
Hypertension 
Hypertension is defined as an elevated systolic blood pressure (SBP) of more than 130 mmHg, 
and a diastolic blood pressure (DBP) of more than 85 mmHg (IDF, 2006). Hypertension is not 
only globally on the increase (80 million in 2000 to 150 million by 2025) (WHO, 2014b), but is 
also considered a major public health challenge in Africa. For example, Garrido et al. (2009) 
reported that 44.0 % of the Batswanas presented with hypertension, while only 22.4 % of 
Ethiopia’s population were hypertensive (Helelo et al., 2014). According to the WHO, almost a 
third of the men and women in Africa presented with hypertension in 2014 (WHO, 2014b), whilst 
more than 20.0 % of adults suffered from hypertension in 2015 worldwide (WHO, 2015c).  
 
In South Africa specifically, earlier studies reported a hypertension prevalence of 36.4 % in 
apparently healthy Black women, and an almost 40.0 % prevalence in participants in Cape 
Town (Crowther & Norris, 2012; Peer et al., 2013). This is lower than the nearly 50.0 % 
hypertension prevalence reported for Black women in more recent studies from the Western 
Cape (Peer et al., 2015; Senekal et al., 2015). Several confounding factors such as ethnicity, 
familial hypertension history, lifestyle factors, and access to healthcare may contribute to the 
prevalence of hypertension (Umscheid et al., 2010; Jeon et al., 2011; Peer et al., 2013; Helelo et 
al., 2014; Kaur, 2014; Rochlani et al., 2015). Studies have also confirmed that sex hormones are 
associated with hypertension. Here, oestrogen plays a protective role by regulating the renin 
angiotensin-aldosterone system (RAAS) through increased angiotensinogen, and decreased 
renin and angiotensin converting enzyme synthesis (Denton et al., 2013; Hilliard et al., 2013; 
Rochlani et al., 2015). However, during ageing, the protective effects of oestrogen on 
hypertension are reduced, leading to the increased prevalence of hypertension among 
postmenopausal women (Denton et al., 2013; Hilliard et al., 2013; Rochlani et al., 2015). 
Additionally, ageing is also associated with hypertension due to arterial thickening and increased 
arterial resistance (Helelo et al., 2014).  
 
Increased stress levels and urbanisation also contribute to hypertension (Jeon et al., 2011; Peer 
et al., 2013; Helelo et al., 2014; Rochlani et al., 2015). Poor lifestyle choices, such as high salt 
intake and processed foods are associated with hypertension, because increased salt intake 
disrupts sodium homeostasis, causing fluid retention, thereby increasing BP (Sheng, 2009; 
Helelo et al., 2014). Hypertension is also associated with other lifestyle factors such as physical 
inactivity, smoking, and alcohol consumption (Helelo et al., 2014). Furthermore, obesity, adipose 
tissue morphology and -distribution, IR, glucose intolerance/diabetes, and dyslipidaemia may 
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also affect BP (Umscheid et al., 2010; Jeon et al., 2011; Peer et al., 2013; Kaur, 2014). Since 
these factors are related to the MetS, it is not surprising that SBP and DBP were significantly 
higher in individuals with the MetS (Nigam et al., 2009; Bremer et al., 2011; Esteghamati et al., 
2011). Hypertension is also associated with glucose intolerance and IR, since hyperinsulinaemia 
increases sodium resorption and leads to vasodilation and volume expansion, and ultimately 
increases BP (Alberti et al., 2006; Kirk & Klein, 2009; Jennings et al., 2009). 
 
Glucose intolerance and insulin resistance 
It is well known that individuals with IR not only present with impaired glucose metabolism, but 
also elevated FBG, hyperglycaemia, reduced glucose clearance due to decreased insulin 
activity, and reduced suppression of glucose production (Kaur, 2014). The prevalence of 
elevated FBG differed between African countries, and ranged from 12.5 % (Ghana) to 26.7 % 
(Botswana) (Garrido et al., 2009; Gyakobo et al., 2012). Several South African studies amongst 
Black and Caucasian women noted that 20.0-25.0 % of participants presented with elevated 
FBG levels (Crowther & Norris 2012; Peer et al., 2015; Senekal et al., 2015). Evans et al. (2011) 
reported clear ethnic differences, where Caucasian women had significantly higher FBG, and 
lower insulin levels compared to Black women. This is possibly due to ethnic differences in 
adipose tissue distribution, where Black women accumulate less visceral adipose tissue (VAT) 
with increasing WC (Evans et al., 2011). Additionally, insulin sensitivity is gender-dependent, 
possibly due to differences in hormonal and adipose tissue distribution – women normally 
present with a higher body fat percentage, total adiposity, and insulin sensitivity (Rochlani et al., 
2015).  
 
Several studies also found significantly elevated levels of FBG and insulin, and homeostasis in a 
model of insulin resistance (HOMA-IR) in participants with the MetS (Nigam et al., 2009; Bremer 
et al., 2011; Esteghamati et al., 2011; Atanassova et al., 2014). Additionally, glucose 
abnormalities have also been associated with dyslipidaemia, since IR has been correlated with 
elevated TG levels, possibly due to impaired enzyme activity (Sumner et al., 2005; Ginsberg & 
Karmally, 2009; Jennings et al., 2009). 
 
Dyslipidaemia 
Elevated, or reduced levels of the different blood lipid fractions are used to characterise 
dyslipidaemia, including elevated TG, low density lipoprotein cholesterol (LDL-c), and reduced 
HDL-c levels (WHO, 1999; NCEP, 2001; IDF, 2006; Alberti et al., 2009). Low HDL-c levels were 
common in some African countries, including Botswana (80.0 %), South Africa (45.0 %), and 
Ghana (42.7 %) (Garrido et al., 2009; Evans et al., 2011; Gyakobo et al., 2012). Crowther & 
Norris (2012) reported a prevalence of 70.1 % in their South African population for reduced 
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HDL-c levels, and 22.3 % exhibited elevated TG levels. In accordance, Crowther & Norris (2012) 
and Peer et al. (2015) also found that low HDL-c levels were more common than elevated TG 
levels in South African women. Regarding ethnicity, an earlier South African study found that 
70.5 % of Black women presented with low HDL-c levels, while elevated TG levels were 
uncommon in this population (prevalence of ~8.0 %) (Hoebel et al., 2011). This is in contrast to 
the study of Evans et al. (2011) in which ethnicity affected all areas of the lipid profile, with 
Caucasian South African women displaying higher total cholesterol, TG, and HDL-c levels, 
compared to their Black counterparts. A recent study by Senekal et al. (2015) reported that a 
third of a South African study population presented with elevated total cholesterol levels. The 
discrepancies in the prevalence reported could be ascribed to several factors, such as grade of 
obesity, gender, ethnicity, and lifestyle factors (Evans et al., 2011; Delisle et al., 2013). These 
findings could also reflect the effects of inflammation, and environmental factors on the lipid 
profile (Evans et al., 2011). 
 
It is also well established that the MetS is associated with dyslipidaemia (IDF, 2006; Shab-Bidar 
et al., 2014). Total cholesterol, LDL-c, and TG levels were all significantly elevated in MetS 
individuals; whereas HDL-c levels were significantly lower (Nigam et al., 2009; Bremer et al., 
2011; Esteghamati et al., 2011; Atanassova et al., 2014). Lipid profiles of normal and obese 
individuals indicated that obesity was a major risk factor for both dyslipidaemia and the MetS. 
This was shown in two different studies, in which obese participants had significantly higher total 
cholesterol, LDL-c and TG levels, and significantly lower HDL-c levels compared to normal 
weight controls (Jeon et al., 2011; Gómez-Ambrosi et al., 2012). All the individual components of 
the MetS can also lead to several pathologies in different physiological systems (Alberti et al., 
2006; Jeon et al., 2011; Crowther & Norris, 2012; Camargo et al., 2014). 
 
1.3  PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
1.3.1 Introduction 
The MetS is a complex of interconnected metabolic-related risk factors; with MetS patients 
suffering from IR, glucose intolerance, postprandial dyslipidaemia, and pro-inflammatory and 
pro-thrombotic states (Alberti et al., 2006; Jeon et al., 2011; Crowther & Norris, 2012; Camargo 
et al., 2014). These alterations frequently lead to several other metabolic-related diseases, such 
as CVD, T2DM, and an increased risk for the development of lifestyle-associated cancer (Alberti 
et al., 2009; Crowther & Norris, 2012; Erasmus et al., 2012; Klug et al., 2012; Lindkvist et al., 
2014; Roswall et al., 2014; Almquist et al., 2015). Although the pathophysiology of the MetS is 
multifaceted, abdominal fat distribution, and IR may be some of the more dominant risk factors 
(Alberti et al., 2006; IDF, 2006; Jeon et al., 2011; Crowther & Norris, 2012; Camargo et al., 
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2014) (Figure 1.2). Insulin resistance refers to a state of reduced sensitivity to the effects of 
insulin, which is closely associated with obesity (Alberti et al., 2006; IDF, 2006; Jeon et al., 
2011; Crowther & Norris, 2012; Camargo et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Outline of the key pathogenic factors involved in the pathophysiology of the metabolic syndrome, 
obesity and insulin resistance. 
(Adapted from: Alberti et al., 2006; IDF, 2006; Jeon et al., 2011; Crowther & Norris, 2012; Camargo et al., 2014). 
 
1.3.2 Obesity 
1.3.2.1 Introduction and health implications of obesity 
Obesity is characterised by excessive lipid storage, and hence weight gain (Mendonça et al., 
2015; WHO, 2015b). Adipose tissue constitutes an estimated 15.0-25.0 % of body mass, and 
has several physiological functions including mechanical support, protection, thermal insulation, 
and energy storage (Levine & Levine, 2014).  
 
In general, fat is stored as white adipose tissue (WAT), and can be further subdivided into (i) 
subcutaneous adipose tissue (SAT), and (ii) VAT, each with its own unique metabolic- and 
biochemical functions, and health risks (Shah et al., 2012; Levine & Levine, 2014; Mendonça et 
al., 2015; Yeoh et al., 2015). Subcutaneous fat is located underneath the skin providing 
mechanical protection, and contribute to normal lipid- and glucose metabolism. The SAT 
deposition normally occurs in the gluteo-femoral region, and contributes to the gynoid-
phenotype obesity, which is commonly seen in premenopausal women (Levine & Levine, 2014; 
Stewart & Sutton, 2012; Kranendonk et al., 2015). The VAT compartment surrounds the internal 
organs, and secretes adipokines and cytokines. Visceral deposition normally occurs in the 
abdominal region and contributes to the android-phenotype obesity, which is more prevalent in 
Hypertension Dyslipidaemia 
Obesity 
IR 
↑ MetS risk 
↑ CVD risk 
↑ cancer risk 
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men (Levine & Levine, 2014; Stewart & Sutton, 2012; Kranendonk et al., 2015). This gender-
dependent fat distribution suggests that oestrogen plays an additive role, since SAT areas are 
more prominent in women, whereas VAT areas are greater in men (Camhi et al., 2011; Schautz 
et al., 2012; Shah et al., 2012). Although adiposity differs between genders, ageing (and thus 
reduced oestrogen levels) was shown to contribute to android adiposity in menopausal women, 
leading to the disappearance of sexual dimorphisms (Alkerwi et al., 2011; Camhi et al., 2011). 
 
The region of fat deposition is closely related to the associated metabolic dysfunction, and 
health implications, since metabolic dysfunction was related to VAT and SAT, with both 
components being positively associated with BMI (Pou et al., 2009; Yim et al., 2010; Camhi et 
al., 2011; Shah et al., 2014; Yeoh et al., 2015). Individuals with a normal BMI tend to generally 
have lower VAT than those with a higher to overweight BMI (Shah et al., 2014). Visceral 
adiposity is also positively associated with the MetS, even in people with a normal BMI, where 
they can exhibit higher visceral adiposity, higher FBG, as well as insulin levels. It is therefore 
suggested that individuals with a normal BMI, but greater visceral adiposity, have a biochemical 
phenotype similar to that of an overweight or obese person (Shah et al., 2014). Recent studies 
found that an increasing VAT to SAT ratio (VAT:SAT) was associated with increasing CVD risk, 
which relates to the fact that VAT is regarded as more metabolically active, and therefore able to 
secrete larger quantities of pro-inflammatory adipokines compared to SAT (Mendonça et al., 
2015; Yeoh et al., 2015). For this reason, visceral adiposity is more frequently related to 
metabolic alterations, such as IR, than subcutaneous adiposity (Shah et al., 2012; Mendonça et 
al., 2015). 
 
Being overweight or obese are associated with adipose tissue dysfunction, which increases the 
risk of developing hypertension, dyslipidaemia, hyperglycaemia, CVD, T2DM, and certain 
lifestyle-associated cancers (Figure 1.3) (Jeon et al., 2011; Gómez-Ambrosi et al., 2012; 
Kuchiba et al., 2012; Kawai et al., 2013; Peer et al., 2013; Helelo et al., 2014; Lindkvist et al., 
2014; Almquist et al., 2015). Increased VAT poses greater health risks due to its proximity to the 
intestines, since VAT facilitates energy storage, and is rich in parasympathetic innervation that 
upregulate visceral lipogenesis (Levine & Levine, 2014). The central location of VAT therefore 
makes it more susceptible to the effects of inflammatory and neuro-hormonal factors (Levine & 
Levine, 2014). 
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Figure 1.3: A brief outline of the pathophysiology of obesity. 
(Adapted from: Jeon et al., 2011; Gómez-Ambrosi et al., 2012; Peer et al., 2013; Helelo et al., 2014). 
 
Different anthropometric assessments are utilised to measure obesity as a risk factor for the 
MetS, and will be discussed in the following section (Anunciação et al., 2014; Cheong et al., 
2015). 
 
1.3.2.2 Abdominal obesity assessment methods 
Several assessment methods exist to describe body composition and fat distribution (Willet & 
Hu, 2013). The most commonly used anthropometric measurements include body weight, BMI, 
skinfold thicknesses, and circumferences (NHANES, 2011). However, abdominal obesity is 
more easily and accurately assessed with the WC, waist-to-hip circumference ratio (W:H), waist-
to-height ratio (W:Ht), or sagittal abdominal diameter (SAD), compared to using total body fat or 
the BMI (Anunciação et al., 2014; Cheong et al., 2015). 
 
Body mass index and bioelectrical impedance analysis  
The BMI (kg/m2) accounts for differences in body composition by defining the level of adiposity 
according to the relationship of body weight and height (Willet & Hu, 2013). The BMI is 
calculated as the body weight (in kilograms) divided by the height (in metres) squared (Equation 
1.1) (Jarvis, 2011; Willet & Hu, 2013). 
 
𝐵𝑜𝑑𝑦 𝑚𝑎𝑠𝑠 𝑖𝑛𝑑𝑒𝑥 (𝑘𝑔/𝑚2) =
𝐵𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚)2
 
Equation 1.1: Calculation of body mass index. 
(WHO, 2004a; NHANES, 2011). 
Obesity 
• Hypertension 
• Dyslipidaemia 
• Hyperglycaemia and IR 
• MetS 
• CVD 
• Lifestyle-associated 
cancers 
↑ risk of: 
Adipose tissue dysfunction 
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The BMI is used to classify individuals as either underweight, normal, overweight or obese 
(summarised in Table 1.3) (Willet & Hu, 2013). Large epidemiological studies often use BMI to 
assess total body fat, and fat distribution, since it is a quick and easy measure (Willet & Hu, 
2013).  
 
Table 1.3: Classification of body mass index.  
CLASS 
BMI 
(kg/m
2
) 
Underweight Severe malnutrition <16.00 
 Moderate malnutrition 16.00-16.99 
 Mild malnutrition 17.00-18.49 
Normal range Normal 18.50-24.99 
Overweight Pre-obese 25.00-29.99 
Obese Obese class I 30.00-34.99 
 Obese class II 35.00-39.99 
 Obese class III ≥40.00 
(WHO, 2004a; NHANES, 2011). 
 
The specific ethnic, as well as gender cut-off values for BMI are also controversial, highlighting 
the need to establish population-, age-, and gender-specific cut-off values for different 
anthropometric measures (WHO, 2008; Stewart & Sutton, 2012). The use of the BMI has some 
disadvantages, including its inability to distinguish between excessive body weight due to fat- or 
muscle mass (Stewart & Sutton, 2012). Furthermore, the index does not reflect adipose tissue 
distribution, which is an important risk factor for several metabolic diseases (Willet & Hu, 2013).  
 
Bioelectrical impedance analysis (BIA) is used to determine the distribution of body fat, and can 
therefore be used to assess VAT and SAT, and extra- and intracellular fluids (Stewart & Sutton, 
2012). Here, electrodes are connected to the limbs of a participant to form a circuit for a small 
current to pass through to determine the body’s impedance, since different tissue types vary in 
resistance to electric current due to differences in water content (Thibault et al., 2012; Stewart & 
Sutton, 2012). For example, fat has a lower water content compared to muscle, which make fat 
a poor conductor with higher resistance than muscle (Santarpia et al., 2009; Stewart & Sutton, 
2012). Tissue reactance and -resistance are used to calculate the phase angle, where a smaller 
phase angle is associated with reduced cell membrane integrity and cell death, which is 
associated with the risk of disease (Santarpia et al., 2009; Thibault & Pichard, 2012). The use of 
BIA is convenient in resource-limited settings, although several factors such as age, associated 
disease state (renal and liver disease for example), dehydration, pregnancy, and earlier 
vigorous exercise, should be considered when using this assessment method, since it may 
influence the accuracy of BIA measurements (Stewart & Sutton, 2012; Thibault & Pichard, 
2012). 
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Some studies use the BMI in combination with BIA for more accurate estimations of the 
percentage storage and visceral fat. However, in some instances, BMI classification and BIA 
has led to diverse conclusions regarding obesity, which is possible since individuals with the 
same BMI class may have different body fat percentages, mainly influenced by factors such as 
ethnicity, gender, and age (Camhi et al., 2011). Gómez-Ambrosi et al. (2012) reported that less 
than a third of individuals classified as having a normal BMI were actually obese according to 
body fat percentage. In addition, less than one percent of the study population classified as 
obese using the BMI, were actually classified as normal when they were assessed using 
percentage body fat (Gómez-Ambrosi et al., 2012). 
 
It is noteworthy to mention that, an individual with a normal BMI can be classified as 
‘metabolically healthy’ or ‘-unhealthy’ depending on the site of fat deposition (Wildman et al., 
2008). Increased adipose tissue storage in the visceral compartment is associated with an 
increased risk of the MetS, CVD, and cancer (Wildman et al., 2008, Shapira, 2009). This is 
opposed to an obese person with predominant adipose tissue storage in the subcutaneous 
compartment, classified as ‘obese and metabolically healthy’, who is at a lower risk of 
developing the MetS, CVD, and cancer (Figure 1.4) (Wildman et al., 2008). Therefore, 
misclassification of participants as overweight using the BMI when participants were actually 
obese according to body fat percentage can be misleading, hence emphasising the importance 
of using more than one measure of obesity assessment (Gómez-Ambrosi et al., 2012). 
 
 
Figure 1.4: Metabolically healthy and -unhealthy, regardless of body mass index class. 
(Adopted from: Wildman et al., 2008). 
* %=US adults (2008) 
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Waist circumference, hip circumference and other obesity assessment methods 
Since BMI cannot accurately describe abdominal obesity, additional surrogate measures such 
as WC, hip circumference (HC), and the calculated W:H and W:Ht are used, because these 
have been shown to be better predictors of fat distribution (Anunciação et al., 2014; Cheong et 
al., 2015).  
 
The WC and HC are used to indirectly assess abdominal adiposity, although these 
measurements may vary depending on several factors, such as time of day, standing position, 
posture, etc. (Willet & Hu, 2013). Strong correlations were evident between the WC, HC, and 
individual components of the MetS (Crowther & Norris, 2012; Cheong et al., 2015). In order to 
classify individuals with the MetS, the IDF (2006) definition was proposed for SSA until further 
population-specific studies are available. Different cut-off values for WC have been identified for 
South African Caucasians (WC≤84.0 cm for women), and Africans (WC≤94.0 cm for women) 
(Hoebel et al., 2014), although very few studies have used these population-specific WC cut-off 
values.  
 
Even though HC measurements are not routinely used, it is important in the calculation of the 
W:H, which estimates the risk for CVD (WC≥80.0 cm, HC≥88.0 cm or W:H≥0.85 for women) 
(IDF, 2006; WHO, 2008; Stewart & Sutton, 2012). With particular reference to disease risk, 
evidence suggests that the W:H is actually an inferior measure to identify individuals who are at 
risk for developing metabolic diseases (Evans et al., 2011; Roswall et al., 2014). Although the 
use of the WC, HC, and W:H is regarded as inferior measures of total body fat, these measures 
have a high capability of determining fat distribution (Willet & Hu, 2013). Abdominal obesity can 
also be assessed using the W:Ht, which is associated with cardiometabolic dysfunction 
(including dyslipidaemia, hypertension, and T2DM), despite normal BMI and WC measurements 
(Li et al., 2011a; Ware et al., 2014). A major advantage of the W:Ht compared to WC, is that this 
measure adjusts for height, and universally accepted cut-off values can be used for different 
ethnic groups (Li et al., 2011a; Schneider et al., 2011). Shorter people may present with a higher 
risk of developing metabolic abnormalities (30 %) compared to taller people (Schneider et al., 
2011). 
 
Excessive abdominal fat (measured by WC, W:H, and/or W:Ht) is a major risk factor for disease 
development, including elevated levels of inflammatory markers, dyslipidaemia, IR, T2DM, 
cardiovascular and respiratory diseases, cancer, and ultimately mortality (Jacobs & Newton, 
2010; Jarvis, 2011; Li et al., 2011a; Ware et al., 2014). Not only is a large WC associated with 
elevated levels of circulating inflammatory markers such as high-sensitivity C-reactive protein 
(hsCRP), interleukin-6 (IL-6) and interleukin-1β (IL-1β), it is also associated with increased 
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mortality in women, irrespective of their BMI (Jacobs & Newton, 2010; Bremer et al., 2011). 
There is also a strong correlation between elevated W:H and an increased risk of several cancer 
types, including oesophageal- and colorectal cancer (Kendall et al., 2013; Cottet et al., 2015). 
Kendall et al. (2013) also reported a significant association between oesophageal cancer and 
another measure of abdominal obesity, the SAD. 
 
Sagittal abdominal diameter 
The SAD relies on the mid-sagittal plane to measure the linear distance across the abdomen, 
and is regarded a good measure of abdominal fat distribution to indirectly assess visceral 
adiposity (NHANES, 2011; Stewart & Sutton, 2012). Several metabolic alterations, such as lipid, 
insulin and glucose levels, and IR have been positively associated with the SAD (Kang et al., 
2010; Yamamoto et al., 2010; Yim et al., 2010; Anunciação et al., 2014; Vasques et al., 2015). 
Hypertension and the associated risk of CVD are also associated with SAD measurements 
(Yamamoto et al., 2010; Carlsson et al., 2014). 
 
1.3.3 Hypertension 
Hypertension, defined as both an elevated SBP higher than 130 mmHg, and a DBP of 85 
mmHg, often leads to other diseases such as CVD, stroke, dementia, and renal failure (Helelo et 
al., 2014; Lloyd-Sherlock et al., 2014). Studies have shown that hypertension is associated with 
ageing, stress, urbanisation, dyslipidaemia, IR and glucose intolerance, as well as obesity 
(Jennings et al., 2009; Jeon et al., 2011; Peer et al., 2013; Kaur, 2014). 
 
Obesity is associated with microvascular dysfunction, affecting blood flow resistance and tissue 
perfusion leading to hypertension (Alberti et al., 2006; de Boer et al., 2011). Hypertensive 
patients present with abnormal vasomotor tone that improves vasoconstriction or reduces 
vasodilation (de Boer et al., 2011). Additionally, it was shown that adipocytes produce 
aldosterone in response to angiotensin II, which implies that adipocytes can affect BP by acting 
as small scale RAAS (Kaur, 2014). Furthermore, hypertension is also associated with other CVD 
risk factors, including significantly elevated total cholesterol, lower HDL-c levels, and abdominal 
obesity (Rochlani et al., 2015).  
 
Although the exact mechanism of hypertension in IR is still vague, activation of the sympathetic 
nervous system and RAAS are thought to play important roles (Jennings et al., 2009; Kirk & 
Klein, 2009; Horita et al., 2011; Sossa et al., 2012; Kaur, 2014; Soleimani, 2015). Studies have 
shown that both hyperglycaemia and -insulinaemia activate the RAAS through increased 
expression of angiotensin II, leading to increased sodium resorption in the kidneys, increased 
cardiac output, vasoconstriction, and elevated BP (Kirk & Klein, 2009; Horita et al., 2011; Kaur, 
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2014; O’Neill & O’Driscoll, 2015; Soleimani, 2015). Additionally, IR diminishes the vasodilatory 
effects of insulin, which leads to hypertension (Kirk & Klein, 2009; Horita et al., 2011).  
 
1.3.4 Glucose intolerance and insulin resistance 
Fasting blood glucose levels higher than 5.6 mmol/L and insulin levels above 1.7 mmol/L are 
positively associated with impaired glucose regulation and hyperinsulinaemia (IDF, 2006). 
Normal insulin sensitivity is associated with normal body weight and the absence of abdominal 
obesity (Kaur, 2014). However, individuals with IR have impaired glucose uptake, which 
explains why blood glucose levels are elevated, and a normal insulin concentration does not 
lead to a normal insulin response (Kaur, 2014). Instead, more insulin is produced (causing a 
state of hyperinsulinaemia) to lower the elevated glucose levels (illustrated in Figure 1.5). 
(Jennings et al., 2009; Sossa et al., 2012; Mendonça et al., 2015). Excessive insulin production 
may eventually impair the pancreatic β-cells to such a degree that an insufficient quantity of 
insulin are secreted, causing a state of hyperglycaemia, clinically diagnosed as T2DM (Jennings 
et al., 2009; Sossa et al., 2012). 
 
 
Figure 1.5: Schematic presentation of the health implications of glucose intolerance and insulin resistance. 
(Adopted from: Kaur, 2014; Mendonça et al., 2015). 
 
Although obesity is not a prerequisite for IR diagnosis, studies have reported positive 
associations between the insulin-resistant state and abdominal obesity (Jennings et al., 2009; 
de Boer et al., 2011; Kaur, 2014). Additionally, several other factors, including geographical 
location of the study population, level of urbanisation, and the criteria used to diagnose IR or the 
MetS may influence the prevalence of IR (Erasmus et al., 2012). Insulin resistance is associated 
with an adverse lipid profile, since studies have reported a positive association between TG 
levels and HOMA-IR, while HDL-c levels were inversely associated with the risk of IR in women 
(Jennings et al., 2009; Sossa et al., 2012; Delisle et al., 2013). Here, IR indirectly elevate TG 
Normal insulin sensitivity: 
Insulin-resistant state: 
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levels by increasing the production and secretion of TG-rich very low density lipoprotein (VLDL) 
particles in the liver and decrease VLDL clearance due to the impaired activity of the lipoprotein 
lipase (LPL) enzyme (Sumner et al., 2005; Ginsberg & Karmally, 2009). 
 
Insulin and the insulin-like growth factor-1  
Insulin share structural homology with insulin-like growth factor-1 (IGF-1), and interacts with the 
same membrane receptors with different affinities (Rajpathak et al., 2012; Ren & Anversa, 
2015). Insulin-like growth factor-1 is an anabolic hormone expressed in nearly all normal cells 
needed for growth and development, although its expression is dependent on age, gender, 
pubertal stage and occurrence of growth disorders, pituitary disease, and malnutrition (Braun et 
al., 2011; Levine & Levine, 2014; Ren & Anversa, 2015). Synthesis of IGF-1 mainly occurs in the 
liver, and to a lesser degree in other tissues including muscle, cartilage, bone, nerves, and skin, 
where production is stimulated by growth hormone (GH) (Westley & May, 2013). The insulin-like 
growth factor binding proteins (IGFBPs) regulate IGF-1 activity (Ren & Anversa, 2015). Free 
IGF-1 (the ligand) binds to the IGF-1 receptor (IGF-1R) and activates the receptor, which in turn 
activates several other metabolic pathways, all of which are regulated by different IGFBPs that 
play a role in the pathogenesis of several diseases (Mendonça et al., 2015; Ren & Anversa, 
2015).  
 
The insulin/IGF-1 pathway play a role in metabolic- and CVD, although the exact relationship 
between IGF-1 and metabolic diseases is still unclear (Ren & Anversa, 2015). Rajpathak et al. 
(2012) found free IGF-1 levels to be positively correlated with BMI and WC, while Friedrich et al. 
(2013) showed that IGF-1 levels were significantly higher in MetS participants. The proposed 
mechanism for this association is that obesity causes an elevation in the quantity of free IGF-1, 
due to its stimulatory effect on adipocyte differentiation (Rajpathak et al., 2012; Westley & May, 
2013). Therefore, an increase in obesity results in an increase in free IGF-1 and a decrease in 
bound total IGF-1. Another proposed mechanism is that IGF-1 levels increase due to increased 
hepatic GH receptor expression, which stimulates hepatic IGF-1 synthesis (Rajpathak et al., 
2012). Evidence suggests that IGF-1 affects glucose homeostasis via increased insulin levels, 
leading to decreased levels of IGFBPs affecting the bioavailability of IGF-1 and increasing free 
IGF-1 levels (Sierra-Johnson et al., 2008; Donohoe et al., 2012; Rajpathak et al., 2012). 
 
On the other hand, Faupel-Badger et al. (2009) found that BMI and W:H were inversely related 
to IGF-1 levels in healthy women. This is possible, since obesity contributes to IR and 
hyperinsulinaemia, which may lead to GH receptor resistance, thereby decreasing IGF-1 levels 
(Westley & May, 2013). Low IGF-1 levels are associated with IR and T2DM, while individuals 
Stellenbosch University  https://scholar.sun.ac.za
  
 
19 
 
with the MetS also presented with significantly lower IGF-1 levels compared to healthy controls 
(Friedrich et al., 2013; Ren & Anversa, 2015). 
 
1.3.5 Dyslipidaemia 
Dyslipidaemia is the most common cause of atherosclerotic CVD, and general characteristics of 
dyslipidaemia include increased TG, VLDL cholesterol (VLDL-c) and small LDL-c, and low HDL-
c levels (summarised in Table 1.4 below) (IDF, 2006; Alberti et al., 2009; Jee & Jo, 2012). 
Increased VLDL-c and LDL-c levels also lead to increased apolipoprotein B (apo B) levels, 
which is directly associated with atherogenic dyslipidaemia (Jee & Jo, 2012). 
 
Table 1.4: Cut-off values for dyslipidaemia. 
 CUT-OFF VALUES 
 Men Women 
HDL-c  <1.03 mmol/L <1.29 mmol/L 
LDL-c  ≥3.00 mmol/L 
TG  ≥1.70 mmol/L 
Total cholesterol  ≥5.00 mmol/L 
(Adopted from: IDF, 2006; Klug et al., 2015). 
 
Several mechanisms exist whereby IR may cause atherogenic dyslipidaemia and CVD (Jee & 
Jo, 2012; Kaur, 2014). Under normal physiologic circumstances, insulin suppresses lipolysis, 
whereas impaired insulin signalling increases lipolysis, thus increasing the free fatty acid (FFA) 
concentration (Kirk & Klein, 2009; Kaur, 2014). These FFAs serve as substrate for the synthesis 
of TGs in the liver (Figure 1.6) (Kaur, 2014). Alternatively, the pathogenesis of dyslipidaemia 
causes an imbalance between the influx and production of FAs, which lead to a non-alcoholic 
fatty liver, and ultimately reduced HDL-c and elevated LDL-c levels (Kirk & Klein, 2009; Shapira, 
2009; O’Neill & O’Driscoll, 2015).  
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Figure 1.6: Pathophysiologic association between insulin resistance and dyslipidaemia. 
(Adapted from: Kirk & Klein, 2009; Jeon et al., 2011; Kaur, 2014; O’Neill & O’Driscoll, 2015). 
 
From this section it is evident that obesity, and all other metabolic-related risk factors of the 
MetS, are all associated with each other, and also exhibit significant health implications. The 
specific link between adipose tissue and metabolic derangements per se, is thought to be 
partially facilitated by adipose tissue-derived adipokines (Shah et al., 2012). 
 
1.3.6 The role of adipokines 
1.3.6.1 Introduction 
Adipose tissue is both metabolically active and exerts an endocrine function (Doyle et al., 2012). 
Factors such as adipose tissue mass and inflammation determine the synthesis and secretion of 
adipokines from VAT (Levine & Levine, 2014; Blüher & Mantzoros, 2015). Excess adipose 
tissue upregulate pro-inflammatory adipokine release, which causes an increased state of low-
grade inflammation, while the anti-inflammatory mechanism is decreased (Donohoe et al., 
2011). Furthermore, changes in adipokine secretion is also associated with IR, and obesity-
related pathologies that contribute to the MetS (Doyle et al., 2012; Shah et al., 2012; Abu-Farha 
et al., 2014). Two of the most prominent adipokines, adiponectin and leptin, are found to be 
implicated in the MetS (Esteghamati et al., 2011; Yun et al., 2011; Cohen et al., 2012; Shah et 
al., 2012; Abu-Farha et al., 2014). 
 
1.3.6.2 Adiponectin 
Adiponectin is almost entirely synthesised by WAT and plays a critical role in lipid- and glucose 
metabolism, enhancing hepatic and skeletal muscle insulin sensitivity, energy homeostasis, and 
act as an insulin-sensitising agent (Abu-Farha et al., 2014). There also appear to be a negative 
↑ risk of the MetS 
Dyslipidaemia 
↑ synthesis of TG, VLDL-c and apo B ↓ breakdown of apo B ↑ HDL-c catabolism 
↑ FFA levels 
↑ lipolysis 
IR and impaired insulin signalling 
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association between adiponectin and percentage body fat, WC and BMI, since a decreased 
secretion of adiponectin by the visceral-omental adipose tissue resulted in an inverse 
association between adiponectin and VAT (Shah et al., 2012; Abu-Farha et al., 2014). Comstock 
et al. (2014) found a significant inverse association between BMI and adiponectin levels. It is 
thus proposed that obesity can reduce adiponectin levels and contribute to IR in this manner, 
whereas higher adiponectin concentrations are associated with insulin sensitivity (Figure 1.7) 
(Braun et al., 2011; Levine & Levine, 2014). Adiponectin levels can also either be positively or 
negatively associated with SBP, HOMA-IR, and HDL-c, TG, FBG levels in the context of the 
MetS (Shah et al., 2012; Abu-Farha et al., 2014; Atanassova et al., 2014). 
 
 
Figure 1.7: The effect of obesity on adiponectin levels that ultimately lead to insulin resistance. 
(Adopted from: Braun et al., 2011). 
 
1.3.6.3 Leptin 
Leptin is produced by WAT, epithelial cells of the stomach, bone marrow, pituitary, liver, and 
skeletal muscle. Furthermore, leptin functions to control eating behaviour, energy expenditure 
and balance, body weight, and plays a role in the immune and reproductive systems (Deng & 
Scherer, 2010; Braun et al., 2011; Kaur, 2014).  
 
Although several factors are known to affect leptin levels, not all studies are in agreement. Ganji 
et al. (2009) found no significant association between ethnicity and leptin levels, while a study by 
Cohen et al. (2012) reported leptin levels to be significantly higher in Black women. These ethnic 
differences in leptin levels may possibly reflect physiological and/or genetic differences in leptin 
production in adipose tissue (Cohen et al., 2012). Obesity also influences leptin levels. Here, 
positive relationships were established between leptin levels and BMI, WC, total adipose tissue 
mass, percentage body fat, and regional adiposity (Yun et al., 2011; Chiu et al., 2012; Cohen et 
al., 2012; Shah et al., 2012; Nakamura et al., 2013; Abu-Farha et al., 2014; Motie et al., 2014; 
de Castro et al., 2015; García-Jiménez et al., 2015). It was proposed that leptin contributes to 
body weight, and hence differences in leptin levels with increasing BMI are anticipated (Deng & 
Scherer, 2010; Kaur, 2014). Apart from increasing leptin levels in these states, a state of leptin 
resistance with concomitant impaired leptin- and insulin signalling follows, which diminishes the 
effects of leptin on appetite regulation, energy expenditure, and body weight (Figure 1.8) (Deng 
Obesity 
↓ adiponectin 
levels 
↓ insulin  
sensitivity 
IR 
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& Scherer, 2010; Kaur, 2014; García-Jiménez et al., 2015). Impaired leptin- and insulin 
signalling associated with the leptin-resistant state worsens the pro-oxidant and inflammatory 
state, further contributing to the development of IR, and obesity-related hypertension (García-
Jiménez et al., 2015). 
 
 
Figure 1.8: The relationship between obesity, leptin, and cardiovascular disease. 
(Adapted from: Deng & Scherer, 2010; Kaur, 2014). 
 
Leptin concentration is associated with various individual components of the MetS and are 
elevated specifically in people with the MetS (Esteghamati et al., 2011; Chiu et al., 2012; Shah 
et al., 2012; Abu-Farha et al., 2014; García-Jiménez et al., 2015). Studies have also reported 
positive associations between hypertension and elevated leptin levels in women with and 
without the MetS (Yun et al., 2011; Cohen et al., 2012; Kaur, 2014). Elevated leptin levels were 
also found to be significantly associated with elevated HOMA-IR, FBG and insulin levels, and 
T2DM (Ganji et al., 2009; Yun et al., 2011; Chiu et al., 2012; Cohen et al., 2012; Shah et al., 
2012; Atanassova et al., 2014; Abu-Farha et al., 2014).  
 
Elevations in leptin concentration are significantly associated with hypercholesterolaemia, 
hypertriglyceridaemia, elevated LDL-c, and reduced HDL-c levels (Yun et al., 2011; Chiu et al., 
2012; Cohen et al., 2012; Shah et al., 2012). Leptin therefore plays an important role in 
facilitating energy homeostasis, and disruptions in leptin secretion may thus cause lipid 
changes, which could also result in FA profile alterations (Kawashima et al., 2009). The FA 
profile is also affected by dietary intake and lipid metabolism, including lipolysis and de novo 
lipogenesis, which influences the physiological components related to the MetS (Hlavaty et al., 
2015).  
↑ risk of: 
IR Obesity-associated hypertension MetS CVD 
Leptin deficiency 
Failure to reduce appetite Failure to increase energy expenditure 
Impaired leptin- and insulin signalling 
Leptin resistance 
Obesity and ↑ leptin levels 
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1.4  FATTY ACIDS 
1.4.1 Introduction 
Fatty acids belong to a class of aliphatic monocarboxylic acids that have several functions, 
including; i) forming the basic building blocks of phospholipids and glycolipids found within the 
human body, ii) attachment to proteins to assist in directing these molecules to the correct place 
in the cell membrane, iii) storage as TGs, and iv) messenger molecules that act on the 
pancreatic β-cells to regulate glucose-stimulated insulin secretion (Horton et al., 2006; Batchu et 
al., 2009; Suburu et al., 2013).  
 
Humans acquire FAs by de novo lipogenesis from carbohydrates or proteins, or from dietary 
sources (Zong et al., 2012; Suburu et al., 2013). Regulation of FA metabolism is critical to 
maintain homeostasis, since changes in FA metabolism can lead to lifestyle-associated 
metabolic diseases (Zong et al., 2012; Suburu et al., 2013).  
 
1.4.2 Basic physiology of fatty acids 
The major biological role of fat is to store energy from carbohydrate-derived carbon precursors 
as compact FAs (Vessby et al., 2002; Suburu et al., 2013). De novo lipogenesis occurs in the 
FA synthesis pathway to produce saturated short-, and then medium chain FAs (Goodridge & 
Sul, 2009). Elongation and desaturation enzymes can further modify and esterify these FAs, and 
convert these to TG molecules to be stored (Vessby et al., 2002; Goodridge & Sul, 2009; Zong 
et al., 2012). De novo synthesised FAs can immediately be used as energy inside the cell, 
whereas dietary FAs require enzymes, transporters, and chaperone proteins to facilitate their 
absorption, transport, and uptake into cells (Suburu et al., 2013).  
 
Dietary FAs must be absorbed from the small intestine, transported as lipoprotein particles, and 
then enter the circulation via the lymphatic system (Suburu et al., 2013). Once the lipoprotein 
particles bind to their respective receptors, the activity of the LPL enzyme releases the FAs (now 
FFAs), which is followed by cellular uptake (Horton et al., 2006; Hodson et al., 2008). Elongation 
and desaturation enzymes can modify these FFAs, similar to the FFAs synthesised by de novo 
lipogenesis (Suburu et al., 2013). Figure 1.9 illustrates the de novo lipogenesis of FAs and 
metabolism of dietary FAs. Fatty acid composition affects membrane properties, metabolic 
signalling, and energy expenditure, all of which are modulated by FA chain length and degree of 
saturation (Vessby et al., 2002; Horton et al., 2006). The desaturase enzymes catalyse 
desaturation of FAs, although these enzymes have different affinities for different FAs (Zong et 
al., 2012). This desaturation process is dependent on the competition between substrates, and 
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product inhibition (Jackson et al., 1997; Vessby et al., 2002). Hence, the effectiveness of 
desaturation is not only dependent on the specific FAs, but the content of the other FAs 
competing for the desaturation enzyme also plays a role (Vessby et al., 2002; Goodridge & Sul, 
2009). The following section presents the different types of FAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Basic fatty acid physiology illustrated for de novo lipogenesis and dietary fatty acids. 
(Adapted from: Vessby et al., 2002; Goodridge & Sul, 2009; Zong et al., 2012; Suburu et al., 2013). 
 
1.4.3 Different types of fatty acids 
The different FAs are functionally divided into short-, medium- and long chain FAs according to 
the number of carbons in the chemical structure (Bahrami, 2009). Saturated and unsaturated 
FAs constitute the two major FA types (Gillingham et al., 2011; Hussein, 2013). Sources of 
unsaturated FAs include vegetable oils, whereas SFAs are more common in animal sources 
(Shapira, 2009). Saturated FAs contain hydrocarbons without double bonds, whereas 
unsaturated FAs have double bonds (Anderson & Ma, 2009). Unsaturated fats are subdivided 
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further into MUFAs and PUFAs, where the former has one double bond, and the latter at least 
two double bonds (Anderson & Ma, 2009; Hussein, 2013). Polyunsaturated FAs can further be 
subdivided into Ω-3 (also n-3), Ω-6 (also n-6), and Ω-9 (also n-9), depending on the position of 
the first double bond (Anderson & Ma, 2009; Gillingham et al., 2011; Hussein, 2013). Figure 
1.10 summarises the different FA classes: 
 
Figure 1.10: Classification of the different fatty acids. 
(Adapted from: Anderson & Ma, 2009; Gillingham et al., 2011; Hussein, 2013). 
 
The two enzyme precursors that are needed to synthesise Ω-3 and Ω-6 FAs, elongase and 
desaturase, are not made in humans, which necessitates these essential FAs to be included in 
the diet (Spector, 2000; Hussein, 2013). Both the degree of saturation and the carbon chain 
length of the FA affect its biological function (Suburu et al., 2013); however, several other factors 
may also influence FA levels. Accurate assessment of FA concentrations in different types of 
tissue, as well as in blood is imperative, since there is a clear relationship between FA, 
metabolic parameters, and the risk of NCDs (Harris, 2009). 
 
1.4.4 Fatty acid assessment methods 
1.4.4.1 Introduction 
Most of the detection methods used to quantify FAs are done to also investigate relationships 
between other clinical and biochemical parameters. Other, indirect methods rely on dietary 
assessment methods, which, in conjunction with biochemical analysis, prove to be more useful 
than a single method (Hodson et al., 2008; Patel et al., 2010; Serra-Majem et al., 2012; Hussein, 
2013; Cottet et al., 2015). The distribution of FAs varies greatly between the different tissues 
and this reflects metabolic changes and physiological functions (Baylin et al., 2005). 
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1.4.4.2 Plasma fatty acids 
Fatty acids are released from adipose tissue and transported in the plasma after complexing 
with albumin (Hodson et al., 2008). The use of blood plasma to determine FA composition is a 
convenient and easy method; however, it only reflects lipid levels several days after a meal 
(Vessby et al., 2002; Hodson et al., 2008; Patel et al., 2010; Serra-Majem et al., 2012). Studies 
have shown that plasma FA composition corresponds with adipose tissue FAs, specifically for 
the PUFAs and MUFAs (Baylin et al., 2005; Hodson et al., 2008), while others reported that 
plasma FA levels are more comparable to red blood cell (RBC) membrane FA composition (Sun 
et al., 2007; Patel et al., 2010; Sertoglu et al., 2014). Although plasma FAs are a potential 
surrogate marker of tissue FAs, sampling should occur in the post-absorptive state, since recent 
dietary intake affect plasma FA levels (Hodson et al., 2008).  
 
1.4.4.3 Red blood cell membrane fatty acids 
Biological membranes consist of FAs, which play a role in the fluidity and integrity of the 
membrane, and activity of the membrane-associated enzymes (Spector, 2000; Suburu et al., 
2013; Zhang et al., 2014). The FA composition of the RBC membrane is mainly regulated by 
endogenous FA synthesis, since these membranes lack de novo FA synthesis, and changes 
because of desaturation or elongation (Spector, 2000; Mahendran et al., 2014). Various studies 
have shown that the RBC membrane FAs, which are unaffected by dietary fat intake, reflect 
medium-term (±120 days) tissue FAs, and are therefore regarded as a better measure than 
plasma FAs due to the longer lifespan of the RBCs (Jackson et al., 1997; Patel et al., 2010; 
Serra-Majem et al., 2012). 
 
The RBC membrane FAs are measured after complex lipid extraction, methylation, and 
separation, followed by quantification, or qualification with gas chromatography (GC) (Jackson 
et al., 1997; Zhang et al., 2012b). Although the assessment of FAs in RBC membranes is 
considered superior to that measured in plasma, the assessment of FAs in adipose tissue 
samples is generally considered the gold standard (Vessby et al., 2002; Patel et al., 2010). 
 
1.4.4.4 Tissue fatty acids 
Adipose tissue biopsies reflect FA levels of the preceding months; however, this method is not 
often used in epidemiological studies due to its invasiveness (Vessby et al., 2002; Patel et al., 
2010). Subcutaneous adipose tissue is generally taken from the buttocks or abdomen, with 
small significant differences in the SAT FA content observed between these different sites, due 
to greater and lesser proportions of SFAs and MUFAs present in the abdomen respectively 
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(Byers & Gieseker, 1997; Hodson et al., 2008). Although tissue FAs is representative of long-
term (six to 18 months) FA levels, it is still unclear whether adipocyte size or changes in adipose 
function will affect FA levels in tissue (Hodson et al., 2008). The FA profile is used to assess the 
risk of metabolic disease using individual FAs and ratios of specific FAs (Lemaitre et al., 2009; 
Lv & Yang, 2012; Novgorodtseva et al., 2013; Jurczyszyn et al., 2014; Sertoglu et al., 2014), 
which is the focus of the next section. 
 
1.4.5 Fatty acid indices 
There appears to be a linear relationship between FA concentrations in the blood, and FA 
metabolism, with some individual FAs implicated in certain disease states (Harris, 2009). 
Different FAs function relative to each other and homeostasis between these FAs is crucial for 
good health (Jackson et al., 1997). Several FA indices have been identified as possible 
predictors for different diseases, including the Ω-3 index, Ω-3 to Ω-6 ratio (Ω-3:Ω-6), n-9 
saturation index (SI), and the stearoyl-CoA desaturase (SCD) enzymes (Jackson et al., 1997; 
Harris, 2009). 
 
1.4.5.1 Omega-3 index 
The Ω-3 index assesses the risk of CVD, dementia, and Alzheimer’s disease, and is calculated 
as the percentage of eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 
22:6n-3) of the total RBC membrane FAs (Lemaitre et al., 2002; Harris, 2009; Witte et al., 2014). 
An Ω-3 index of four percent or less is considered high risk for disease, while values greater 
than eight percent are indicative of a low disease risk (summarised in Table 1.5) (Harris, 2009; 
von Schacky, 2011). 
 
Table 1.5. The risk of disease associated with the omega-3 index. 
OMEGA-3 INDEX RISK FOR DISEASE 
≤4.00 % High 
4.10-8.00 % Intermediate 
≥8.10 % Low 
(Adopted from: Harris, 2009; von Schacky, 2011). 
 
A study by Howe et al. (2014) found that the Ω-3 index is inversely associated with certain 
measures of adiposity, such as BMI and WC. A possible mechanism for the beneficial effects is 
that the Ω-3 PUFAs mediate insulin and carbohydrate control of lipogenic and glycolytic genes 
that promote fat oxidation and inhibit fat storage (Clarke et al., 2001). Furthermore, the Ω-3 
index is not affected by either the fed or the fasted state, although diet, age, BMI, gender, 
alcohol consumption, and Ω-6 FAs seem to play a role (von Schacky, 2011). 
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1.4.5.2 Omega-3 to omega-6 ratio 
The Ω-3:Ω-6 is another clinically significant FA ratio which estimates the proportions of the Ω-3 
FAs (EPA and DHA) to the Ω-6 FAs (linolenic acid (LA, 18:2n-6) and arachidonic acid (AA 
(20:4n-6)) (Odegaard, 2009). Functions of the Ω-6 FAs include its pro-inflammatory effects, the 
synthesis of lipid mediators, and its role in the production of cell membranes (Spector, 2000; 
Strandvik, 2011; Hussein, 2013; Suburu et al., 2013). High Ω-6 levels may attenuate the 
beneficial effects of Ω-3 FAs, and for this reason the Ω-3:Ω-6 was established to determine 
chronic health implications (Shapira et al., 2009). Clinically, the Ω-3:Ω-6 is considered important 
because the different FAs compete for the same elongase and desaturase enzymes in different 
metabolic pathways to affect cellular responses (Odegaard, 2009; Strandvik, 2011). For 
example, AA (Ω-6) competes with EPA and DHA (Ω-3) for enzymes and space in the cell 
membrane (Hussein, 2013). 
 
Unlike Ω-3 and Ω-6 FAs, the Ω-9 FAs are not considered essential FAs because the human 
body can produce these FAs from unsaturated FAs. However, the Ω-9 FAs, in particular the n-9 
SI and the SCD (Δ-9) enzymes play important roles in certain disease states (Jackson et al., 
1997; Kawashima et al., 2009; Shannon et al., 2010; Pouchieu et al., 2014). 
 
1.4.5.3 n-9 saturation index 
The “saturation index” is a substrate-to-product ratio, and refers to the ratio of SFAs to MUFAs, 
(Chajès et al., 2011). The n-9 SI is calculated as the ratio of stearic acid (SA, 18:0) to oleic acid 
(OA, 18:1n-9), and this is regarded as a measure of cancer risk, since cancer patients present 
with significantly lower values (Jackson et al., 1997; Shannon et al., 2010). An n-9 SI value 
between 0.7 and 1.0 is suggestive of cancer, whereas values below 0.7 are considered a 
marker of cancer (see Table 1.6) (Jackson et al., 1997). 
 
Table 1.6: The n-9 saturation index and associated cancer risk. 
n-9 SI CANCER RISK 
0.70-1.00  Suggestive of cancer 
<0.70 Marker of cancer 
(Adopted from: Jackson et al., 1997). 
 
The concept behind this index is to compare the ratio of SA, the most common SFA, with OA, 
the most common MUFA (Chajès et al., 2011). In cancer cases, SA levels are significantly 
lower, while OA levels are higher, possibly due to increased lipid peroxidation, and it is proposed 
that SA is directly involved in inhibition of tumour development (Chajès et al., 1999; Pandey et 
al., 2003). 
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1.4.5.4 Stearoyl-CoA desaturase enzymes 
The SCD enzymes are responsible for the desaturation of FAs, e.g. palmitic acid (PA, 16:0) to 
palmitoleic acid (PLA, 16:1n-7), and SA (18:0) to OA (18:1n-9), which are produced as a result 
of de novo lipogenesis (Hodson et al., 2008; Zong et al., 2012). The Δ-9 SCD 1 and -2 enzymes 
mediate lipogenesis for the conversion of SFAs to MUFAs (Hodson et al., 2008; Kawashima et 
al., 2009; Patel et al., 2010; Zong et al., 2012; Kim et al., 2013). The conversion of PA (a SFA) 
to PLA (a MUFA) to OA (a MUFA) occurs with the aid of the Δ-9 SCD 1 enzyme, whereas the Δ-
9 SCD 2 enzyme catalyses the conversion of SA to OA (Vessby et al., 2002; Goodridge & Sul, 
2009). Figure 1.11 illustrates the effects of the desaturation enzymes. 
 
 
 
 
 
 
 
Figure 1.11: Conversion of saturated to monounsaturated fatty acids with the aid of the delta-9 SCD 1 and -2 
and elongation enzymes. 
(Adapted from: Vessby et al., 2002; Goodridge & Sul, 2009). 
 
Studies investigating desaturase activities generally report estimated desaturase activity values, 
rather than actual values, because direct measurement is a complex process (Kawashima et al., 
2009; Patel et al., 2010). Therefore, indices of the different FAs are used as surrogate markers 
of enzyme activity (Patel et al., 2010; Shannon et al., 2010). It was shown that changes in SCD 
expression is related to concurrent changes in tissue FA levels, with these indices being 
calculated as the product-to-precursor ratio (Table 1.7) (Hodson et al., 2008; Warensjӧ et al., 
2008). 
 
Table 1.7: Calculation of the different desaturase enzymes using product-to-precursor ratios. 
DESATURATION ENZYMES 
PRECURSOR 
(SFA) 
PRODUCT 
(MUFA) 
RATIO 
(product ÷ precursor) 
Δ-9 SCD 1 16:0 16:1n-7 (16:1n-7) ÷ (16:0) 
Δ-9 SCD 2 18:0 18:1n-9 (18:1n-9) ÷ (18:0) 
(Adapted from: Warensjӧ et al., 2008; Patel et al., 2010). 
 
Changes in these indices have been associated with several metabolic alterations, including 
alterations in body fat, insulin sensitivity, the MetS, and cancer (Warensjӧ et al., 2008; 
Kawashima et al., 2009; Patel et al., 2010; Pouchieu et al., 2014). A possible explanation for this 
association is that SCD activity may influence FA metabolism by promoting MUFA synthesis and 
SFA: MUFA: 
16:0 
(PA) 
Δ-9 SCD 1 
16:1n-7 
(PLA) 
18:0 
(SA) 
Δ-9 SCD 2 
18:1n-9 
(OA) 
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decreasing FA oxidation (Chajès et al., 2011). Monounsaturated FAs serve as mediators of cell 
differentiation, and ultimately an imbalance of these mediators can promote carcinogenesis 
(Chajès et al., 2011). Lifestyle- (such as smoking and diet) and metabolic factors (obesity, BP, 
IR, and dyslipidaemia) may also have a negative impact on Δ-9 SCD activity. 
 
1.4.6 Factors influencing fatty acid levels 
1.4.6.1 Smoking status 
Several studies reported on the negative impact of smoking status on FA levels – Hodson et al. 
(2008) reported significantly higher PLA and OA levels in smokers compared to non-smokers, 
and hypothesised that smoking alters the conversion of MUFAs to SFAs in blood lipids, thereby 
negatively affecting FA catabolism. Smokers have lower levels of Ω-3 PUFAs compared to non-
smokers (Hodson et al., 2008; Mozaffarian et al., 2010; Chiuve et al., 2012). Furthermore, 
smoking increases the conversion of the Ω-3 FA EPA to docosapentaenoic acid (DPA, 22:5n-3) 
(Hodson et al., 2008). Harris et al. (2012) also suggested that the lower Ω-3 FA levels noted in 
smokers might be due to the oxidative destruction of the highly unsaturated FAs and/or 
alterations in Ω-3 metabolism. 
 
1.4.6.2 Diet 
Dietary intake is a major environmental determinant of the MetS (Grosso et al., 2015). A 
Westernised diet is mostly associated with energy-dense processed products, snack foods, and 
fast and convenient meals (Feeley et al., 2012; Steyn et al., 2013; Bosu, 2014). Additionally, 
there is an increased consumption of red and processed meat, saturated and trans-fats, and 
decreased intake of fruit and vegetables, dietary fibre, and plant protein (Abrahams et al., 2011; 
Steyn et al., 2012; Dolman et al., 2013; Shab-Bidar et al., 2014). Studies have also reported 
significant positive associations between the consumption of different FAs and components of 
the MetS. For example, a high SFA intake is associated with obesity, reduced glucose 
metabolism and insulin sensitivity, IR, and elevated LDL-c levels (Anderson & Ma, 2009; de 
Oliveira et al., 2012; Nettleton et al., 2014; Shab-Bidar et al., 2014). 
 
Contrasting to the Westernised diet, the Mediterranean diet, rich in fruits and vegetables, whole 
grains and fish, and low in red meat and dairy products, which may reduce the risk of the MetS 
(Gotsis et al., 2014; Grosso et al., 2015). The health benefits associated with the Mediterranean 
diet depend on the high intake of antioxidants, PUFAs and MUFAs, and low intake of SFAs and 
trans-FAs (Grosso et al., 2015). Poly- and monounsaturated FA consumption is associated with 
a reduced risk of developing the MetS, since it improves insulin sensitivity, and reduces BP and 
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LDL-c levels (Anderson & Ma, 2009; Nettleton et al., 2014; Shab-Bidar et al., 2014). High intake 
of SFAs upregulates desaturase activities thereby increasing MUFA levels, whereas PUFA 
intake is negatively associated with desaturase activities (Kawashima et al., 2009; Bjermo & 
Risérus, 2010). Elevated de novo lipogenesis results in hypertriglyceridaemia, IR and obesity; a 
finding that is supported by significantly higher de novo lipogenesis in MetS participants 
compared to healthy controls (Zong et al., 2013). 
 
1.4.6.3 Metabolic syndrome risk factors 
Changes in FA metabolism could possibly explain the link between visceral adiposity and 
metabolic dysfunction (Žák et al., 2014). Studies have shown that the concentrations of some 
FAs differed significantly between individuals with the MetS and healthy controls. Here, SFA and 
MUFA levels were significantly higher, and PUFA levels significantly lower in MetS participants 
(Kabagambe et al., 2008; Kawashima et al., 2009; Novgorodtseva et al., 2011; Zhang et al., 
2012a; Zong et al., 2013; Žák et al., 2014).  
 
Since elevated levels of some FAs, including PA, PLA, and SA are associated with the number 
of MetS risk factors, it is anticipated that the different types of FAs will have diverse effects on 
the individual components of the MetS. For example, obesity contributes to changes in the FA 
profile, since overweight MetS participants presented with significantly higher SFA levels 
compared with normal weight counterparts (Klein-Platat et al., 2005). Additionally, PLA levels 
were also positively associated with increased BMI and WC (Zong et al., 2012). This notion is 
supported by the positive association between obesity and SCD activity, which is involved in the 
de novo synthesis of MUFAs from SFAs (Klein-Platat et al., 2005; Warensjӧ et al., 2005; Hlavaty 
et al., 2015). Compared to normal weight persons, PUFA levels were significantly lower in 
overweight persons (Klein-Platat et al., 2005). It is suggested that the Ω-3 FAs have beneficial 
effects on preventing and improving obesity by increasing FA β-oxidation, which reduces fat 
mass and body weight (Klein-Platat et al., 2005; Kawashima et al., 2009). 
 
Studies have also reported that different FAs have opposing effects on BP, since BP was 
positively associated with elevated MUFA levels, and negatively with PUFA levels (Zhang et al., 
2012a; Zong et al., 2012; Kim et al., 2013). Kim et al. (2013) suggested then that the MetS-
associated impaired FA metabolism, accelerates arterial stiffness, and this contributes to 
hypertension. Glucose intolerance and IR have also been shown to affect the FA profile, since 
OA and PLA levels were significantly associated with glycaemic status, while elevated Δ-9 SCD 
1 activity was associated with IR (Bjermo & Risérus, 2010; Kurotani et al., 2012; Cho et al., 
2014). This is possible since Δ-9 SCD activity is the rate-limiting enzyme for conversion of SFAs 
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to MUFAs, and this suggests that the Δ-9 SCD is protective against lipotoxicity caused by 
elevated SFA levels (Cho et al., 2014). The association between Ω-3 FAs and insulin sensitivity 
remain unclear, since some found no clear association, whereas others found either inverse or 
positive associations (Sethom et al., 2011; Kurotani et al., 2012; Mirmiran et al., 2012; Vanhala 
et al., 2012; Mayneris-Perxachs et al., 2014). 
 
A positive relationship was also established between elevated cholesterol levels and PA and 
PLA levels, and Δ-9 SCD activity (Zong et al., 2012; Hlavaty et al., 2015). Additionally, 
hypertriglyceridaemia was thought to be the major link between FAs and the risk of the MetS, 
since de novo lipogenesis produce MUFAs, which are crucial substrates for TG synthesis (Zong 
et al., 2013). In contrast to the SFAs and MUFAs, PUFA levels are associated with HDL-c 
levels, while a negative association was reported for TG levels (Mirmiran et al., 2012; Vanhala et 
al., 2012). This is possible since Ω-3 FAs have a beneficial effect on lipoprotein profiles through 
the promotion of FA β-oxidation, which reduces the synthesis of TGs in the liver (Kawashima et 
al., 2012). 
 
1.5  THE ASSOCIATION BETWEEN THE METABOLIC SYNDROME AND FATTY 
ACIDS 
1.5.1 Introduction 
The dysregulation of FA metabolism has been linked to several metabolic alterations 
(Kabagambe et al., 2008; Patel et al., 2010; Novgordtseva et al., 2011; Žák et al., 2014). When 
investigating individual SFA levels of MetS and non-MetS individuals, PA and SA levels were 
significantly higher in the former group (Nigam et al., 2009; Tremblay-Franco et al., 2015). 
Sethom et al. (2011) found similar results for PA levels in the MetS group; however, contrasting 
results were reported for SA levels. Neither Novgorodtseva et al. (2011), nor Žák et al. (2014) 
observed any significant difference in PA levels in the MetS and the non-MetS participants, 
although SA levels were significantly higher in the MetS groups. Reasons for these 
discrepancies may include the added effects of chronic diseases, since participants suffering 
from chronic diseases were included in the sample population, and these studies used different 
definitions of the MetS. The studies by Nigam et al. (2009) and Tremblay-Franco et al. (2015) 
used fasting plasma samples, adding to the possible contrasting results, since plasma FA levels 
reflect short-term FA intake (Patel et al., 2010; Serra-Majem et al., 2012). Although all of these 
studies used GC to determine FA levels, different methods were used to identify the individual 
FAs. For example, Sethom et al. (2011) used an internal standard, while studies by 
Novgorodtseva et al. (2011) and Tremblay-Franco et al. (2015) used different methylated FA 
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standards and controls for FA identification, and these different methods may explain the 
contrasting results. 
 
Contrasting results have also been reported for both PLA and OA levels. Novgorodtseva et al. 
(2011) found PLA levels to be significantly lower in a MetS group, whilst others reported PLA 
levels to be significantly elevated (Nigam et al., 2009; Sethom et al., 2011; Žák et al., 2014). The 
altered FA profile in MetS subjects might be related to both metabolic- and dietary changes, 
since Nigam et al. (2009) reported a positive association between PA levels and IR, suggesting 
that impaired insulin sensitivity was associated with increased Δ-9 SCD 1 activity. Mayneris-
Perxachs et al. (2014) also noted significant positive associations between PA levels and the 
individual components of the MetS, including WC, TG and glucose levels, and suggested that 
individuals with the MetS have significantly higher SFA levels, that triggers higher Δ-9 SCD 1 
activity that may lead to significantly higher PLA levels. Furthermore, lifestyle factors such as 
physical inactivity and dietary intake that promote obesity, may affect Δ-9 SCD 1 enzyme 
activity, since obesity is associated with reduced FA oxidation (Warensjӧ et al., 2005; Sethom et 
al., 2011).  
 
Studies by Nigam et al. (2009) and Žák et al. (2014) found that OA levels did not differ; however, 
Sethom et al. (2011) found that OA levels were significantly higher in the MetS group. Glucose 
is an activator of the Δ-9 SCD 2 enzyme that is needed for the conversion of SA to OA (Vessby 
et al., 2002). A significant difference in OA levels can be explained by the higher FBG levels; 
therefore, increased Δ-9 SCD 2 enzyme activity, and increased OA levels in the MetS group in 
the study by Sethom et al. (2011). Furthermore, the study by Nigam et al. (2009) included 
participants with chronic diseases and medications, which could also play a role in the 
contrasting findings. 
 
Sethom et al. (2011) reported significantly higher Δ-9 SCD 2 activity in participants with the 
MetS, but a more recent study by Mayneris-Perxachs et al. (2014) found that the Δ-9 SCD 2 
was significantly lower. Contrasting to others, Žák et al. (2014) reported no significant difference 
in Δ-9 SCD 2 activity of MetS and non-MetS participants. These studies however differed on 
several levels, including study design, inclusion and exclusion criteria, as well as the use of 
different MetS definitions. 
 
Elevated total PUFA levels were significantly associated with a reduced risk of the MetS 
(Mayneris-Perxachs et al., 2014). Although some studies did not report any significant 
differences between α-linolenic acid (α-LA, 18:3n-3) or DPA levels of persons with and without 
the MetS (Nigam et al., 2009; Sethom et al., 2011; Žák et al., 2014), Cespedes et al. (2015) 
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found that α-LA levels in individuals with the MetS were significantly lower. Also, even though 
both the studies by Nigam et al. (2009) and Cespedes et al. (2015) used the ATP III to diagnose 
the MetS, contrasting results were obtained, while Sethom et al. (2011) and Žák et al. (2014) 
obtained similar results using the IDF definition. Interestingly, the study by Sethom et al. (2011) 
used plasma samples, whereas Cespedes et al. (2015) used SAT biopsies with similar 
outcomes. The SAT represents the long-term integrated measure of exposure to FA dietary 
intake, and desaturation and elongation (Cespedes et al., 2015). 
 
Omega-3 FA levels also differed between the MetS and non-MetS groups. Nigam et al. (2009) 
and Zhang et al. (2012a) found that EPA and DHA levels of individuals with the MetS were 
significantly lower compared to healthy controls. Although Sethom et al. (2011) did not find any 
significant differences for EPA levels; DHA levels were significantly lower as compared to the 
results of Nigam et al. (2009). Here, the different findings between these two studies may be 
ascribed to the inclusion of individuals with history of acute myocardial infarction. Differences in 
the Ω-3 FA levels of persons with the MetS consequentially led to a significant difference in the 
Ω-3 index between the MetS and non-MetS groups, where the MetS group presented with a 
significantly lower Ω-3 index compared to controls (Nigam et al., 2009). 
 
Referring to the Ω-6 FAs, no significant differences were noted between the AA levels of 
persons with and without the MetS (Nigam et al., 2009; Žák et al., 2014); however, studies by 
Sethom et al. (2011) and Novgorodtseva et al. (2011) both reported that AA levels were 
significantly lower. Omega-3 and Ω-6 FA levels were lower and higher respectively, and this 
resulted in a significantly lower Ω-3:Ω-6 in the MetS compared to the non-MetS group (Nigam et 
al., 2009; Sethom et al., 2011). Even though differences in FA levels were observed between 
the MetS and non-MetS groups, it is not known whether one or more of the MetS risk factors are 
responsible for these differences. The individual components of the MetS and its effects on FA 
levels will be discussed in the following sections. 
 
1.5.2 Metabolic syndrome risk factor effects on fatty acids 
1.5.2.1 Obesity 
Fatty acids are considered major physiological role players in obesity and IR (Boden, 2009). 
Adipose tissue stores excess calories as TG to maintain glucose- and lipid homeostasis 
(Tuvdendorj et al., 2013). Obesity stimulates lipolysis resulting in mobilising FFAs into circulation 
(Boden, 2009; Mendonça et al., 2015). The elevated FFAs lead to an increase in 
gluconeogenesis, TGs, and VLDL-c (illustrated in Figure 1.12) (Boden, 2009; Mendonça et al., 
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2015). Additionally, the FFAs affect insulin sensitivity that inhibit glucose uptake and result in 
increased insulin secretion, causing a state of hyperinsulinaemia that ultimately leads to IR 
(Boden, 2009; Mendonça et al., 2015). 
 
 
Figure 1.12: Health implications of obesity on dyslipidaemia and hyperinsulinaemia. 
(Adapted from: Boden, 2009; Mendonça et al., 2015). 
 
There are distinct differences in the FA composition of normal weight, overweight, and obese 
individuals with and without the MetS. It was reported that FA levels in obese persons were 
significantly higher than those of normal weight individuals (Klein-Platat et al., 2005; Jeon et al., 
2011). Studies by Klein-Platat et al. (2005) and Tremblay-Franco et al. (2015) specifically 
investigated these differences and found that MetS obese people presented with higher levels of 
SA and PA compared to non-MetS obese and normal weight participants. Although no 
significant differences were reported for OA levels, the results also pointed to distinct differences 
in the activity of the Δ-9 SCD 1 and -2 enzymes between these groups, since the activity of the 
Δ-9 SCD 1 enzyme increased, while that of the Δ-9 SCD 2 decreased (Tremblay-Franco et al., 
2015). A positive association was also reported between Δ-9 SCD activity and WC, which is 
suggestive of reduced FA oxidation and increased de novo lipogenesis, which may be related to 
the development of non-alcoholic fatty liver disease (Kawashima et al., 2009; Vinknes et al., 
2013; Tremblay-Franco et al., 2015). Visceral obesity is associated with increased lipolytic 
activity, increased hepatic FA uptake, and reduced FA oxidation, which lead to hepatosteatosis 
(Golbidi et al., 2012). Additionally, elevated SFA levels also induce hepatosteatosis, which is 
also directly associated with IR and non-alcoholic fatty liver disease (Golbidi et al., 2012; Vessby 
et al., 2012). 
 
This is in contrast to the beneficial effects of the Ω-3 FAs on obesity, since these FAs increase 
FA oxidation to lower body weight (Kawashima et al., 2009). However, DPA, DHA, and EPA 
levels did not differ between normal weight and obese persons with or without the MetS, while 
AA levels were significantly lower in normal weight compared to obese persons without the 
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MetS (Tremblay-Franco et al., 2015). Different FAs have been associated with measures of 
obesity, since Kabagambe et al. (2008) found that BMI and WC were positively correlated with 
SFA and Ω-6 levels, and negatively correlated with MUFA and Ω-3 levels, as well as the Ω-3 
index in participants with the MetS. Polyunsaturated FAs have been shown to contribute to the 
regulation of lipogenesis and fat oxidation, and can contribute to obesity and the MetS in this 
manner (Kabagambe et al., 2008). 
 
Additionally, a reduced capacity of adipose tissue to store TGs can lead to a flux of FFAs to 
other tissues, which promote the redistribution of fat (Tuvdendorj et al., 2013). Increasing 
subcutaneous adipocyte size is associated with adipocyte IR and hypertrophy, which cause 
increased lipolysis, and reduced TG storage in SAT (Tuvdendorj et al., 2013; Heemskerk et al., 
2015). Upper body SAT accounts for the majority of FFAs that are released into systemic 
circulation, despite VAT expansion, a mechanism which is referred to as the “FA theory” 
(Grundy, 2015). The quantity and the type of FAs released play an important role in the 
pathophysiology of obesity (Heemskerk et al., 2015). Subcutaneous adipose tissue of obese 
women contained significantly higher levels of EPA, DPA, and DHA compared to controls, 
possibly to reduce obesity-associated inflammation, since Ω-3 FAs have anti-inflammatory 
properties (Heemskerk et al., 2015). 
 
Fatty acids have also been shown to interfere with BP, since both the Ω-3 PUFAs, EPA and 
DHA, are known precursors of lipoxins, resolvins and protectins, which are all involved in the 
regulation of vascular tone and BP (Kabagambe et al., 2008; Novgordtseva et al., 2011; Sethom 
et al., 2011). 
 
1.5.2.2 Hypertension 
Different studies have shown that PUFA levels were negatively correlated with SBP and DBP, 
whereas Ω-3 FAs were shown to exert beneficial effects on BP per se (Kabagambe et al., 2008; 
Sethom et al., 2011; Cabo et al., 2012). Following desaturation and elongation, α-LA is 
converted to EPA, which is a precursor of three series of prostaglandins and five series of 
leukotrienes, which have been shown to play a role in mediating vasoconstriction (Spector, 
2000; Cabo et al., 2012). Next, EPA is elongated and desaturated to DHA (Cabo et al., 2012). 
Figure 1.13 illustrates the metabolism of Ω-3 and -6 PUFAs, and its relation to BP. 
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Figure 1.13: Metabolism of omega-3 fatty acids in relation to blood pressure. 
(Adapted from: Novgordtseva et al., 2011; Cabo et al., 2012). 
 
A study by Zhang et al. (2012a) found that participants in the highest DHA quartile had a 
significantly lower risk of developing hypertension, whereas a very recent study did not find this 
relationship (Cespedes et al., 2015). These studies had different study designs, since the former 
study was a case-control, while the more recent study by Cespedes et al. (2015) was a cross-
sectional study. Different methods to study the FA profiles were also used and this may have 
influenced the findings, since the RBC membrane FAs reflect medium-term FA exposure, while 
gluteal SAT reflects long-term FA exposure. 
 
Blood pressure may further be influenced by the SFAs, since studies by Kabagambe et al. 
(2008) and Novgordtseva et al. (2011) found significant positive associations between SBP and 
SFA levels of MetS participants. Results from a study by Novgordtseva et al. (2011) indicated 
that the MetS could lead to various changes in FA composition: (i) it can affect the charge on 
cell membranes, (ii) it can increase membrane microviscosity, (iii) it can activate a pro-
inflammatory state, and (iv) it can increase the sensitivity of arterial smooth muscle cells to result 
in vasoconstriction effects. This chain of events contributes to hypertension (Figure 1.14). 
 
Figure 1.14: Effect of metabolic syndrome and the associated changes in fatty acid composition on 
hypertension. 
(Adopted from: Novgordtseva et al., 2011). 
Regulation of BP 
DHA 
EPA 
3 series of prostaglandins Thromboxanes 5 series of leukotrienes 
α-LA  
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Changes in membrane FA composition 
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Not only do FAs affect BP, but insulin sensitivity is also affected, since several studies indicated 
that MUFA levels are positively associated with insulin levels, and IR (Nigam et al., 2009; 
Sethom et al., 2011; Kurotani et al., 2012; Sertoglu et al., 2014). In agreement, Cho et al. (2014) 
also reported significantly higher PLA levels in MetS compared with non-MetS participants. This 
is likely, since insulin stimulates hepatic de novo lipogenesis, and reduces FA oxidation 
(Sertoglu et al., 2014).  
 
1.5.2.3 Glucose intolerance and insulin resistance 
The occurrence of IR causes adipose tissue hypertrophy, which then releases large quantities of 
FFAs into the hepatic portal vein. These FFAs are transported to the liver where it is believed to 
upregulate glucose release, as well as TG- and VLDL particle synthesis (Levine & Levine, 2014; 
Mendonça et al., 2015). This causes a state of lipotoxicity that impair glucose-stimulated insulin 
release, and ultimately leads to β-cell apoptosis and dysfunction (Levine & Levine, 2014). 
Generally, the shift from impaired glucose tolerance to T2DM is characterised by elevated 
plasma FFAs (Mendonça et al., 2015). Both IR and T2DM are related to lipid disorders, 
including FFA disorders, since elevated FFAs released from adipocytes damage pancreatic β-
cells, and affect insulin signalling pathways (Liu et al., 2010a). 
 
Positive correlations were evident between SFA levels and glucose- and insulin levels, as well 
as for the HOMA-IR in participants with the MetS (Kabagambe et al., 2008; Patel et al., 2010). A 
2011 study that compared individuals with the MetS, and individuals with the MetS and IR to 
healthy controls, found that both experimental study groups presented with significantly higher 
SFA levels (Novgorodtseva et al., 2011). Glucose, insulin, and the HOMA-IR were also 
positively associated with MUFA levels (Sethom et al., 2011; Mayneris-Perxachs et al., 2014). 
The MetS is associated with elevated FBG and insulin levels, which enhance hepatic de novo 
lipogenesis and reduce FA oxidation (Sethom et al., 2011). Activity of the Δ-9 SCD 1 enzyme 
was significantly associated with reduced insulin sensitivity, and the MetS (Krӧger et al., 2010; 
Mahendran et al., 2014; Mayneris-Perxachs et al., 2014). This is possible since elevated PA 
levels in the insulin-resistant state prevent glucose uptake in insulin-sensitive cells, and elevated 
glucose levels activate the Δ-9 SCD 1 enzyme to convert PA to PLA, resulting in elevated PLA 
levels (Vessby et al., 2002).  
 
Endogenous SFA synthesis is increased due to increased glucose- and insulin uptake, since 
glucose and insulin are activators of the Δ-9 SCD 2 enzyme that converts SA to OA (Figure 
1.15) (Vessby et al., 2002; Kawashima et al., 2009; Mayneris-Perxachs et al., 2014; Sertoglu et 
al., 2014). However, T2DM patients present with low insulin levels, which are therefore 
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insufficient to activate the Δ-9 SCD 2 enzyme, which is vital for the conversion of SA to OA 
(Sertoglu et al., 2014). Hence, individuals with T2DM presents with significantly higher SA levels 
compared to controls. However, the same study also found that RBC membrane OA levels were 
significantly higher in the T2DM group compared to controls, which reflect increased lipogenesis 
and Δ-9 SCD 2 enzyme activity (Igal, 2011; Sertoglu et al., 2014). These associations may be 
due to the influence of FA composition on cell membrane functions, because changes in SFA 
levels affect membrane fluidity, ion permeability, and insulin receptor binding (Patel et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Major activators of the delta-9 SCD 2 enzyme, that is necessary for conversion of stearic to oleic 
acid in humans. 
(Adapted from: Vessby et al., 2002; Sertoglu et al., 2014). 
 
In contrast to the adverse effects of SFA on insulin sensitivity, Nigam et al. (2009) noted an 
inverse association between the Ω-3 FAs and IR in MetS participants. It was hypothesised that 
this inverse association is related to the beneficial effects of the Ω-3 FAs on insulin signalling 
(Clarke et al., 2001; Kabagambe et al., 2008; Nigam et al., 2009). In agreement, a 2011 study 
comparing individuals with the MetS, and individuals with the MetS and IR to healthy controls, 
found that both experimental study groups presented with significantly lower PUFA levels, 
(Novgorodtseva et al., 2011).  
 
Kabagambe et al. (2008) reported significant negative associations between insulin and the 
HOMA-IR, and the Ω-6 FAs, thereby suggesting that Ω-6 FAs may have beneficial effects on IR. 
Furthermore, Sartorelli et al. (2010) also noted an increased Ω-3:Ω-6, which was associated with 
normal glycaemic status in persons with IR. Linolenic acid was also shown to have beneficial 
effects on glucose metabolism in these insulin-resistant persons, independent of dietary SFA 
intake, hypertension, hypertriglyceridaemia, and abdominal obesity. Sartorelli et al. (2010) then 
suggested that it is likely that an inflammatory process is involved in the association between LA 
and IR. 
SFA: MUFA: 
Activators of the Δ-9 SCD 2 enzyme: 
- Insulin 
- Glucose 
- Dietary factors 
 
Membrane SA  
(18:0) 
Δ-9 SCD 2 enzyme 
Membrane OA  
(18:1n-9) 
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Dietary intake of different fat subtypes may affect the risk of IR and glucose intolerance by 
altering the phospholipid composition of cell membranes, and this may affect insulin secretion 
that ultimately cause dysregulation of blood glucose levels (Sartorelli et al., 2010). Fatty acids 
have also been shown to interfere with the lipid profile, since elevated TG levels are positively 
correlated with MUFA levels, especially PLA and OA levels, in participants with the MetS (Zong 
et al., 2012, 2013; Mayneris-Perxachs et al., 2014; Hlavaty et al., 2015). Mozaffarian et al. 
(2010) also reported that PLA was associated with favourable HDL-c levels. 
 
1.5.2.4 Dyslipidaemia 
The positive association reported between MUFAs and TG levels is probable, since PLA is a 
direct regulator of metabolism, it is a primary product of the Δ-9 SCD 1, and is a crucial 
component for the synthesis of TGs (Mozaffarian et al., 2010; Zong et al., 2012). Vinknes et al. 
(2013) reported a positive association between cholesterol levels and Δ-9 SCD 1 activity, while 
Mayneris-Perxachs et al. (2014) also reported a positive association between Δ-9 SCD 1 and -2, 
and TG levels. A significant negative association was also noted for Δ-9 SCD 2 and HDL-c 
levels (Mayneris-Perxachs et al., 2014). 
 
The SFAs have been implicated in dyslipidaemia, altering both lipoprotein metabolism and -
concentrations (Ruiz-Núñez et al., 2016). However, the association between SFAs and lipid 
levels vary according to the specific SFA that is studied, since some studies found that PA have 
unfavourable effects on the lipid profile, while other SFAs such as SA were associated with a 
favourable lipid profile (Mayneris-Perxachs et al., 2014; Hlavaty et al., 2015). This was also 
evident in an earlier study by Zong et al. (2013) that reported a negative association between 
SA and TG levels. It is proposed that differences in chain length might be responsible for these 
contrasting effects of the different SFAs on the lipid profile (Micha & Mozaffarian, 2010). 
 
An earlier study by Klein-Platat et al. (2005) reported a weak negative association between the 
Ω-3 FAs and TG levels, while a positive association was noted for HDL-c levels. In contrast, 
Kabagambe et al. (2008) and Nigam et al. (2009) found no significant relationship between the 
Ω-3 FAs and any of the blood lipid fractions. Studies that are more recent also noted inverse 
associations between TG levels and individual Ω-3 FAs, and the Ω-3 index, which is possible 
since Ω-3 FAs reduce β-oxidation and hepatic production of TGs (Shearer et al., 2011; Harris et 
al., 2012; Mirmiran et al., 2012). The differences between these studies may be attributed to the 
inclusion of different Ω-3 FAs, since the effects of the individual Ω-3 FAs differ. For example, α-
LA exerts most of its effects by modulating lipoproteins, whereas EPA and DHA reduce TG 
synthesis and adiposity (Poudyal et al., 2011). Kabagambe et al. (2008) reported significant 
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negative associations between TG and LDL-c levels, and the Ω-6 FAs, which is possible since 
IR and the MetS are associated with reduced TG clearance. Mayneris-Perxachs et al. (2014) 
supported this finding, by reporting an inverse relationship between LA and TG levels, and a 
greater LA deficiency, which was associated with greater TG biosynthesis. 
 
Although various studies have attempted to determine the negative effects of the MetS, and its 
risk factors on FA levels, long-term FA intake may actually be of benefit. The next section will 
explore the effect of long-term FA intake on the MetS status and the components thereof. 
 
1.5.3 Effect of long-term fatty acid intake on metabolic syndrome status and its risk 
factors 
Long-term studies have proposed that eating a balanced healthy diet, especially focussing on 
PUFA intake; can reduce the risk of the MetS and/or its components (Buckley & Howe, 2009; 
Serra-Majem et al., 2012; Braeckman et al., 2013). 
 
Few, and inconsistent results exist for the effects of long-term FA supplementation on the risk of 
the MetS. The consumption of Ω-3 PUFAs (found in fatty fish, seafood, and lean meat) has 
shown several health benefits, such as reducing BP and markers of systemic inflammation, 
improving IR and the lipid profile, and reducing the risk of the MetS (Buckley & Howe, 2009; 
Cabo et al., 2012; Harris et al., 2012; Serra-Majem et al., 2012). However, Zhang et al. (2012a) 
did not find any association between long-term EPA and DPA intake and the risk of the MetS. 
Specifically in the context of obesity, dietary intake of Ω-3 FAs was associated with modest 
reductions in body weight, and improvement in body composition in people with the MetS 
(Buckley & Howe, 2009; Tierney et al., 2011). The proposed mechanism here was that 
enhancement of postprandial satiety led to lower dietary intake, enhanced fat oxidation, and 
regulation of adipogenesis to reduce fat deposition (Buckley & Howe, 2009). Although Ω-3 
supplementation reduced body weight, WC measurements remained unchanged in this group 
(Tierney et al., 2011). Compared to diets supplemented with Ω-3 or -6 FAs, MUFA 
supplementation also seemed to reduce SBP in persons with the MetS, as well as in healthy 
controls (Gillingham et al., 2011; Tierney et al., 2011; Grieger et al., 2014). 
 
Monounsaturated FAs have been shown to regulate glycaemic response and improve insulin 
sensitivity. Nonetheless, dietary interventions to reduce SFA intake did not show any 
improvement in insulin sensitivity, fasting insulin and FBG levels or the HOMA-IR in people with 
the MetS (Gillingham et al., 2011; Tierney et al., 2011). Similarly, a study by Clevenger et al. 
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(2015), comparing the effects of diets supplemented with different fat types (SFA, MUFA and 
PUFA), did not find significant changes in FBG levels. 
 
Following SFA and MUFA supplementation, HDL-c levels in persons with the MetS improved 
(Gillingham et al., 2011; Tierney et al., 2011). Increased MUFA intake was shown to reduce TG 
levels in obese and overweight participants with the MetS (Gillingham et al., 2011). A Ω-3 
supplementation study by Grieger et al. (2014) did not find any significant differences in blood 
lipid levels. From the studies mentioned above, evidence seems to suggest that MUFA 
supplementation may be more beneficial in altering the different risk factors of the MetS 
compared to PUFA supplementation (Gillingham et al., 2011). These effects are summarised in 
Figure 1.16. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: The beneficial health effects of dietary monounsaturated fatty acid intake. 
(Adapted from: Gillingham et al., 2011; Tierney et al., 2011; Grieger et al., 2014). 
 
1.6  ASSOCIATION BETWEEN THE METABOLIC SYNDROME AND CANCER 
1.6.1 Introduction 
Scientific evidence describes the relationship between the MetS and increased risk of certain 
lifestyle-associated cancers (Kuchiba et al., 2012; Leiba et al., 2012; Reeves et al., 2012; Kawai 
et al., 2013; Wiedman et al., 2013; Li et al., 2014; Lindkvist et al., 2014; Roswall et al., 2014; 
Almquist et al., 2015). Although the exact mechanisms remain unclear, it has been claimed that 
obesity might be implicated. This is largely due to evidence showing that increased adiposity 
results in a pro-tumorigenic state, since adipose tissue hypertrophy causes the infiltration of 
macrophages and T-cells that produce adipokines (Donohoe et al., 2010; Blüher & Mantzoros, 
2015). Additionally, adiposity is associated with hyperinsulinaemia and elevated IGF-1 levels, 
contributing to the promotion of cancer development (Donohoe et al., 2010). 
 
 
↓ risk of MetS ↑ MUFA levels 
↓ abdominal obesity 
↓ TG levels 
↑ HDL-c levels 
↓ SBP  
↓ DBP 
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1.6.2 Metabolic syndrome risk factors, biochemical risk factors and cancer 
Many studies have shown that the components of the MetS are major risk factors for several 
cancer types (Hӓggstrӧm et al., 2011; Kuchiba et al., 2012; Leiba et al., 2012; Kawai et al.,2013; 
Wiedman et al., 2013; Li et al., 2014; Lindkvist et al., 2014; Roswall et al., 2014). Factors 
associated with the MetS, such as obesity, and elevated FBG and insulin levels have all been 
associated with an increased cancer risk (Johansen et al., 2010; Wulaningsih et al., 2012; 
Lindkvist et al., 2013; Westley & May, 2013; Wiedman et al., 2013; Li et al., 2014). Figure 1.17 
illustrates the increasing risk for cancer with increasing BMI, and FBG and insulin levels. 
 
 
Figure 1.17: Components of the metabolic syndrome in relation to cancer risk, where increased body mass 
index, and blood glucose and insulin levels all contribute to an increased cancer risk. 
(Adopted from: Westley & May, 2013). 
 
1.6.2.1 Obesity 
Many studies have shown that obesity is a major risk factor for several cancer types (Kuchiba et 
al., 2012; Leiba et al., 2012; Kawai et al.,2013; Wiedman et al., 2013; Li et al., 2014; Lindkvist et 
al., 2014; Roswall et al., 2014). Cancer cases were shown to be more frequently obese 
compared to being overweight (Leiba et al., 2012; Lindkvist et al., 2013; Wiedman et al., 2013; 
Pouchieu et al., 2014; Roswall et al., 2014). Furthermore, studies also reported an increased 
cancer risk with increasing BMI (summarised in Table 1.8). 
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Table 1.8: Association between different body mass index classes and cancer risk. 
CANCER TYPE 
BMI RANGE 
REFERENCES 
Underweight 
BMI≤18.49 
kg/m
2
 
Normal 
BMI=18.50-
24.99 kg/m
2
 
Overweight 
BMI=25.00-
29.99 kg/m
2
 
Obese 
BMI≥30.00 
kg/m
2
 
Female CNS    + Wiedman et al., 2013 
Female colorectal   + + Kuchiba et al., 2012 
Female pancreatic    + Johansen et al., 2010 
Female thyroid  + + + Almquist et al., 2015 
Lung    + Smith et al., 2012 
Oesophageal +    
Kendall et al., 2013; 
Lindkvist et al., 2014 
Postmenopausal breast   + + 
Li et al., 2014; Kawai et 
al., 2013 
Urethra   +  Leiba et al., 2012 
 
Although various studies have shown an association between cancer risk and BMI, others 
reported no association between BMI and overall cancer risk, or the risk for breast or gastric 
cancers (Jaggers et al., 2009; Murff et al., 2011). A possible reason could include the specific 
area of fat deposition (Reeves et al., 2012; Comstock et al., 2014; Roswall et al., 2014; Cottet et 
al., 2015). Fat deposition, specifically VAT, was implicated in promoting pro-tumorigenesis 
through its effect on the production of inflammatory cytokines (IL-6 and tumour necrosis factor-α 
(TNF-α)), which causes a state of chronic low-grade inflammation (Donohoe et al., 2012). 
Adipose tissue can act in both a paracrine and autocrine manner to promote the formation of 
cancerous lesions (Doyle et al., 2012). The less studied paracrine mechanisms include changes 
in the local production of inflammatory cytokines, adipokines, insulin, IGF-1, and growth factors, 
all of which have been shown to play a role in angiogenesis, cell proliferation, and apoptosis 
(Donohoe et al., 2011; Doyle et al., 2012). The autocrine or systemic effects of adiposity are 
well-studied, and include modifications to the insulin- and IGF-1 pathways, adipokine production, 
cancer cell signalling, and inflammatory pathways (Doyle et al., 2012). Commonly used 
measures to diagnose adiposity include WC, W:H, and SAD, all of which have been linked to 
certain cancer types, as shown in Table 1.9. 
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Table 1.9: Association between abdominal obesity and the associated cancer risk. 
MEASURES OF ABDOMINAL OBESITY CANCER TYPE 
↑ WC Colon 
Colorectal 
Female bladder 
Oesophageal 
Postmenopausal breast 
↑ W:H Colorectal 
Oesophageal  
Pancreatic 
Postmenopausal breast 
↑ SAD Oesophageal 
(Adapted from: Reeves et al., 2012; Kendall et al., 2013; Roswall et al., 2014; Comstock et al., 2014; Cottet et al., 
2015). 
 
Increased abdominal fat has been independently linked to the increased risk of several cancer 
types, including colorectal, breast, and oesophageal (Reeves et al., 2012; Comstock et al., 
2014; Roswall et al., 2014; Cottet et al., 2015). Abdominal adiposity is also associated with 
several hormonal and metabolic alterations, such as IR, hyperinsulinaemia, T2DM, 
hypertension, and CVD (Jeon et al., 2011; Peer et al., 2013; Helelo et al., 2014). Adiposity in 
conjunction with the other risk factors for the MetS, further increases the risk of cancer 
development (Doyle et al., 2012). Although some studies reported that WC and HC 
measurements were not associated with either pancreatic or colorectal cancer risk, the 
combination of WC and HC in the W:H was associated with increased pancreatic, oesophageal, 
and colorectal cancer risk (Bracci, 2012; Kendall et al., 2013; Cottet et al., 2015). Even though 
obesity is suggested to be the main contributor for cancer risk, the other risk factors of the MetS 
must also be explored. 
 
1.6.2.2 Hypertension 
Hypertension was shown to have different effects on overall cancer risk, as well as different 
types of cancer. An earlier study found that history of hypertension was associated with 
increased risk of cancer-related mortality (Lee et al., 2009a), whereas Jaggers et al. (2009) 
found no association between hypertension and cancer risk in men. A European study found 
that elevated BP (SBP above 140 mmHg and DBP above 90 mmHg) was not significantly 
associated with bladder cancer in women (Hӓggstrӧm et al., 2011), and no association between 
hypertension and breast or gastric cancer was also evident in women older than 65 years 
(Reeves et al., 2012; Lindkvist et al., 2013). Although hypertension may not be directly 
responsible for the increased risk of cancers, it may lead to cancer development through 
hormonal, inflammatory or growth factor pathways instead (Reeves et al., 2012). 
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1.6.2.3 Glucose intolerance and insulin resistance 
History of T2DM was associated with an increased risk of cancer-related mortality (Lee et al., 
2009a; Reeves et al., 2012; Rahman et al., 2015). Women were significantly more susceptible 
to develop pancreatic, gastric, or colon cancer if glucose levels were elevated (Johansen et al., 
2010; Wulaningsih et al., 2012; Lindkvist et al., 2013). Jaggers et al. (2009) found glucose to be 
responsible for an increased cancer risk of about 22.0 %. A specific association was also 
evident between HOMA-IR, insulin, and the risk of oesophageal cancer in older adults (mean 
age 61 years) (Duggan et al., 2013), whereas insulin levels were elevated in existing colorectal 
cancer patients (Ho et al., 2012). Table 1.10 summarises the association between cancer risk 
and the HOMA-IR, and glucose and insulin levels. 
 
Table 1.10: Association between measures of glucose intolerance, insulin resistance, and the associated 
cancer risk. 
MEASURES OF GLUCOSE INTOLERANCE AND IR CANCER TYPE 
↑ glucose levels Pancreatic 
Gastric 
Colon  
↑ insulin levels Oesophageal  
Colorectal  
↑ HOMA-IR Oesophageal  
(Adapted from: Johansen et al., 2010; Wulaningsih et al., 2012; Ho et al., 2012; Duggan et al., 2013; Lindkvist et al., 
2013). 
 
High levels of trophic hormones, such as insulin and IGF-1, related to the MetS, have been 
proposed as possible mechanisms linking cancer, IR, and glucose intolerance (Jeon et al., 
2011; Erasmus et al., 2012; Klug et al., 2012; Camargo et al., 2014; Lindkvist et al., 2014). The 
IGF-1 is a critical component in cancer development, since it can promote cell proliferation, 
invasion, metastasis, drug resistance, and survival of tumour cells (Levine & Levine, 2014). 
Overexpression of the IGF-1R has also been reported in cancerous cells, most probably as a 
result of mutations that may occur in the tumour suppressor genes, thereby altering IGF-1 and 
insulin signalling pathways (Braun et al., 2011; Mendonça et al., 2015). 
 
Circulating insulin levels affect IGF-1 levels through its downregulatory effect on IGFBP-1 and -
2, thereby increasing the bioavailability of IGF-1 (Doyle et al., 2012). Both IGF-1 or -2 can bind 
to the IGF-1R that is located in the IGF-axis, which plays a role in cell proliferation, 
differentiation, and prevention of apoptosis (Doyle et al., 2012; Mendonça et al., 2015). The 
insulin receptor is identical to the IGF-1R, and these receptors are able to form heterodimers 
(IGF-1/IR-A) that control cell survival and -proliferation (Mendonça et al., 2015). In addition, 
elevated IGF-1 and insulin levels have been linked to receptor overstimulation, and eventually 
cancer development (Mendonça et al., 2015).  
Stellenbosch University  https://scholar.sun.ac.za
  
 
47 
 
Research has recently indicated that IGF-1, which is essential for cell proliferation, growth, and 
metabolism, plays a pivotal role in IR and the MetS, and its link to cancer (Braun et al., 2011; 
Mendonça et al., 2015). Hyperinsulinaemia, one of the components of the MetS, may lead to 
increased cancer risk, since the effect of both hyperinsulinaemia and obesity can influence GH 
levels through the IGF-1 system (Braun et al., 2011; Doyle et al., 2012; Mendonça et al., 2015). 
Elevated IGF-1 levels have been associated with colorectal, oesophageal, lung, breast, and 
pancreatic cancers (Donohoe et al., 2010; Doyle et al., 2012). Additionally, an adverse lipid 
profile has also been linked with an increased cancer risk (Jaggers et al., 2009; Braun et al., 
2011; Wulaningsih et al., 2012). 
 
1.6.2.4 Dyslipidaemia 
A study by Jaggers et al. (2009) found that elevated TG and reduced HDL-c levels each 
increased cancer risk by 25.0 %. Lee et al. (2009a) and Lindkvist et al. (2013) corroborated 
these results. A positive association was evident between TG, HDL-c levels, and oesophageal 
cancer risk, TG levels and colon cancer risk, and total cholesterol and rectal cancer risk 
(Wulaningsih et al., 2012). While no association was evident between total cholesterol levels 
and risk of gastric, and bladder cancer (Hӓggstrӧm et al., 2011; Lindkvist et al., 2013), the study 
by Wulaningsih et al. (2012) found an inverse relationship between HDL-c and gastric cancer 
risk. Table 1.11 summarises the correlation between several different cancer types with 
dyslipidaemia. 
 
Table 1.11: Dyslipidaemia and associated cancer risk. 
DYSLIPIDAEMIA CANCER TYPE 
↑ LDL-c - Oesophageal 
↑ TGs 
- Colon 
- Gastric 
- Oesophageal 
- Pancreatic 
↑ total cholesterol Rectal 
↓ HDL-c 
- Gastric 
- Oesophageal 
(Adapted from: Johansen et al., 2010; Wulaningsih et al., 2012; Lindkvist et al., 2013). 
 
Various mechanisms have been proposed to help explain the link between the altered lipid 
profile and increased cancer risk, including inflammation and lipid peroxides in lipoproteins that 
can induce cellular damage to promote carcinogenesis (Wulaningsih et al., 2012). Studies have 
shown that adipokines might also be related to cancer risk (Dalamaga et al., 2009; Ho et al., 
2012; Mendonça et al., 2015). 
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1.6.2.5 Adipokines 
Although the role of leptin is well studied in obesity, several of its other functions have recently 
been elucidated, which include its inflammatory response, suppression of gluconeogenesis and 
FA biosynthesis, its effect on insulin signalling and satiety sensation, as well as its role in 
carcinogenesis (Mendonça et al., 2015). 
 
Elevated plasma leptin (hyperleptinaemia) and its circulating levels have been linked to 
adiposity, and cancer risk, a state known as leptin resistance (Doyle et al., 2012; Mendonça et 
al., 2015). A direct link between the MetS and cancer with regards to leptin is evident, because 
leptin stimulates human cancer cell growth (Mendonça et al., 2015). Although several studies 
have revealed the carcinogenic effects of leptin, human studies still lack the necessary evidence 
(Dalamaga et al., 2009; Ho et al., 2012). In addition, leptin resistance was associated with 
increased angiogenesis and cell proliferation, and neuroendocrine and pro-inflammatory effects 
(summarised in Figure 1.18) (Mendonça et al., 2015). 
 
 
Figure 1.18: Obesity and its effect on cancer risk. 
(Adapted from: Levine & Levine, 2014; Mendonça et al., 2015). 
 
Adiponectin, on the other hand, has been shown to possess anti-carcinogenic properties by 
increasing apoptosis, and inhibiting inflammation, angiogenesis and cell proliferation (Donohoe 
et al., 2011; Levine & Levine, 2014). For example, adiponectin was shown to inhibit colorectal 
cancer cell growth, possibly due to its anti-inflammatory properties and its negative regulatory 
effects on angiogenesis (Braun et al., 2011). An earlier study by Dalamaga et al. (2009) found 
that women with pancreatic cancer had significantly higher adiponectin levels than controls; 
however, a more recent study found that adiponectin levels were not associated with colorectal 
cancer in women (Chandler et al., 2015). The discrepancies between these findings may be due 
to several factors, such as differences in gender and the associated fat deposition patterns, 
obesity, insulin sensitivity, and the adiponectin fraction measured (Shah et al., 2012; Abu-Farha 
et al., 2014; Chandler et al., 2015). Even though studies confirmed a relationship between the 
MetS and cancer, risk factors other than those responsible for the development of the MetS may 
be involved in the association between the MetS and the risk for cancer development. 
↑ cancer risk 
 ↑ angiogenesis and cell proliferation  Neuroendocrine and pro-inflammatory effects 
Leptin resistance 
 IR  T2DM 
Obesity 
↑BMI ↑ WC and/or VAT 
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1.6.3 Other factors linking metabolic syndrome to cancer 
Various other risk factors can also influence the risk for cancer, including insufficient physical 
activity, unhealthy diet, increased alcohol consumption, tobacco use, ageing, and genetic 
predisposition (de Oliveira et al., 2012; Steyn et al., 2012; Hoebel et al., 2013; Miglani et al., 
2015; Salonen et al., 2015; Strand et al., 2015). Figure 1.19 compared the number of cancer-
related deaths in high- to middle- and low-income countries for some of the risk factors 
mentioned above. Tobacco use poses the greatest risk for cancer death, although largely in 
high-income countries, followed by increased alcohol consumption, and overweight and obesity 
(WHO, 2007; 2015a). In middle- and low-income countries, low fruit and vegetable intake, and 
alcohol consumption posed a significant risk for cancer-related deaths (WHO, 2007; 2015a). 
 
 
Figure 1.19: The effect of several risk factors on global cancer deaths in high-, and middle and low-income 
countries. 
(Adopted from: WHO, 2007; 2015a). 
 
The effect of each of the alternative risk factors on cancer risk will be discussed in the following 
sections. 
 
1.6.3.1 Physical activity 
Sedentary lifestyle is regarded as the fourth global cause of death (WCRFI, 2014). The WHO 
recommends that adults between the ages 18-64 years should partake in at least 150 minutes of 
moderate-intensity exercise, or 75 minutes of vigorous-intensity physical activity weekly (WHO, 
2011). Hallal et al. (2012) estimated that 31.1 % of the global population were physically 
inactive, and that women tended to be more inactive compared to men (33.9 % vs 27.9 %). 
Interestingly, on the African continent, ~30.0 % of the population do not reach the recommended 
levels of physical activity (Hallal et al., 2012). 
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Anthropometric measures (BMI and WC) and body composition (percentage body fat) are 
inversely associated with sufficient physical activity, and decreases the risk of developing the 
MetS (Salonen et al., 2015; Strand et al., 2015). Physical inactivity and sedentary lifestyles have 
been shown to contribute an estimated six to ten percent of the NCDs, which includes coronary 
heart disease, T2DM, and breast and colon cancers (Lee et al., 2012). 
 
Physical activity is also related to cancer risk, and this was illustrated in a study by Kawai et al. 
(2013), that reported a positive correlation between five or more hours of physical activity per 
week and reduced risk of developing breast cancer. Even low levels of physical activity have 
been associated with a decreased risk of breast, colon, colorectal, endometrial, postmenopausal 
breast, and pancreatic cancer (Ho et al., 2012; Miglani et al., 2015). In contrast, other studies 
have found that physical activity was unrelated to colorectal or CNS cancer (Wiedmann et al., 
2013; Chandler et al., 2015). These contrasting results might be due to differences in inclusion 
criteria (men and women vs postmenopausal women), and the type of cancer studied. 
 
The WHO reported that almost 50.0 % of South Africans were inactive, with women being more 
inactive than men (51.6 % vs 42.2 %) (WHO, 2010b). van Zyl et al. (2012) also reported that 
more urban (66.5 %) than rural (27.3 %) South Africans were inactive, since individuals in rural 
areas were more physically active by working as manual laborours and walking as a means of 
transport, compared to their urban counterparts, who often work indoors and use transport as 
opposed to walking. Increased urbanisation do not only lead to insufficient physical acitivity, but 
commonly also lead to changes in dietary patterns (Abrahams et al., 2011; Steyn et al., 2012; 
Shab-Bidar et al., 2014). 
 
1.6.3.2 Diet 
Different dietary types and the intake of specific food products have been related to increased or 
reduced cancer risk. Dietary variety have been shown to correlate with greater diet quality and 
intake of healthy food groups (fruit, vegetables, fibre, and dairy intake), and this is protective 
against the development of the MetS and lifestyle-associated cancers (de Oliveira et al., 2012; 
Song et al., 2015). High salt intake, another contributor in the Westernised diet, is also 
associated with elevated BP, CVD, and gastric cancer (WCRFI, 2014). A strong association with 
colorectal cancer was also evident in studies employing the “Western diet”, a diet high in red 
and processed meat, animal fat, snack foods, and sugar sweetened beverages (including fruit 
juices), and low in dietary fibre (Theodoratou et al., 2013; Song et al., 2015; Lucas et al., 2016). 
Consumption of energy-dense, highly processed foods cause overweight and obesity, and this 
could lead to a multitude of other diseases, including cancer (Song et al., 2015; Lucas et al., 
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2016). Theodoratou et al. (2013) found that coffee intake is associated with reduced colorectal 
cancer risk, since it has anti-carcinogenic properties and increases motility in the large intestine. 
Not only can diet and coffee intake affect cancer risk, but smoking may also play a role. 
 
1.6.3.3 Smoking 
Smoking has mainly been associated with increased cancer risk; however, results have been 
inconsistent (Jaggers et al., 2009; Dalamaga et al., 2009; Johansen et al., 2010; Hӓggstrӧm et 
al., 2011; Murff et al., 2011; Ho et al., 2012; Kawai et al., 2013; Wiedmann et al., 2013; 
Pouchieu et al., 2014; Chandler et al., 2015; Cottet et al., 2015; Rahman et al., 2015). 
Differences between the findings of these studies may be attributed to several factors including 
underreporting of smoking habits, the specific cancer type studied, the effects of lifestyle factors 
such as alcohol intake, and metabolic factors such as obesity and IR/diabetes (Dalamaga et al., 
2009). It is further suggested that smoking modifies the association between metabolic factors 
and cancer risk, although the extent of this is still unclear (Johansen et al., 2010). These studies 
also used different methods to quantify smoking, since some only differentiated between non-
smoking and smoking, while others further differentiated between previous- and current 
smoking, the number of cigarettes smoked per day, and how long a person has been smoking. 
Furthermore, the respective studies included vast age ranges, from 20 to 88 years, and this may 
have contributed to the contrasting findings.  
 
1.6.3.4 Age 
It is well documented that age influences the development of the MetS (Hoebel et al., 2013; 
Clevenger et al., 2015). A recent study found that the prevalence of the MetS increased 
significantly in women between the ages 48 and 52 years, due to lower oestradiol levels, and 
redistribution of VAT associated with menopause (Hoebel et al., 2013; Clevenger et al., 2015; 
Strand et al., 2015). Furthermore, ageing was also associated with an increasing number of 
individual MetS risk factors (Hoebel et al., 2013). A recent local study found that the risk of 
female obesity increases significantly with age, since the prevalence of obesity was significantly 
higher in the older (older than 50 years) compared to the younger group (younger than 30 years) 
(prevalence of 58.5 % vs 20.0 %) (Senekal et al., 2015). The risk of hyperglycaemia, elevated 
HOMA-IR, and T2DM increase significantly with age (Leung et al., 2009; Erasmus et al., 2012; 
Frank et al., 2014; Strand et al., 2015). Similarly, hypertension was significantly higher in older 
(40-50 years) than younger (31-40 years) persons (Garrido et al., 2009; Gyakobo et al., 2012; 
Helelo et al., 2014). 
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A South African study determined the age-specific incidence of specific cancer types, and found 
that for oesophageal cancer, the incidence increases with age up to the maximum age of 69 
years (Somdyala et al., 2010). The incidence of lung cancer was different to that of oesophageal 
cancer, since it increased rapidly between 35 and 39 years, and reached a maximum peak at 59 
years of age (Somdyala et al., 2010). Additionally, studies have also found that different FAs 
may have pro- and anti-carcinogenic effects (Doyle et al., 2012; Høstmark & Haug, 2013; 
Mendonça et al., 2015). 
 
1.6.4 Possible link to fatty acids 
Some FAs have anti-carcinogenic effects, and essential FAs can either inhibit or promote 
carcinogenesis (Høstmark & Haug, 2013). This effect is mainly thought to occur via the release 
of FFAs because of increased body weight, and its effect on IR, insulin levels, and ultimately the 
bioavailability of IGF-1 (illustrated in Figure 1.20). This process creates a pro-tumorigenic 
environment associated with reduced apoptosis and increased cell proliferation (Boden, 2009; 
Doyle et al., 2012; Mendonça et al., 2015). 
 
 
 
 
 
 
 
 
 
Figure 1.20: Diagrammatic representation of the association between fatty acids and carcinogenesis. 
(Adapted from: Boden, 2009; Mendonça et al., 2015). 
IR 
↓IGFBP-1/-2 
↑ IGF-1 bioavailability 
↑ insulin 
Adipocyte dysfunction: 
↑ pro-inflammatory adipokines (leptin) ↓ anti-inflammatory adipokines (adiponectin) 
↑ FFA, ↑ TG, ↑ TNF-α,  
↑ body weight  
Pro-tumorigenic environment 
↓apoptosis 
↑cell proliferation 
Insulin receptor IGF-1R 
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Some FAs also have unfavourable effects on cancer risk, and may possibly play a role in the 
metabolic alterations that are ultimately associated with cancer, although contrasting results 
have been obtained (Anderson & Ma, 2009; Shannon et al., 2010; Pouchieu et al., 2014). 
Studies by Mikirova et al. (2004) and Shannon et al. (2010) found that SA and PA levels of 
cancer patients were significantly lower compared to healthy controls, while a more recent study 
by Pouchieu et al. (2014) found an inverse association between SFAs and overall cancer risk. 
However, a 2015 study found that SFA levels were not associated with the risk of colorectal 
cancer (Cottet et al., 2015). The difference in study design, specific cancer type studied, and the 
blood pool used for sampling to determine FA levels may explain these conflicting results. 
  
Furthermore, Mikirova et al. (2004) suggested that carcinogenesis is associated with alterations 
in lipid metabolism, since tumour cells exhibit decreased desaturase activity, which was evident 
from the lower SA and higher OA levels seen in cancer patients. Although the exact 
mechanisms are still unclear, desaturase activity is also under hormonal and nutritional control, 
and these factors may have played a role in the conflicting results (Mikirova et al., 2004; 
Pouchieu et al., 2014). The study by Mikirova et al. (2004) also found that OA and PLA levels 
were higher in cancer patients compared to healthy controls, and in addition, Kojima et al. 
(2005) found that MUFAs were positively associated with colorectal cancer risk.  
 
The equilibrium of the different FAs to each other is essential for good health, and for this 
reason the SA to OA ratio (SA:OA), or n-9 SI was established as an indicator of cancer risk 
(Jackson et al., 1997; Chavarro et al., 2013). An earlier study found that the n-9 SI was a 
predictor of postmenopausal breast cancer, and even though the exact role of the n-9 SI in 
cancer is still unclear, it was shown that unsaturated FAs enhance membrane fluidity, with a 
higher n-9 SI being protective against malignancies (Mikirova et al., 2004; Shannon et al., 2010).  
 
Polyunsaturated FAs have shown both pro- and anti-carcinogenic effects, possibly by affecting 
gene expression, alteration of signal transduction molecules involved in cell growth, 
angiogenesis, and metastasis (Hussein, 2013). A study by Pouchieu et al. (2014) found that 
total PUFA levels were directly associated with overall cancer risk. The total PUFA levels 
include the Ω-3 and Ω-6 PUFAs, which have pro- and anti-inflammatory effects respectively, and 
this may explain the contrasting associations with cancer risk (Strandvik, 2011; Hussein, 2013). 
 
An earlier study by Bagga et al. (2002) found that the total Ω-3 PUFAs were inversely 
associated with breast cancer risk in women, which was corroborated by Kojima et al. (2005) for 
colorectal cancer risk and Pouchieu et al. (2014) for overall cancer risk. A study by Kuriki et al. 
(2007) also found that the total Ω-3 PUFAs were inversely associated with gastric cancer risk, 
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because the Ω-3 PUFAs, EPA and DHA, are said to play roles in competitive inhibition against 
tumour development. When specifically looking at individual Ω-3 PUFAs, one study found a 
weak negative association between DPA and colorectal cancer risk (Kojima et al., 2005). 
Omega-3 FAs have demonstrated to have beneficial effects on carcinogenesis, since Ω-3 FAs 
provide substrates for lipid peroxidation, while lipid peroxidation is inversely associated with cell 
division and tumour growth (Mikirova et al., 2004; Anderson & Ma, 2009). Several mechanisms 
exist describing the beneficial effects of Ω-3 FAs on carcinogenesis, including lipid peroxidation, 
eicosanoid synthesis alterations, enhanced immunity, intercellular communication, membrane 
fluidity, intercellular communication, and hormone secretion (Mikirova et al., 2004). Figure 1.21 
illustrates some of the anti-carcinogenic effects of the Ω-3 PUFAs. 
 
 
Figure 1.21: Proposed mechanism whereby omega-3 fatty acids can prevent cancer. 
(Adopted from: Hussein, 2013). 
 
Increasing Ω-6 PUFA levels has also been associated with cancer risk, in particular breast 
cancer risk (Murff et al., 2011). However, the risk of colorectal cancer was not associated with 
the total Ω-6 levels of abdominal SAT samples (Cottet et al., 2015). Overall cancer risk was 
inversely related to dihomo-γ-linolenic acid (DGLA, 20:3n-6) levels (Pouchieu et al., 2014), 
although Cottet et al. (2015) found that DGLA levels were positively related to colorectal cancer 
risk in women older than 45 years. Another study, this time comparing plasma DGLA levels of 
female participants (mean age 51.3 years) with and without cancer, found that the DGLA levels 
of the former group were lower (Pouchieu et al., 2014). Results on the effects of Ω-6 FAs on 
cancer risk however, remain inconclusive and further research is needed to establish a 
relationship between Ω-6 FA levels and cancer risk (Anderson & Ma, 2009). It is also evident 
from this section that FAs are associated with cancer risk, although the exact mechanisms are 
still unclear.  
Ω-3 PUFA 
↑ EPA-derived eicosanoids 
↑ apoptosis 
↓ inflammation  
↓ TG 
↓ BP 
↓ angiogenesis 
↓ tumour endothelial cell 
adhesion 
Cancer prevention 
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1.7 SUMMARY AND SIGNIFICANCE OF THE STUDY 
The prevalence of the MetS and other metabolic-associated diseases are on the rise, 
particularly in developing countries, and this is a major concern as it poses a risk for developing 
CVD, T2DM, and cancer (Alberti et al., 2009; Jeon et al., 2011; Erasmus et al., 2012; Klug et al., 
2012; Hoebel et al., 2013; Camargo et al., 2014). Childhood obesity rates are also on the 
increase, leading to a pattern of overweight children becoming obese adults (Doyle et al., 2012). 
The MetS is associated with alterations in lipid- and FA metabolism that leads to an adverse FA 
profile, which is associated with an increased risk of the individual components of the MetS, and 
the MetS itself (Shab-Bidar et al., 2014; Žák et al., 2014).  
 
Findings suggest that the development of several lifestyle-associated cancers is also on the 
increase in developing countries, and this is affected by the increasing prevalence of the MetS 
(Lindkvist et al., 2014; Almquist et al., 2015; Miglani et al., 2015). In South African adults, 
obesity and inadequate physical activity are the greatest cancer risk factors (WHO, 2014c). 
Several studies established a strong relationship between obesity, dietary fat intake (more 
specifically the effects of individual FAs), the components of the MetS, and cancer risk (Kuchiba 
et al., 2012; Leiba et al., 2012; Reeves et al., 2012; Kawai et al., 2013; Wiedman et al., 2013; Li 
et al., 2014; Lindkvist et al., 2014; Almquist et al., 2015).  
 
This MetS is related to a multitude of metabolic-related diseases and cancers that lead to high 
morbidity and mortality rates, which ultimately affects socioeconomic factors (WHO, 2010a). A 
proper understanding of the relationship between the MetS and cancer risk may have a 
significant clinical and economic influence on health systems, since cancer is a common cause 
of death worldwide. The financial and social NCD-burden in resource-limited settings debilitates 
public health care systems, because the burden of communicable diseases (such as human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis (TB), 
and malaria) is on the increase (Crowther & Norris, 2012). Currently, the prevalence of the MetS 
is largely unknown in the Western Cape, and consequentially, MetS-associated cancer risk is 
undetermined. Patients with the MetS are often in a state of chronic low-grade inflammation, 
which cause the release of high levels of trophic hormones (including insulin and IGF-1), and 
these are related to elevated cancer risk (Blüher & Mantzoros, 2015). Genetic-, lifestyle- (dietary 
habits, smoking, and physical inactivity), metabolic-, and environmental factors all play a role in 
the aetiology of the MetS, which warrants further research (Steyn et al., 2012). 
 
Findings suggest a direct link between obesity, the MetS, and cancer risk, since adipose tissue 
is influenced by dietary intake (Shab-Bidar et al., 2013). This necessitates the evaluation of the 
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relationship between dietary intake and adipocyte dysfunction. Although various studies have 
focussed on the MetS in a South African setting, limited studies investigated the association of 
FA profiles, the MetS, and possible link to cancer risk in different South African ethnic groups. 
This study may also provide baseline data for future studies on the long-term effect of the MetS 
on nutritional status and cancer risk.  
 
Since the present study uses additional parameters (adipose tissue biomarkers, FA levels, etc.) 
to describe the MetS, this may add value to future development of new or existing clinical 
definitions for different South African ethnic groups. Lastly, it is important to raise awareness 
among South Africans concerning lifestyle choices to steer the nutrition transition into a more 
positive direction in an attempt to delay the onset of various chronic diseases. 
 
1.8 AIM 
The present study therefore aimed to describe the association and interaction between the MetS 
and specific FAs and FA ratios, anthropometric measures, dietary intake, and a possible link to 
cancer risk in a female population from the Western Cape Province, South Africa. 
 
1.9 OBJECTIVES 
The following objectives were identified: 
- To determine the prevalence of the MetS in a female farm worker population in the 
Stellenbosch Municipal region of the Western Cape Province, South Africa; 
- To determine the possible associations between specific RBC membrane FAs and FA 
ratios, anthropometric measures, dietary intake, and cancer risk in female participants 
with and without the MetS; 
- To study the association between specific RBC membrane FAs and FA ratios, 
anthropometric measures, dietary intake, and cancer risk in participants according to 
different BMI classes in these different groups. 
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CHAPTER 2: MATERIALS & METHODS 
 
2.1 INTRODUCTION 
This chapter will describe research materials, as well as methods used to collect data. Eligibility 
criteria of participants, study variables, and the statistical measures used to determine variables 
are also outlined and explained. 
 
2.2 ETHICAL CONSIDERATIONS 
Ethical clearance was obtained from the Human Research Ethics Committee (HREC) of 
Stellenbosch University (N13/04/052) (Appendix A). This research project was conducted in 
accordance with the principles of the Declaration of Helsinki (2000), Good Clinical Practice, and 
the constitution of South Africa. All relevant parties were contacted and consulted prior to the 
initiation of any data collection.  
 
Different farming areas around Stellenbosch were approached and the necessary information 
about the study was communicated to possible participants. All interested participants signed 
up, where after research visits were arranged on different days in the weeks to follow. Two 
nurse practitioners and the operational manager of the Owethu Clinic on the Villiera farm 
assisted in arranging appointments on Tuesdays and Thursdays, whereas staff at the Solms-
Delta wine estate (outside of Franschoek) and Neethlingshof wine estate (outside of 
Stellenbosch) arranged appointments on Wednesdays and Fridays respectively. 
 
On the day of data collection, the aims and objectives of the study were thoroughly explained to 
each participant in Afrikaans, English or isiXhosa (with the help of a translator) prior to 
volunteers signing the informed consent form (Appendix B). A copy of the information leaflet with 
all relevant information regarding the purpose and procedures of the study was handed to each 
participant to read through in their own time. Participants were made aware of any possible risks 
and benefits in partaking in the study, although no major risks were anticipated. All participants 
had the right to withdraw from the study at any point in time, even after signing the informed 
consent form. Throughout the data collection process, the participants were often asked whether 
they were still interested in taking part in the study. All participants were also reassured of their 
anonymity throughout the study. All raw data collected were coded, preventing any links to 
names and personal details. After the participants agreed to participate, the informed consent 
form was signed, after which data collection commenced. 
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2.3 STUDY DESIGN 
Initially, a cohort study was planned to determine the effect of urbanisation on the association 
and interaction between the MetS, anthropometric measures, dietary intake, and a possible link 
to cancer risk in a female population from different areas in the Western Cape Province, South 
Africa. However, due to financial constraints, the study design was changed to a descriptive 
cross-sectional study that was conducted around the Stellenbosch farming areas in the Boland 
district, Western Cape Province, South Africa (Figure 2.1). Data collection took place at the 
Owethu Clinic of the Pebbles Project Health Program (situated on the Villiera wine estate just 
outside of Stellenbosch), Neethlingshof wine estate (Stellenbosch) and Solms-Delta wine estate 
(Franschoek) from March to July 2015. 
 
 
Figure 2.1: Regional map of the Cape Winelands area indicating the location of Stellenbosch. 
(From: https://www.google.co.za/maps/place/Stellenbosch/). 
 
2.4 STUDY POPULATION 
The sample population consisted of female farm workers between the ages of 20 and 60 years 
that were permanent residents of the Stellenbosch surrounding area (Boland district). All 
participants were recruited from March to July 2015. 
 
2.4.1 Samples size 
The sample size was calculated using a power analysis test with the help of a biostatistician. 
This study focused on the assessment of mean values for metabolic-associated blood 
parameters, RBC membrane FAs, IGF-1 and leptin levels, specific anthropometric 
measurements, and three-day dietary intakes. A model for participant recruitment was designed 
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for statistical power to be reached to indicate statistically significant differences between 
participant groups. Using Equation 2.1 with the confidence interval set at 5 %, the sample size 
was calculated. 
 
n =
1.962σ2
d2
 
Equation 2.1: Formula to calculate sample size. 
(Israel, 1992). 
 
A total of n=24 participants per group were needed to determine mean values for metabolic-
associated blood parameters, RBC membrane FAs, IGF-1 and leptin levels, anthropometric 
measurements and dietary intakes with 80 % power. In total, the following number of 
participants was needed per group: 
 n=24 females with the MetS and overweight according to BMI classification; 
 n=24 females with the MetS and obese according to BMI classification; 
 n=24 females without the MetS and normal weight according to BMI classification; 
 n=24 females without the MetS and overweight according to BMI classification; 
 n=24 females without the MetS and obese according to BMI classification. 
This gave a total study population of n=120 participants. To account for possible incomplete 
datasets or other difficulties, an additional ten percent was calculated to give a final sample size 
of n=132 participants. 
 
Although a convenient sample was chosen from the Stellenbosch farming areas, the study 
population was specifically chosen to represent a population that might be in a nutrition 
transition. A random sample of n=80 was drawn from the total female study population recruited 
(n=145) to exclude possible selection bias based on the five groups mentioned above. 
 
2.4.2 Recruitment of participants 
All volunteering participants were recruited at the respective sites according to the following 
inclusion and exclusion criteria: 
Inclusion criteria: 
 Participants had to be of South African descent from any ethnic group, and permanent 
residents of the Western Cape Province; 
 Participants had to be female farm workers between the ages 20 to 60 years; 
 Participants were only included if they agreed to participate by signing the informed consent 
form. 
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Exclusion criteria were: 
 Participants that were not of South African descent and not permanent residents of the 
Western Cape Province; 
 Participants that were younger than 20 years of age, and/or older than 60 years of age; 
 Participants who did not agree to partake, or withdrew their consent. 
 
Once the participants gave written informed consent, data collection commenced. This specific 
sample population was chosen to provide information on the prevalence of the MetS, and 
furthermore to describe the effects of the MetS and its components on RBC membrane FAs, 
IGF-1 and leptin levels, and its possible association to cancer risk. Participants were first 
screened for the MetS using the IDF criteria (IDF, 2006). This definition stated that a person is 
diagnosed with the MetS if they have an increased WC ≥80 cm (females) and any two of the 
following criteria: 
. Fasting plasma glucose ≥5.6 mmol/L, impaired fasting glucose or T2DM; 
. TG levels ≥1.7 mmol/L; 
. HDL-c levels ≤1.3 mmol/L (females); 
. BP ≥130/≥85 mmHg or treatment for hypertension. 
 
The total study sample population (n=191) included both genders, of which n=42 were males. 
From the remaining female sample population (n=149), n=four were excluded, and the 
remainder of the group (n=145) categorised into either the MetS (n=68), or non-MetS (n=77) 
groups. Each of these groups were then subdivided according to BMI values into either normal 
weight (BMI=18.5-24.9 kg/m2), overweight (BMI=25.0-29.9 kg/m2) or obese (BMI≥30.0 kg/m2) 
categories (WHO, 2004a; NHANES, 2011) (see Figure 2.2). 
 
Figure 2.2: A diagram explaining the exclusion of participants and group allocation of total participants 
recruited. 
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(n=36) 
OBMetS- 
 (n=13) 
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After females were classified into their respective groups, a random sample was drawn from 
each group (with the exception of two groups) to yield a total of n=80. From the n=68 that 
presented with the MetS, a random sample of n=34 were drawn. In this group, n=17 females 
were overweight (OWMetS+) and n=17 were obese (OBMetS+). Forty-six females were 
randomly selected from the non-MetS group, sixteen of which presented with a normal BMI 
(NMetS-), n=17 were classified as overweight (OWMetS-) and n=13 were obese (OBMetS-). For 
a full description of the final study population, refer to Figure 2.3. 
 
 
Figure 2.3: The random allocation of participants into the different study groups. 
 
2.5 DATA COLLECTION 
Each research visit was scheduled in order to collect data from between ten to twelve 
participants. All data sheets were numbered and each participant received a unique number for 
the entire data collection process. The following procedures were subsequently followed: 
 
2.5.1 Systolic-, diastolic blood pressure and heart rate 
After signing consent, volunteers were seated in a comfortable chair for five to ten minutes 
before BP was measured, twice on the right arm using an aneroid sphygmomanometer (Erka 
Perfect Aneroid 48, Germany) and stethoscope (Littmann 3M stethoscope, United States of 
America). Heart rate was also assessed during this procedure using a finger pulse 
plethysmograph (Contec medical systems, China). Participants who showed severe 
hypertension during this assessment were referred to the nursing staff for medical treatment. 
 
2.5.2 Haematology 
All blood sampling was performed by a registered phlebotomist using sterile procedures. The 
venous blood sample was collected from the cubital vein in the right arm using a vacutainer or 
sterile butterfly infusion set (BD Vacutainer® Safety-Lok™, Becton, Dickinson and Company, 
United Kingdom). Blood was collected into two serum separating tubes (2x4 mL SST), one 
♀ population  
(N=80) 
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(n=34) 
OWMetS+  
(n=17) 
OBMetS+  
(n=17) 
Non-MetS 
(n=46) 
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(n=16) 
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(n=17) 
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(n=13) 
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plasma sodium fluoride (1x4 mL) and two plasma ethylenediaminetetraacetic acid (2x4 mL 
EDTA) tubes. The EDTA tubes were immediately centrifuged at 4 000 revolutions per minute 
(rpm) for ten minutes, followed by separation of the plasma from the blood cells. The SST tubes 
were left to clot for ten minutes at room temperature (22 °C) and then centrifuged. The serum 
from one of the SST tubes and the plasma from the two EDTA tubes were aliquoted into 
Eppendorf tubes and immediately placed on dry ice for later analyses. The RBCs from one of 
the EDTA tubes were wash-treated according to a specific protocol (section 2.5.2.1) and placed 
on dry ice for RBC FA analysis (Opperman & Benade, 2013). All serum and plasma samples 
were stored at -80 °C for IGF-1 and leptin analysis, once transferred from the dry ice to a bio-
freezer at the Department of Physiological Sciences’ analytical laboratory. 
 
The remaining SST tube and the sodium fluoride tube (required no centrifugation) were stored at 
four degrees Celsius until transport to the local PathCare laboratory for subsequent analysis. A 
fasted lipogram profile (total cholesterol, LDL-c, HDL-c, and TG), and insulin were determined 
from the SST tube, whereas glucose was determined from the sodium fluoride tube. The MetS 
status was then determined by evaluating WC, BP, HDL-c, glucose and TG levels (IDF, 2006), 
and participants were categorised into the different study groups. 
 
2.5.2.1 Fatty acid profile analyses 
The EDTA tube containing the RBCs was washed three times with sterile 0.9 % saline, followed 
by a four minute spin at 2500 rpm between each of the wash steps (Opperman & Benade, 
2013). During each of these steps, care was taken to remove the buffy coat (white blood cells, 
WBCs) together with the saline, to render a WBC-free RBC sample for FA analysis. After the 
final removal of the saline, the RBCs were immediately frozen on dry ice in the EDTA tube. 
 
Fatty acid analyses were done at the Functional Foods Research Unit at Cape Peninsula 
University of Technology (CPUT). On the day of analysis, chloroform-methanol (2:1 v/v) was 
used until complete phase separation was achieved. Following centrifugation (at 2 000 rpm for 
four minutes), the lower chloroform phase was transferred into transmethylation tubes and 
evaporated to dryness under a nitrogen stream in a 50-60 ˚C water bath. This was followed by 
the transesterification of FAs to fatty acid methyl esters (FAMEs), where bound FAs were 
hydrolysed and methylated simultaneously with toluene and methanol sulphuric acid for two 
hours at 70 °C. 
 
Distilled water and hexane were added, and after shaking and settling, the hexane layer 
containing the FAMEs (top layer) were transferred to a second set of transmethylation tubes and 
the FAMEs evaporated to dryness under a nitrogen stream in a 50-60 ˚C water bath. A small 
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quantity of hexane (100 μL) was added, followed by mixing, whereafter the remaining sample 
was transferred into specific gas liquid chromatography (GLC) vials for analysis using GLC 
(GLC, Thermo, Focus) equipped with a flame ionisation detector and BPX 70 capillary column 
(oven temperature: three degrees Celcius per minute from 160 to 220 °C) (Bligh & Dryer, 1959; 
Jackson et al., 1997; Harris, 2009; Opperman & Benade, 2013) (see Appendix C for the full 
protocol). For FA identification and analysis, the peaks on the chromatograph were identified 
based on the known retention times of commercial standards. Results were expressed as the 
relative percentage of the total FA area. 
 
The main FA fractions of interest for this specific study included: (a) the Ω-3 index (EPA+DHA); 
(b) n-9 SI (SA:OA) and (c) Ω-3:Ω-6 (EPA+DHA:LA+AA). The desaturase activity, an indicator of 
FA metabolism, was also estimated using FA product-to-precursor ratios of individual FAs to 
calculate (d) Δ-9 SCD 1 (PLA:PA) and (e) Δ-9 SCD 2 (OA:SA). 
 
2.5.2.2 Insulin-like growth factor-1 analyses 
Serum samples for IGF-1 analysis were transferred from the -80 °C bio-freezer unit to a -20 °C 
freezer one day before the IGF-1 enzyme-linked immunosorbent assay (ELISA) (Abcam 
ELISATM, ab100545, United Kingdom). This ELISA uses an affinity tag labelled capture antibody 
and a reporter conjugated detector antibody that immunocaptures the sample analyte in 
solution.  
 
A thorough literature search, based on populations similar to that of our study, revealed that 
serum samples had to be diluted 20x (Yee et al., 2010; Bogin et al., 2015; Koeglenberg et al., 
2015). For assay procedures, a 100 ng/mL IGF-1 stock standard was prepared, followed by 
serial dilutions to yield the following standards necessary for generating the standard curve: 30 
ng/mL, 12 ng/mL, 4.8 ng/mL, 1.92 ng/mL, 0.768 ng/mL, 0.307 ng/mL and 0.123 ng/mL. Samples 
and standards were added in duplicate to the respective wells and incubated for two and a half 
hours at room temperature (22 °C). The plate was washed thoroughly and a biotinylated IGF-1 
detection antibody was added, followed by incubation for a further hour. Following another wash 
step, horseradish peroxidase (HRP) was added to the plate and incubated for 45 minutes. The 
plate was washed again, and 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution added and 
incubated in a dark section of the analytical laboratory for 30 minutes. The stop solution was 
then added to terminate the colour reaction and a proportional signal was generated to the 
amount of bound analyte, after which its intensity was measured using a universal microplate 
reader (EL800, Bio-tek Instruments, Inc. Analytical & Diagnostic Products, United States of 
America) at a wavelength of 450 nm (see Appendix D1 for the complete protocol). 
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2.5.2.3 Leptin analyses 
The serum leptin analyses were performed using a commercially available ELISA kit (Abcam 
SimpleStep ELISATM, ab179884, United Kingdom). Exploring scientific literature, based on leptin 
levels of similar populations, indicated that all serum samples had to be diluted 40x for samples 
from normal and overweight females, and 90x for obese participants regardless of their MetS 
status (de Castro et al., 2015; García-Jiménez et al., 2015; Jafari-Vayghan et al., 2015). Initially, 
a 2 500 pg/mL leptin stock standard solution was prepared, followed by serial dilutions to yield 
the following standards: 750 pg/mL, 375 pg/mL, 187.5 pg/mL, 93.8 pg/mL, 46.9 pg/mL, 23.4 
pg/mL and 11.7 pg/mL. These standards were used to construct the standard curve in order to 
determine the leptin concentration. Following sample dilution, the samples and standards were 
added to the plate wells in duplicate. An antibody cocktail was added to each microplate well 
and the plate was incubated for one hour at room temperature (22 °C) using a laboratory shaker 
(Stovall life science incorporated, United States of America) on a gentle shaking cycle. 
 
After incubation, the plates were washed three times to remove any unbound material and 
subsequently a TMB substrate was added to each well. The plate was incubated for another ten 
minutes in a dark section of the analytical laboratory area on a gentle shaking cycle. The stop 
solution was then added and a change in colour from blue to yellow was noted. The samples 
were analysed using a universal microplate reader (EL800, Bio-tek Instruments, Inc. Analytical & 
Diagnostic Products, United States of America) at a wavelength of 450 nm (see Appendix D2 for 
the complete protocol). 
 
2.5.3 Anthropometric measurements 
All anthropometric assessments were performed by a level one technician anthropometrist using 
standardised and calibrated equipment (Stewart & Sutton, 2012). All data collected were 
entered in a structured International Society for Advancement of Kinanthropometry (ISAK) 
proforma Microsoft Excel data sheet in duplicate or triplicate (Appendix E) (Stewart & Sutton, 
2012). Anthropometric assessments were done using technical error of measurement (TEM), 
which entailed a third measurement in cases where the second measurement differed more 
than five percent from the first. The same standard equipment was used throughout the study 
for all measurements. 
 
Participants were informed of the measurements being done and what was expected of them. 
All participants were instructed to remove any loose and heavy items from their pockets (Stewart 
& Sutton, 2012). All measurements were done on the right side of the body, unless a volunteer 
presented with any physical abnormality. The following anthropometric measures were taken: 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
65 
 
2.5.3.1 Base measurements: weight and stretched stature 
Participants were instructed to remove all heavy clothing, shoes, hair ornaments, and hats. 
Participants were weighed to the nearest 0.01 kilograms using a SECA 634 digital electronic 
scale (Seca United Kingdom, Birmingham, England). The scale was placed on a flat surface and 
the volunteer was then asked to stand in the centre of the platform with their weight evenly 
distributed between the feet, and the hands at the sides. 
 
Stretched stature was obtained using a portable Leicester stadiometer (Leicester, England) to 
the nearest 0.5 cm. Volunteers were positioned with their head in the Frankfort plane with the 
feet together. When measuring height, the participant’s head, shoulders, buttocks, calves and 
heels were in contact with the measuring rod (Figure 2.4). With the participant in this position, 
the Broca plane of the stadiometer was gently pressed down until it made contact with the 
vertex of the head. Volunteers were instructed to inhale and hold their breath until the 
measurement was taken, after which they were instructed to exhale. During the inhalation, slight 
upward pressure to the head was applied to ensure maximum stretched stature (NHANES, 
2011; Stewart & Sutton, 2012). 
 
 
Figure 2.4: The correct position to measure stretched stature. 
(NHANES, 2011). 
 
2.5.3.2 The body mass index  
The BMI (kg/m2) was calculated using the standard equation of weight divided by the height 
squared (Jarvis, 2011; Willet & Hu, 2013). The volunteers’ BMIs were recorded and they were 
then classified according to the WHO (2004a) guidelines (Table 2.1): 
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Table 2.1: Classification of the body mass index.  
CLASS BMI  
(kg/m
2
) 
Underweight 
Severe malnutrition <16.00 
Moderate malnutrition 16.00-16.99 
Mild malnutrition 17.00-18.49 
Normal range Normal 18.50-24.99 
Overweight Pre-obese 25.00-29.99 
Obese 
Obese class I 30.00-34.99 
Obese class II 35.00-39.99 
Obese class III ≥40.00 
(WHO, 2004a). 
 
2.5.3.3 Waist- and hip circumferences, waist-to-height ratio and waist-to-hip 
ratio  
The WC, HC, W:Ht, and W:H were used to indirectly assess abdominal obesity (IDF, 2006; 
Anunciação et al., 2014; Cheong et al., 2015). These measures served as surrogates used to 
indirectly assess subcutaneous- and visceral fat tissue distribution (NHANES, 2011). All 
circumferences were measured using a flexible and inelastic Lufkin tape measure (Lufkin, 
United States of America). Both the WC and HC measurements were done with the participant 
standing with their feet evenly spread apart and arms relaxed to the sides. The participants were 
instructed to abduct their arms to allow the tape measure to be passed around the abdominal 
region (Stewart & Sutton, 2012). 
 
The WC measurement was assessed to the nearest 0.1 cm at the level of the lower 10th costal 
rib and superior iliac crest on the narrowest part of the abdomen using the cross-handed 
technique (Figure 2.5). The measuring tape was held parallel to the floor and tight, ensuring that 
the skin was not pinched (WHO, 2008; Jarvis, 2011; Stewart & Sutton, 2012). 
 
 
Figure 2.5: Correct position of the tape measure for the waist- and hip circumference measurements. 
(Adopted from: Jarvis, 2011). 
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Different WC measurements are associated with anticipated health risks. In women a WC of 80 
cm or more is associated with an increased risk of metabolic diseases, whereas a WC of 88 cm 
or more is associated with a substantially increased risk of such diseases (IDF, 2006; WHO, 
2008). The HC was measured at the level of the greatest posterior protuberance, perpendicular 
to the long axis of the trunk, and included bony structures, muscle and fat, although this 
measurement tend to reflect the muscle component (WHO, 2008; Willet & Hu, 2013). 
 
To further assess the distribution of VAT, the WC, HC and height were respectively used to 
estimate the W:H and W:Ht. A normal W:H is <0.85, while a W:H ≥0.85 increases the risk of 
metabolic diseases (WHO, 2008). 
 
2.5.3.4 Sagittal abdominal diameter  
The Holtain Kahn sagittal abdominal calliper (Holtain Kahn, United Kingdom) was used to 
determine the external distance between the abdomen and the lumbar vertebrae at the level of 
the iliac bone. Participants were instructed to lie in the supine position on an examination bed 
with the knees at a 90° angle with their feet resting on the bed. The participants were then asked 
to raise their hips in order to slip the lower arm of the calliper underneath the back of the 
participant. The shaft of the calliper was then adjusted in a vertical manner while the upper arm 
was moved to barely touch the participant’s abdomen (Figure 2.6) (Stewart & Sutton, 2012). 
 
 
Figure 2.6: Correct measurement of the sagittal abdominal diameter by A) determining the iliac level and B) 
alignment of the upper arm of the calliper with the iliac. 
(Adapted from: NHANES, 2011; Stewart & Sutton, 2012). 
 
Before taking the reading, it was ensured that the lower arm of the abdominal calliper was 
aligned with the participants’ upper arm. The mean of at least two SAD measurements were 
recorded in this manner (NHANES, 2011; Stewart & Sutton, 2012). 
A B 
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2.5.3.5 Bioelectrical impedance analysis  
Bioelectrical impedance analysis was performed using the BioScan920-II multi-frequency (5 
kHz, 50 kHz, 100 kHz and 200 kHz) analyser (Maltron BioScan 920II, United Kingdom), which 
passes a small electric current through the body when connected to the electrodes (Appendix F) 
(Bodystat, United Kingdom Ltd). Prior to the BIA measurement, a pre-test protocol had to be 
followed for all volunteers. Ensuring no electrical interference occurred; participants were 
instructed to remove any jewellery, metal objects, cell phones or other electronic equipment 
prior to the test. Participants were also instructed to empty their bladders prior to testing. 
 
Impedance measurements for the SAT were done by placing the electrodes as illustrated in 
Figure 2.7. Using the umbilicus as reference point, electrodes labelled channel 2 and 4 were 
placed seven cm to either side of the umbilicus. From here, electrodes labelled channel 1 and 3 
were placed five cm from the electrodes from channel 2 and 4. 
 
 
 
Figure 2.7: Correct placement of the electrodes for the subcutaneous adipose tissue impedance 
measurement. Channels 2 and 4 are red and channels 1 and 3 are black. 
(Maltron BioScan 920II Manual, 2003). 
 
For the assessment of VAT, the diameter (d on Figure 2.8) was calculated as the WC (in cm) 
divided by eight. Channel 1 was placed just above the umbilicus. The distance (d) was then 
measured to the left-hand side of the participant where channel 2 was placed on the same level 
of the abdomen as that of channel 1. Channel 3 was placed in the small of the back in line with 
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channel 1 and 2. Again, the distance (d) was measured to the left of the participant where 
channel 4 was placed. 
 
Figure 2.8: Correct placement of the electrodes for the visceral adipose tissue impedance measurement. 
Colour of electrodes 1 to 4 is indicated by the label colour. The distance “d” is calculated at the waist 
circumference (in cm) divided by eight. 
(Maltron Bioscan 920II Manual, 2003). 
 
For both SAT and VAT measurements, the phase angle and impedance measurements were 
recorded from the Maltron BioScan 920 BIA machine. These values together with the WC were 
entered into the Maltron BioScan 921 v1.1 software programme that calculated the SAT and 
VAT areas (in cm2), VAT:SAT and respective VAT and SAT percentages. Furthermore, the 
software also determined the adiposity status according to VAT and SAT distribution of the 
participant by classifying them into either the normal, overweight and obese categories. 
 
2.5.4 Three-day food diary 
A three-day food diary assessment tool was used to quantify food intake over a three-day period 
of time (Appendix G). All questionnaires were available in Afrikaans or English, and a translator 
from the local community was used for isiXhosa-speaking participants where needed. Each 
volunteer was introduced to the food record and after a thorough explanation; they were 
instructed to record any food or beverages that were consumed over a three-day time period 
following data collection. Each participant also received a leaflet with all relevant information of 
the three-day food records, including an example of a food record. 
 
Accuracy of dietary intake was established by recording the time any food or beverage was 
consumed, the type of meal (breakfast, in between, lunch, snack, dinner), what product was 
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consumed, the recipe of the product (e.g. was milk or sugar added), and the amount that was 
consumed (half a cup or a full cup). The Food Photo Manual (N.P. Steyn and M. Senekal, 2004) 
was used for life-sized sketches of food portions, food types, and food preparation methods. 
Household measures (cups, mugs, plates, etc.) and two-dimensional life-size drawings of foods 
were used to estimate portion sizes. Participants were encouraged to provide complete 
homemade recipes where possible to improve the accuracy of the dietary intake data. 
Completed three-day food records were then collected from participants and entered in the 
password-protected FoodFinderTM3 software program (MRC, FoodFinder III). The 
FoodFinderTM3 software program is able to use coding to convert household measures to grams 
to ultimately quantify the intake of specific macro- and micronutrients (energy, protein, 
carbohydrate, fat, vitamin and mineral intakes).   
  
2.5.5 Questionnaires 
Several studies have indicated that different lifestyle factors may influence metabolic- and 
biochemical parameters, anthropometric measurements, body composition, and ultimately risk 
of CVD and cancer (Steyn et al., 2012; Lindkvist et al., 2014; Almquist et al., 2015; Miglani et al., 
2015). For this reason, each participant also completed questionnaires for familial cancer 
history, smoking/tobacco use, alcohol consumption, and physical activity. 
 
2.5.5.1 Familial cancer history 
An immediate family member with cancer history may also influence cancer risk of other family 
members (Bracci, 2012; Lindkvist et al., 2014). Consequently, the familial cancer history 
questionnaire of the current study included questions regarding the relation of the cancer patient 
to the participant, type of cancer, current status of cancer, and treatment of the cancer 
(Appendix H1). 
 
2.5.5.2 Lifestyle factors  
The current study used a standardised questionnaire to assess smoking/tobacco use, and 
alcohol consumption (Appendix H2). Participants were asked to indicate if they were non-, 
previous- or current smokers and drinkers. 
 
The Global physical activity questionnaire (GPAQ) was used to indirectly assess physical 
activity of study participants (Appendix H3) (WHO, 2004b). The WHO developed the GPAQ to 
assess physical activity in epidemiological studies using a standardised questionnaire. The 
GPAQ consists of different sections with questions relating to activities at work, travelling 
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(walking or using a bicycle), recreational activities (sports, fitness or leisure), and sedentary 
behaviour. Physical activity is also assessed according to intensity (moderate or vigorous), 
duration, and frequency. 
 
2.6 DATA MANAGEMENT 
The consent forms, which included the participant names and linking codes, were kept in a 
lockable storage cabinet in the data storage room at the Department of Physiological Sciences 
at Stellenbosch University, separate from the rest of the data files. All other data files were also 
stored in this lockable cabinet. Only the principle investigator and co-investigator had access to 
the original records and data. A sign in and sign out system was used during data capturing. 
 
Data entry in Microsoft Excel 2010 was done on the day of data collection to minimise 
inconsistencies and missing data. All data were entered on the premises of the Department of 
Physiological Sciences. Data were cleaned and also cross-checked to ensure accuracy. 
Checking of the data was done by verifying the data in the Microsoft Excel data sheet with the 
participant data files. All data entered were stored under a password-protected system on the 
main frame of Stellenbosch University, which is saved and backed up daily. The database was 
saved on two separate password-protected computed systems for security purposes. 
 
2.7 STATISTICAL ANALYSIS 
The Microsoft Excel database was exported to Statistica version 12 (Statistica Version 12. 
Copyright© StatSoft, 2007 Southern Africa-Research (Pty) Ltd) for statistical analysis. Statistical 
analysis was performed with the help of a biostatistician at Stellenbosch University.  
 
Normality was assessed both graphically (by using box-and-whisker plots and histograms) and 
statistically (using Shapiro-Wilk tests). Descriptive statistical analysis was done for the entire 
study population, where after group demographics together with clinical characteristics were 
summarised and compared. For nominal data, the student t-tests were used to indicate 
differences between two groups if the data were normally distributed, whereas Mann-Whitney U 
tests were performed for abnormally distributed data. 
 
In order to compare more than two groups, a factorial analysis of variance (ANOVA) was used 
together with a Bonferroni post hoc test to assess the significance of the differences found. 
Pearson’ correlations coefficients were calculated to determine possible associations between 
variables. For all analyses, a p<0.05 was considered statistically significant, and the mean±SEM 
were calculated for all parameters reported.  
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CHAPTER 3: RESULTS 
 
3.1 INTRODUCTION 
This chapter describes the study population, as well as the different study groups. Initially, the 
descriptive profile of the study population is provided, followed by a comparison of the non-MetS 
and the MetS groups. Lastly, the groups were compared according to metabolic status and BMI. 
The anthropometric (BMI, W:H, W:Ht, SAD) and metabolic-associated parameters, BIA 
characteristics, RBC membrane FA profile, biochemical analyses for IGF-1 and leptin, and 
dietary intake are also provided as part of each section. The chapter concludes with relevant 
relationships between some of the physiological parameters of interest. 
 
3.2  DESCRIPTIVE PROFILE OF THE STUDY POPULATION ACCORDING TO 
METABOLIC STATUS 
The study population consisted of n=80 volunteering female participants between the ages of 20 
and 60 years, with a mean age of 37.2±1.2 years. Using IDF criteria (IDF, 2006), a total of n=34 
(42.5 %) MetS participants were identified and n=46 (57.5 %) participants were recruited into the 
non-MetS group (Figure 3.1). 
 
 
 
 
 
 
 
 
 
Figure 3.1: Proportion of study participants from the total study population, with (n=34) and without (n=46) 
the metabolic syndrome. 
 
3.2.1 Distribution and prevalence of the metabolic syndrome risk factors 
Since the MetS consists of several individual components, the distribution of participants that 
displayed one, two, three, four, and five risk factors were determined, as well as the prevalence 
of each of these individual components. For the MetS group, three risk factors were most 
common (n=20, 58.8 %), whereas an equal number of participants presented with four (n=7, 
20.6 %), and five (n=7, 20.6 %) risk factors. The majority of the participants in the non-MetS 
group presented with two risk factors (n=25, 54.3 %), followed by one risk factor (n=14, 30.4 %). 
42.50 % 
57.50 % 
MetS
Non-MetS
n=34 n=46 
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Six participants (13.0 %) also had no risk factors for the MetS, and one non-MetS participant 
presented with three risk factors (2.2 %) (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Distribution of risk factors according to the IDF criteria for participants diagnosed with (n=34) and 
without (n=46) the metabolic syndrome. 
 
The prevalence of each of the MetS risk factors differed between the two groups. For the MetS 
group, abdominal obesity (n=34, 100 %) was predominant, with an almost equal number of 
participants presenting with hypertension (n=28, 82.4 %) and low HDL-c levels (n=26, 76.5 %). 
For the non-MetS group, hypertension (n=22, 47.8 %) was the most common risk factor, 
followed by abdominal obesity (n=18, 39.1 %), and low HDL-c levels (n=16, 34.8 %). The 
prevalence of hypertriglyceridaemia (n=4, 8.7 %) and hyperglycaemia (n=4, 8.7 %) was similar 
in the non-MetS group. These two MetS components were also shown to be less prevalent in 
the MetS group (n=19, 55.9 % for hypertriglyceridaemia, and n=14, 41.2 % for FBG) (Figure 
3.3).  
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Figure 3.3: Prevalence of the individual metabolic syndrome-associated risk factors for participants 
diagnosed with (n=34) and without (n=46) the metabolic syndrome. 
 
3.2.2 Anthropometric and metabolic-associated blood parameters 
The participants from the MetS group were significantly older compared to the non-MetS 
participants (35.0±1.5 vs 40.2±1.8 years, p<0.05). Anthropometric measures from participants in 
the MetS group appeared to be significantly higher compared to the non-MetS group for weight 
(81.4±2.6 vs 70.9±2.9 kg, p<0.05), BMI (32.6±1.0 vs 28.7±1.1 kg/m2, p<0.05), and WC 
(91.9±1.8 vs 79.6±1.8 cm, p<0.001).  
 
Significant differences were also observed for SBP (141.9±3.2 vs 128.5±2.3 mmHg, p<0.001) 
and DBP (89.3±2.3 vs 82.7±1.6 mmHg, p<0.05) in the MetS and non-MetS groups. Similarly, 
participants in the MetS group showed significantly elevated blood glucose (6.1±0.6 vs 4.7±0.1 
mmol/L, p<0.05) and TG levels (2.0±0.2 vs 1.1±0.1 mmol/L, p<0.001), whereas HDL-c was 
significantly lower (1.1±0.0 vs 1.4±0.1 mmol/L, p<0.001). Furthermore, the participants in the 
MetS group also presented with significantly higher insulin (34.4±5.1 vs 15.6±2.0 mIU/L, 
p<0.001) and LDL-c levels (3.2±0.2 vs 2.7±0.2 mmol/L, p<0.05), compared to those from the 
non-MetS group. 
 
Several other anthropometric indices for adiposity were also determined, including HC, W:H, 
W:Ht and SAD (Table 3.1). Both the W:H (0.8±0.0 vs 0.8±0.0; p<0.001) and W:Ht (0.6±0.0 vs 
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0.5±0.0, p<0.001) were significantly higher in the MetS group, as was the SAD (25.4±0.5 vs 
22.6±0.6 cm, p<0.001). Similarly, a statistical trend was also noted for HC (111.1±2.1 vs 
104.7±2.4 cm, p=0.06). Table 3.1 indicates the basic participant characteristics, metabolic-
associated parameters and anthropometric measures of the MetS and the non-MetS groups. 
 
Table 3.1: Descriptive characteristics, including anthropometric and metabolic-associated blood parameters 
for the MetS and the non-MetS groups. 
VARIABLE 
MetS 
(n=34) 
 Non-MetS 
(n=46) 
P-VALUE * 
Age (years) 40.24±1.80  34.96±1.45 p<0.05 
Height (m) 1.58±0.01  1.57±0.01 ns 
Weight (kg) 81.43±2.63  70.88±2.93 p<0.05 
BMI (kg/m
2
) 32.59±0.97  28.66±1.07 p<0.05 
WC (cm) 91.90±1.80  79.60±1.76 p<0.001 
SBP (mmHg) 141.88±3.18  128.54±2.29 p<0.001 
DBP (mmHg) 89.29±2.29  82.72±1.55 p<0.05 
Heart rate (b/m) 83.18±2.30  79.39±2.27 ns 
Blood glucose levels (mmol/L) 6.11±0.57  4.66±0.12 p<0.05 
Insulin levels (mIU/L) 34.42±5.13  15.61±1.98 p<0.001 
HDL-c levels (mmol/L) 1.05±0.03  1.36±0.05 p<0.001 
LDL-c levels (mmol/L) 3.20±0.15  2.70±0.16 p<0.05 
TG levels (mmol/L) 2.04±0.19  1.08±0.10 p<0.001 
HC (cm) 111.14±2.07  104.68±2.43 p=0.06 
W:H 0.83±0.01  0.76±0.01 p<0.001 
W:Ht 0.58±0.01  0.51±0.01 p<0.001 
SAD (cm) 25.44±0.54  22.56±0.62 p<0.001 
*  All values presented as mean±standard error of the mean (SEM). ns indicates not significant. 
 
3.2.3 Bioelectrical impedance analysis characteristics 
Bioelectrical impedance data, presented in Table 3.2, indicated that the VAT area was 
significantly greater in the MetS compared to the non-MetS group (343.4±3.3 vs 283.6±10.7 
cm2, p<0.001). The SAT % (27.6±1.1 vs 33.1±1.1 %), and VAT % (72.4±1.1 vs 66.9±1.1 %), and 
therefore the VAT:SAT (2.8±0.2 vs 2.2±0.1) were also significantly different between these two 
groups (p<0.001 for all). 
 
Table 3.2: Bioelectrical impedance data for visceral- and subcutaneous adipose tissue for the MetS and non-
MetS groups.  
* All values are presented as mean ± standard error of the mean (SEM). ns indicates not significant. 
 
3.2.4 Red blood cell membrane fatty acid profile 
No FAs or FA ratio differences were observed between the MetS and non-MetS groups (Table 
3.3). 
 
VARIABLE 
MetS 
(n=34) 
Non-MetS 
(n=46) 
P-VALUE * 
SAT area (cm
2
) 217.29±7.35 174.35±7.68 ns 
VAT area (cm
2
) 343.38±3.25 283.57±10.67 p<0.001 
SAT % 27.56±1.11 33.08±1.11 p<0.001 
VAT % 72.44±1.11 66.92±1.11 p<0.001 
VAT:SAT 2.82±0.15 2.20±0.12 p<0.001 
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Table 3.3: Red blood cell membrane fatty acid levels for the total population categorised according to 
metabolic syndrome status. 
VARIABLE 
MetS 
(n=34) 
Non-MetS 
(n=46) 
P-VALUE * 
Individual FAs 
(%) 
16:0 (PA) 18.83±0.63 17.32±0.81 ns 
16:1n-7 (PLA) 0.28±0.02 0.26±0.02 ns 
18:0 (SA) 9.45±0.29 8.92±0.39 ns 
18:1n-9 (OA) 9.24±0.35 8.86±0.44 ns 
18:2n-6 (LA) 8.86±0.40 8.50±0.43 ns 
18:3n-3 (α-LA) 0.02±0.01 0.05±0.01 ns 
20:4n-6 (AA) 11.37±0.44 10.71±0.52 ns 
20:5n-3 (EPA) 0.74±0.07 0.76±0.08 ns 
22:5n-3 (DPA) 1.67±0.06 1.59±0.08 ns 
22:6n-3 (DHA) 5.93±0.35 5.80±0.34 ns 
FA ratios 
Ω-3 index 6.67±0.40 6.55±0.40 ns 
Ω-3:Ω-6 0.34±0.02 0.35±0.02 ns 
Δ-9 SCD 1 0.01±0.00 0.01±0.00 ns 
Δ-9 SCD 2 0.98±0.04 0.98±0.03 ns 
n-9 SI 1.10±0.07 1.12±0.08 ns 
* All values presented as mean±standard error of the mean (SEM). ns indicates not significant. 
 
3.2.5 Biochemical blood analysis for insulin-like growth factor-1 and leptin 
From the total sample (n=80), n=14 (17.5 %) participants displayed IGF-1 levels below the 
detection limit (n=three from the MetS group, and n=11 from the non-MetS group), whereas 
n=17 (21.3 %) participants had leptin levels below the detection limit (n=four from the MetS 
group, and n=13 from the non-MetS group). An additional n=four (5.0 %) participants’ IGF-1 
levels (n=two from the MetS group, and n=two from the non-MetS group), and n=three (3.8 %) 
participants’ leptin levels (n=two from the MetS group, and n=one from the non-MetS group) 
were excluded from the statistical analysis because the concentrations were too high (outliers) 
and skewed the data. 
 
Insulin-like growth factor-1 from the remaining participants (n=62) were significantly higher in the 
MetS group (103.1±17.6 vs 53.9±7.2 ng/mL, p<0.05), whereas leptin levels (n=60) were 
significantly lower (684.9±97.7 vs 1119.0±162.7 pg/mL, p<0.05) (Table 3.4). 
 
Table 3.4: Insulin-like growth factor-1 and leptin levels for participants with and without the metabolic 
syndrome. 
VARIABLE MetS Non-MetS P-VALUE * 
IGF-1 concentration (ng/mL) 
▲ 103.14±17.55 53.92±7.16 p<0.05 
Leptin concentration (pg/mL) 
■ 684.92±97.66 1118.98±162.67 p<0.05 
* All values presented as mean±standard error of the mean (SEM). 
▲ 
MetS (n=29, 46.8 %) and non-MetS (n=33, 53.2 %). 
■
 MetS (n=28, 46.7 %) and non-MetS (n=32, 53.3 %). 
 
3.2.6 Familial cancer history 
Data on familial cancer history revealed that n=27 (33.8 %) participants either had a mother, 
father, or sibling with cancer (Figure 3.4). From the n=27, n=five (5.3 %) participants reported 
familial cancer history from more than one family member. Two participants had a mother and 
father with cancer history, while three participants had a father and sibling with cancer history. 
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Among the participants with familial cancer history, breast cancer was the most common cancer 
type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: The percentage of participants with no familial cancer history, compared to participants with a 
father, mother, or sibling with cancer history. 
 
3.3 DIFFERENCE BETWEEN RESPECTIVE GROUPS ACCORDING TO METABOLIC 
STATUS AND BODY MASS INDEX 
 
In order to describe the interaction of both BMI and metabolic status on various anthropometric, 
BIA and blood-specific parameters, the following groups were identified and compared with each 
other: (1) non-MetS with normal BMI (NMetS-), (2) MetS with overweight BMI (OWMetS+), (3) 
non-MetS with overweight BMI (OWMetS-), (4) MetS with obese BMI (OBMetS+), and (5) non-
MetS with obese BMI (OBMetS-). 
 
Following BMI calculation, the participants were classified as normal, overweight or obese 
(Figure 3.5). In the total study population, the majority of participants were categorised as being 
overweight (n=34, 42.5 %), or obese (n=30, 37.5 %) (Figure 3.5A). In the MetS group, the 
overweight and obese groups included n=17 participants each (Figure 3.5B). Of the n=46 
participants in the non-MetS group, n=16 (34.8 %) presented with normal weight, n=17 (37.0 %) 
were classified as overweight, and n=13 (28.3 %) were obese (Figure 3.5C).  
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Figure 3.5: The distribution of participants according to their body mass index for (A) the total study 
population (n=80), (B) the MetS group (n=34), and (C) the non-MetS group (n=46). 
 
3.3.1 Distribution and prevalence of the individual components of the metabolic 
syndrome 
The different components of the MetS (IDF, 2006) are presented in Figure 3.6. Here, WC was 
significantly higher in all subgroups (OWMetS+, OWMetS-, OBMetS+ and OBMetS-) compared 
to the NMetS- group (p<0.001 for all) (Figure 3.6A). Furthermore, WC measurements for both 
the OBMetS+ and OBMetS- groups were significantly higher compared to their overweight 
counterparts (99.7±2.3 vs 84.1±0.7 cm for MetS and 95.1±2.2 vs 78.0±1.3 cm for non-MetS, 
p<0.001 for both). A statistical trend was also observed between the OWMetS+ and OWMetS- 
groups (84.1±0.7 vs 78.0±1.3 cm, p=0.06). 
 
Systolic blood pressure was significantly higher in the OBMetS+ group compared to the 
OBMetS- group (143.7±4.7 vs 123.1±3.5 mmHg, p<0.05) (Figure 3.6B). No significant 
differences were observed for DBP (Figure 3.6C) or blood glucose levels (Figure 3.6D). Both the 
NMetS- and the OWMetS- groups had higher HDL-c levels compared to the OWMetS+ group 
(p<0.05 for both) (Figure 3.6E). Triglyceride levels were significantly higher in the OWMetS+ 
group compared to the NMetS- group (2.3±0.3 vs 1.1±0.2 mmol/L, p<0.01). Additionally, a 
significant difference was noted between the OWMetS+ and OWMetS- groups (2.3±0.3 vs 
1.1±0.2 mmol/L, p<0.01) (Figure 3.6F).  
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Figure 3.6: MetS risk factors according to IDF criteria for: (A) waist circumference, (B) systolic-, and (C) 
diastolic blood pressure, (D) blood glucose, (E) high-density lipoprotein cholesterol, and (F) triglycerides. 
Solid lines represent IDF normal cut-off values (IDF, 2006). * p<0.05, ** p<0.01, *** p<0.001. 
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3.3.2 Anthropometric parameters 
Apart from WC, all other anthropometric indices were grouped and illustrated in Figure 3.7. All 
groups had significantly higher BMIs compared to the NMetS- group (p<0.001 for all except 
OWMetS-, p<0.01 for OWMetS-) (Figure 3.7A). The OBMetS+ and OBMetS- also differed 
significantly from the OWMetS+ and OWMetS- groups, respectively (37.2±1.0 vs 27.9±0.4 kg/m2 
for the MetS groups and 38.5±1.5 vs 26.9±0.4 kg/m2 for the non-MetS groups, p<0.001 for both). 
Similar results were obtained for HC (Figure 3.7B). 
 
The W:H was significantly higher in the OBMetS+ group compared to the NMetS- group 
(p<0.01) (Figure 3.7C). A statistical trend was also observed between the NMetS- and 
OWMetS+ groups (0.8±0.0 vs 0.8±0.0, p=0.07). The SAD was significantly higher in all the 
respective groups (p<0.001 for all), except between the NMetS- and OWMetS- group (Figure 
3.7D). Furthermore, SAD was significantly higher in the obese compared to the overweight 
groups (28.1±0.6 vs 23.0±0.3 cm for the MetS group and 28.2±0.9 vs 21.2±0.4 cm for the non-
MetS group, p<0.001). 
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Figure 3.7: Anthropometric indices including, (A) body mass index, (B) hip circumference, (C) waist-to-hip 
ratio, and (D) sagittal abdominal diameter for all groups, categorised according to metabolic status and body 
mass index class. Solid lines represent normal WHO cut-off values.  
(WHO, 2004a; 2008). 
* p<0.05, ** p<0.01, *** p<0.001.  
 
3.3.3 Bioelectrical impedance analysis characteristics 
3.3.3.1 Subcutaneous and visceral adipose tissue area 
The SAT areas for the OWMetS+, OBMetS+ and OBMetS- groups were significantly greater 
compared to the NMetS- group (p<0.001 for all). The SAT area of the OBMetS- group was also 
significantly greater than that of the OWMetS- group (225.0±13.9 vs 167.8±10.3 cm2, p<0.01) 
(Figure 3.8A). 
 
Similar results were obtained for VAT (p<0.001 for all). Here, a statistical trend was also noted 
between the OWMetS+ and OWMetS- groups (336.8±6.2 cm2 vs 300.2±13.0, p=0.051) (Figure 
3.8B).  
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Figure 3.8: Subcutaneous adipose tissue area (A), and visceral adipose tissue area (B), for all groups, 
categorised according to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.3.2 Percentage subcutaneous and visceral adipose tissue, and VAT:SAT 
The SAT % for all subgroups was significantly lower compared to the NMetS- group (p<0.001 
for all groups) (Figure 3.9A). All results for VAT % were contrary to that obtained for SAT % 
(p<0.001 for all groups except OWMetS-, p<0.01) (Figure 3.9B). Significant differences were 
also evident between the OWMetS+, OWMetS- and their respective obese groups for SAT % 
and VAT % (68.7±1.4 vs 76.1±1.2 % for the MetS groups and 66.9±1.1 vs 75.0±1.3 % for the 
non-MetS groups, p<0.001 for both). The VAT:SAT showed similar results to that obtained for 
VAT %; however, no significant difference was observed between the NMetS- and OWMetS- 
(Figure 3.9C).  
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Figure 3.9: Percentage subcutaneous adipose tissue (A), percentage visceral adipose tissue (B), and (C) 
VAT:SAT for groups, categorised according to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.4 Red blood cell membrane fatty acid profile 
The following sections present the results for the Ω-3 index, α-LA and DPA levels, Ω-3:Ω-6, FA 
metabolism desaturase enzymes, and n-9 SI. 
 
3.3.4.1 The omega-3 index 
No significant differences were observed for EPA, DHA, and the Ω-3 index (EPA+DHA) (Figure 
3.10).   
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Figure 3.10: Eicosapentaenoic acid (A), docosahexaenoic acid (B), and the omega-3 index (C) for groups, 
categorised according to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.4.2 Additional omega-3 fatty acids 
The results for α-LA and DPA levels did not yield any statistical significant differences (Figure 
3.11).  
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Figure 3.11: Alpha-linoleic acid (A), and docosapentaenoic acid (B) for groups categorised according to 
metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.4.3 The omega-3 to omega-6 ratio 
No significant differences were observed for any of the Ω-6 FAs (LA and AA) or the Ω-3:Ω-6 
(Figure 3.12).  
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Figure 3.12: Linoleic acid (A), arachidonic acid (B), and the omega-3:omega-6 (C) for groups categorised 
according to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.4.4 Fatty acid metabolism: delta-9 SCD 1 
No significant differences were observed for PA, PLA, and the Δ-9 SCD 1 (PLA/PA) (Figure 
3.13).  
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Figure 3.13: Palmitic acid (A), palmitoleic acid (B), and the delta-9 SCD 1 (C) for groups categorised according 
to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.4.5 Fatty acid metabolism: delta-9 SCD 2 and the n-9 saturation index 
Stearic acid, OA and the Δ-9 SCD 2, calculated as OA:SA levels, showed no statistically 
significant differences (Figure 3.14A-C). The n-9 SI, calculated as SA:OA levels, indicated no 
statistically significant differences or statistical trends between groups (Figure 3.14D). 
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Figure 3.14: Stearic acid (A), oleic acid (B), the delta-9 SCD 2 (C), and the n-9 saturation index (D) for groups 
categorised according to metabolic status and body mass index class. 
* p<0.05, ** p<0.01, *** p<0.001. 
 
3.3.5 Biochemical blood analysis for insulin-like growth factor-1 (IGF-1) and 
leptin 
The IGF-1 concentration of the OBMetS+ group was significantly higher than that of the NMetS- 
group (121.9±29.9 vs 41.0±8.1 ng/mL, p<0.05) (Figure 3.15A). Albeit so, the OBMetS+ 
presented with IGF-1 concentration two and a half times higher than the OBMetS- women. 
Although, no statistically significant difference was also noted for leptin concentrations, the 
OWMetS- group presented with a leptin concentration 1.7 times higher than the OWMetS+ 
group. Similarly, leptin concentration of the OBMetS+ group was two times higher than the 
OBMetS- group (Figure 3.15B) 
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Figure 3.15: Biochemical analysis for (A) insulin-like growth factor-1 and (B) leptin. 
* p<0.05, ** p<0.01, *** p<0.001. 
▲NMetS- (n=13, 39.4 %), OWMetS- (n=12, 36.4 %), OWMetS+ (n=14, 48.3 %), OBMetS- (n=8, 24.2 %), OBMetS+ (n=15, 51.7 %). 
■ NMetS- (n=9, 28.1 %), OWMetS- (n=13, 40.6 %), OWMetS+ (n=13, 46.4 %), OBMetS- (n=10, 31.3 %), OBMetS+ (n=15, 53.6 %). 
 
3.4 THREE-DAY FOOD DIARY 
Although a small proportion (n=23, 28.8 %) of the total study participants used in the current 
study completed the three-day food diaries, a frequency table of the top ten food items for 
carbohydrate, protein, and fat macronutrient intake are presented in Table 3.5. Potatoes were 
the most commonly consumed carbohydrate food, followed by breakfast cereals and porridge, 
and brown- and white bread. Small and equal quantities of crackers, pizzas and pies were also 
consumed. For most commonly eaten protein-rich foods, the majority of participants consumed 
full cream milk and cheese, while beef was the most common meat source consumed, followed 
by chicken and pork. Only a small number of participants consumed lamb and mutton. 
Sunflower oil, followed by polyunsaturated margarine and hard margarine were the most 
commonly used fats and oils. Consumption of brick margarine, 50 % polyunsaturated margarine, 
and salad dressings were similar. 
 
Table 3.5: Frequency table for the three-day food records of carbohydrate, protein, and fat intake. 
FREQUENCY CARBOHYDRATES PROTEIN FATS 
1 Potatoes Full cream milk Sunflower oil 
2 Breakfast cereals and porridge Cheese Polyunsaturated margarine 
3 Brown bread Beef Hard margarine 
4 White bread Chicken Mayonnaise 
5 Rice Pork Butter 
6 Pasta Low fat and 2 % milk Olive oil 
7 Muffins, cookies, cakes and puddings Eggs Butro 
8 Crackers Fish Brick margarine 
9 Pizza Lamb and mutton 50 % polyunsaturated margarine 
10 Pies Full fat yoghurt Salad dressing 
 
From all the carbohydrates, protein and fats listed in Table 3.5, the top ten food products 
consumed were also determined (Figure 3.16). Full cream milk was the most common food 
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product consumed by participants. Similar quantities of cheese and sunflower oil were 
consumed, as well as equal quantities of pork, and low fat and two percent milk. 
 
 
Figure 3.16: The frequency of the top ten food products consumed by the study participants. 
 
3.5 CORRELATION ANALYSES 
Correlations were performed in order to establish the possible associations between selected 
physiologically-relevant parameters. The following correlation coefficient values were 
considered: (i) r-values greater than 0.70 were regarded very strong, (ii) r-values between 0.40 
and 0.69 as strong, (iii) r-values between 0.30 and 0.39 as moderate, and (iv) r-values between 
0.20 and 0.29 as weak. R-values less than 0.19 indicated no relationship (Scally, 2014). For all 
correlation purposes, the NMetS- groups are indicated in the figures labelled A and D (G, J and 
M), the OWMetS+ and OWMetS- groups in figures B and E (H, K and N), and the OBMetS+ and 
OBMetS- groups in figures C and F (I, L and O). 
 
3.5.1 Body mass index correlations 
Body mass index positively correlated with the VAT:SAT for all groups, except the OWMetS+ 
group (Figure 3.17A-C). Significant strong correlations were only observed in the obese groups 
(r=0.67, p=0.00 for OBMetS+ and r=0.61, p=0.00 for OBMetS-) (Figure 3.17C). Similar results 
were observed between BMI and VAT % (Figure 3.17D-F). Here, the OBMetS+ and the 
OBMetS- correlations were also significant (r=0.64, p=0.01 for OBMetS+ and r=0.57; p=0.04 for 
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OBMetS-) (Figure 3.17F). Although the correlation between BMI and SAT % showed opposing 
results (Figure 3.17G-I), the OBMetS+ and OBMetS- groups’ correlations were also significant 
(r=-0.64, p=0.01 for OBMetS+ and r=-0.57, p=0.04 for OBMetS-), with similar correlation 
coefficients and p-values to that observed for the correlation between BMI and VAT %. 
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Figure 3.17: Associations between body mass index and VAT:SAT, body mass index and percentage visceral adipose tissue, and body mass index and subcutaneous 
adipose tissue in the NMetS- (A, D, G), OWMetS+ and OWMetS- (B, E, H), and OBMetS+ and OBMetS- (C, F, I) groups. 
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3.5.2 Systolic blood pressure correlations 
Systolic blood pressure was correlated with EPA (Figure 3.18A-C), DPA (Figure 3.18D-F), DHA 
(Figure 3.18G-I), Ω-3 index (Figure 3.18J-L) and Ω-3:Ω-6 (Figure 3.18M-O), with most of the 
correlations either showing a weak relationship or no association. Moderate to strong positive 
associations were evident when SBP was correlated with EPA levels in all groups, except for the 
NMetS- and OBMetS- groups (Figure 3.18A and 3.18C). When SBP was correlated with DPA, 
weak and strong negative correlations were evident in the OWMetS- and OBMetS- groups, 
respectively (Figure 3.18E and 3.18F). For SBP and DHA, a weak negative correlation was also 
evident in the OBMetS- group, while a strong positive association was observed for the 
OWMetS+ group (Figure 3.18H and 3.18I). Similar associations were evident when SBP was 
correlated with the Ω-3 index, while strong positive trends were observed between SBP and 
EPA (r=0.46, p=0.06) (Figure 3.18B), and SBP and DHA (r=0.45, p=0.07) (Figure 3.18H). A 
strong positive trend was also evident for SBP and the Ω-3 index (r=0.46, p=0.06) (Figure 
3.18K), while a significant positive correlation was observed for SBP and the Ω-3:Ω-6 (r=0.49, 
p=0.046) in the OWMetS+ group (Figure 3.18N). 
 
Stellenbosch University  https://scholar.sun.ac.za
  
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Correlations between systolic blood pressure and eicosapentaenoic, docosapentaenoic and docosahexaenoic acid levels, the omega-3 index, and the 
omega-3:omega-6 in the NMetS- (A, D, G, J, M), OWMetS+ and OWMetS- (B, E, H, K, N), and OBMetS+ and OBMetS- (C, F, I, L, O) groups. 
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3.5.3 Subcutaneous adipose tissue area correlations 
Subcutaneous adipose tissue area was positively correlated with the Ω-3 index (Figure 3.19A-C) 
and Ω-3:Ω-6 (Figure 3.19D-F) for all groups, except the NMetS- group. Significant, strong 
positive correlations between SAT area and the Ω-3 index were evident in the OWMetS+ group 
(r=0.51, p=0.04) (Figure 3.19B), and the OBMetS- group (r=0.56, p=0.04) (Figure 3.19C). 
Correlations between the SAT area and the Ω-3:Ω-6 indicated statistically significant, strong 
positive correlations in the OWMetS+ (r=0.54, p=0.02) OBMetS+ groups (r=0.51, p=0.04). 
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Figure 3.19: Relationship between the subcutaneous adipose tissue area and the omega-3 index, and subcutaneous adipose tissue and the omega-3:omega-6 in the 
NMetS- (A, D), OWMetS+ and OWMetS- (B, E), and OBMetS+ and OBMetS- (C, F) group.
A B C 
D E F 
100,00
120,00
140,00
160,00
180,00
200,00
220,00
0,00 5,00 10,00 15,00
S
A
T
 a
re
a
 
 (
c
m
2
) 
Omega-3 index NMetS-
Linear (NMetS-)
A 
r=-0.38, p=0.16 
100,00
120,00
140,00
160,00
180,00
200,00
220,00
0,15 0,35 0,55 0,75
S
A
T
 a
re
a
  
(c
m
2
) 
Omega-3:Omega-6 
NMetS-
Linear (NMetS-)
r=-0.32, p=0.23 
D 
100,00
120,00
140,00
160,00
180,00
200,00
220,00
240,00
260,00
280,00
300,00
0,00 5,00 10,00 15,00
S
A
T
 a
re
a
  
(c
m
2
) 
Omega-3 index 
OWMetS+
OWMetS-
Linear (OWMetS+)
Linear (OWMetS-)
B 
r=0.51, p=0.04 
r=0.35, p=0.17 
100,00
120,00
140,00
160,00
180,00
200,00
220,00
240,00
260,00
280,00
300,00
0,10 0,30 0,50 0,70 0,90
S
A
T
 a
re
a
  
(c
m
2
) 
Omega-3:Omega-6 
OWMetS+
OWMetS-
Linear (OWMetS+)
Linear (OWMetS-)
r=0.54, p=0.02 
r=0.31, p=0.23 
E 
140,00
160,00
180,00
200,00
220,00
240,00
260,00
280,00
300,00
320,00
0,00 5,00 10,00 15,00
S
A
T
 a
re
a
  
(c
m
2
) 
Omega-3 index 
OBMetS+
OBMetS-
Linear (OBMetS+)
Linear (OBMetS-)
r=0.31, p=0.23 
r=0.56, p=0.04 
C 
140,00
160,00
180,00
200,00
220,00
240,00
260,00
280,00
300,00
320,00
0,15 0,35 0,55
S
A
T
 a
re
a
  
(c
m
2
) 
Omega-3:Omega-6 
OBMetS+
OBMetS-
Linear (OBMetS+)
Linear (OBMetS-)
F 
r=0.51, p=0.04 
r=0.31, p=0.30 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
  
 
97 
 
CHAPTER 4: DISCUSSION 
 
4.1 INTRODUCTION 
The present study aimed to describe the prevalence of the MetS in a female farm worker 
population. Furthermore, the associations between the components of the MetS and specific 
individual FAs and FA ratios, anthropometric measures, dietary intake, and possible cancer risk 
were also explored. This chapter will focus on interpreting the results found in the current study 
by using relevant literature. 
 
4.2 PREVALENCE OF THE METABOLIC SYNDROME 
It was reported in a few studies reported on the prevalence of the MetS on the African continent. 
Several factors are at play that could help explain the lack of information on prevalence studies 
in SSA, including the use of different definitions to identify the MetS. Studies conducted in 
Europe, China, Iran, and Mexico have shown the MetS prevalence to range between 21.1 to 
33.8 % (Alkerwi et al., 2011; Esteghamati et al., 2011; Chiu et al., 2012; García-Jiménez et al., 
2015). A study in South Africa reported that 42.1 % of the population presented with the MetS 
using the JIS definition (Crowther & Norris, 2012). Two studies, one in Botswana and the other 
in Nigeria, found the MetS prevalence to differ significantly when using the ATP III criteria. 
Gyakobo et al. (2012) found the MetS prevalence in Ghana to be as high as 35.9 %, much 
higher than the MetS prevalence of 12.1 % reported in Nigeria (Adegoke et al., 2010). It was 
reported by a South African study that 25.0 % of women from Kwa-Zulu Natal presented with the 
MetS with IDF criteria among (Motala et al., 2011), while Erasmus et al. (2012) described a 
higher MetS prevalence of 67.8 % among women in the Western Cape Province using the IDF 
definition. A bit closer to home, a more recent Cape Town study by Peer et al. (2015), reported a 
much lower overall MetS prevalence of 30.7 % (43.5 % for women and 16.5 % for men), when 
using the JIS definition. Our population, although only females, had a prevalence of 42.5 % 
when IDF criteria was used (Figure 3.1), which is still considered high compared to other South 
African studies.  
 
Several inconsistencies between these studies and the present study may contribute to the 
different findings, one of which includes the sample size. Both Motala et al. (2011) and Erasmus 
et al. (2012) included much larger sample sizes (n=947 and n=642, respectively) compared to 
the sample size of the current study (n=80). The present study included Caucasian, Coloured, 
and Black women, whereas Motala et al. (2011) and Erasmus et al. (2012) only included Black 
and Coloured participants, respectively. Lifestyle- and genetic factors may also have influenced 
the difference in prevalence. Poor dietary choices, including high intake of salt, processed foods, 
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and saturated and trans-fat, all contribute to the increased prevalence of the individual MetS 
components, which ultimately increase the risk of developing the MetS (Jeon et al., 2011; Peer 
et al., 2013; Helelo et al., 2014). Smoking, alcohol consumption, and physical inactivity are also 
considered major risk factors for the components of the MetS (Helelo et al., 2014). Dietary 
intake of the women of the current study indicated a generally unhealthy diet (Table 3.5), with 
most women being current drinkers (Appendix I.1) who participated in moderate-intensity work 
and recreational activities (Appendix I.2), the majority of which did not smoke (Appendix I.1). It is 
therefore likely that diet, alcohol consumption, and physical activity may have contributed to the 
high prevalence of the MetS in our population. 
 
Age is also considered a confounding factor, since the females’ mean age in the present study 
was 37.2 years, while the mean age in the studies by Motala et al. (2011) and Erasmus et al. 
(2012) ranged between 46.5 years and 50.9 years, respectively. Ageing is associated with an 
increased prevalence of the individual MetS components and an increased risk of developing 
the MetS (Alkerwi et al., 2011; Camhi et al., 2011; Peer et al., 2013; Helelo et al., 2014; 
Rochlani et al., 2015). This was also evident in the current study, since the participants in the 
MetS group (mean age 40.2 years) were significantly older than their non-MetS (mean age 35.0 
years) counterparts (Table 3.1). 
 
The effect of gender may also contribute to the discrepancies between these studies, since 
findings suggest that the prevalence of the MetS is higher in women (Garrido et al., 2009; 
Motala et al., 2011, Erasmus et al., 2012; Gyakobo et al., 2012; Peer et al., 2015). For example, 
Peer et al. (2015) reported a MetS prevalence of 43.5 % among women, while only 16.5 % of 
men presented with the MetS. It is also likely that gender disparities in lipid- and glucose 
metabolism could have accounted for the variation in the prevalence of the individual 
components of the MetS (Hoebel et al., 2013; Rochlani et al., 2015).  
 
The studies mentioned thus far also made use of different MetS definitions. Some studies 
actually tried to establish the prevalence of the MetS by comparing different definitions with one 
another to determine which definition would yield a higher MetS prevalence. Alkerwi et al. (2011) 
compared the MetS prevalence in women using the JIS, IDF, and ATP III definitions and found 
almost similar results (JIS: 20.4 %, IDF: 19.3 % and ATP III: 18.5 %). However, when the IDF 
definition was compared to that of the ATP III, Gyakobo et al. (2012) reported a two times higher 
MetS prevalence according to the IDF definition (35.9 % vs 15.0 %). Reasons for this 
discrepancy include the lower cut-off values for WC (female WC≥80 cm for IDF and ≥88 cm for 
ATPII) and FBG (≥5.6 mmol/L for IDF and ≥6.1 mmol/L for ATP III) used in the IDF definition.  
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4.3 DISTRIBUTION AND PREVALENCE OF THE METABOLIC SYNDROME RISK 
FACTORS 
Although we report a relatively high prevalence of the MetS, the specific combination of risk 
factors, or even the prevalence of an individual risk factor, are extremely important, since these 
risk factors can individually, or collectively increase the risk for the development of CVD, T2DM, 
and lifestyle-associated cancers (Alberti et al., 2009; Klug et al., 2012; Crowther & Norris, 2012; 
Erasmus et al., 2012; Roswall et al., 2014; Almquist et al., 2015). For the Mets group, the 
majority of participants presented with three risk factors (58.8 %). However, what is somewhat 
concerning is that 20.6 % of the participants in the MetS group presented with four and five risk 
factors respectively, while only 13.0 % of participants in the non-MetS group presented with no 
MetS risk factors and were therefore not at risk of developing the MetS. Similar to findings from 
Strand et al. (2015), our results showed that in the non-MetS group, two risk factors were most 
prevalent (54.3 %) (Figure 3.2).  
 
The prevalence of each of the individual MetS risk factors in the present study also differed 
between the two groups. Abdominal obesity was the most prevalent individual risk factor in the 
MetS group, which is expected since WC is the determining factor for MetS diagnosis according 
to the IDF. This was followed by hypertension (82.4 %), and low HDL-c levels (76.5 %) (Figure 
3.3). Our finding of the clustering of WC, hypertension, and low HDL-c levels is in agreement 
with that reported by Gyakobo et al. (2012). Here, the IDF definition was also used and the 
same three risk factors were shown to be largely responsible for the MetS prevalence in a rural 
population from Ghana. 
 
For the non-MetS group of the present study, hypertension was the most common individual 
MetS risk factor (47.8 %), followed by abdominal obesity (39.1 %), and low HDL-c levels (34.8 
%). Contrasting results have been reported for the least, and most prevalent individual MetS risk 
factors, since earlier studies by Garrido et al. (2009) (using the ATP III definition) and Motala et 
al. (2011) (using the JIS definition) found low HDL-c levels to be the most prevalent MetS risk 
factor. However, more recent studies found increased WC to be more prevalent (Hoebel et al., 
2011; Gyakobo et al., 2012; Peer et al., 2015; Salonen et al., 2015; Strand et al., 2015). 
Although the IDF definition do not routinely use the BMI to assess obesity, studies have 
indicated that obesity is a major contributor to dyslipidaemia (de Boer et al., 2011; Evans et al., 
2011), which was also a common risk factor in the women of the current study. Here, the mean 
BMIs for the MetS and non-MetS groups were 32.6 kg/m2 and 28.7 kg/m2 respectively (Table 
3.1), which is indicative of an overweight and obese population, and studies have shown that 
under these conditions, lipolysis is increased and HDL-c levels are reduced (Boden, 2009; 
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Mendonça et al., 2015). Furthermore, ethnicity may also influence lipid profiles, since a study by 
Evans et al. (2011) observed that Black women exhibited significantly lower HDL-c levels 
compared to Caucasians, possibly due to the higher prevalence of obesity among Black 
compared to Caucasian women. The current study included Black, Coloured, and Caucasian 
women, and inclusion of the different ethnic groups may have influenced the prevalence of 
specific MetS risk factors. 
 
A recent investigation by Strand et al. (2015) found that hypertension was the second most 
prevalent individual risk factor, which is similar to our findings for the MetS group. Ageing is 
associated with arterial thickening and increased arterial resistance, which contributes to 
hypertension (Helelo et al., 2014). The MetS group (mean age 40.2 years) of the current study 
was significantly older than their non-MetS (mean age 35.0 years for non-MetS) counterparts, 
which may also explain the prevalence of hypertension in this population, specifically in the 
MetS group (Table 3.1).  
 
Several lifestyle factors may also contribute to the development of hypertension, including diet, 
tobacco use, alcohol intake, and physical inactivity (Jennings et al., 2009; Jeon et al., 2011; 
Peer et al., 2013, Helelo et al., 2014; Kaur, 2014). Even though the participants in the current 
study were not grouped according to number of cigarettes smoked, or amount of alcohol units 
consumed, fewer women in the MetS group were current smokers and drinkers compared to the 
non-MetS group (35.3 vs 43.5 % for current smokers, and 55.9 vs 71.7 % for current drinkers) 
(Appendix I.1). As a result, it is unlikely that smoking and alcohol consumption could potentially 
have contributed to the high prevalence of hypertension in this population.  
 
Concerning physical activity, 17.7 % of MetS and 20.0 % of the non-MetS participants did 
vigorous-intensity work, while 5.9 % of MetS and 10.9 % of the non-MetS participants did 
vigorous-intensity recreational activities (Appendix I.2). Fewer participants in the MetS group 
(50.0 % vs 55.6 %) participated in moderate-intensity work, whereas more participants in the 
MetS group (76.5 % vs 69.6 %) participated in moderate-intensity recreational activities. It is 
therefore possible that physical activity or lack thereof in the MetS group could have potentially 
contributed to the high prevalence of the individual components of the MetS in this population. 
Although stress and levels of urbanisation were not assessed in the current study, these factors 
are known to contribute to hypertension (Jennings et al., 2009; Jeon et al., 2011; Peer et al., 
2013, Helelo et al., 2014; Kaur, 2014), and might be worth investigating in the future. 
 
Studies have indicated that abdominal obesity plays a significant role in hypertension, since 
obesity is associated with microvascular dysfunction and abnormal vascular tone, which 
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increases vasoconstriction and leads to hypertension (de Boer et al., 2011; Peer et al., 2013, 
Helelo et al., 2014; Kaur, 2014). Several measures used to assess abdominal obesity were 
significantly higher in the MetS group of the current study, indicating that obesity may have 
played a role in the prevalence of hypertension in this population (Table 3.1). Another 
component of the MetS, glucose intolerance/IR, have also been proposed to contribute to 
hypertension, although the exact mechanism is still unclear (Jennings et al., 2009; Kirk & Klein, 
2009; Horita et al., 2011; Sossa et al., 2012; Kaur, 2014; Soleimani, 2015). Although one such 
mechanism proposes that IR attenuates the vasodilatory effects of insulin, and this contributes 
to hypertension (Kirk & Klein, 2009; Horita et al., 2011), not all are in consensus. An alternative 
mechanism may involve the RAAS system. Here, hyperglycaemia and -insulinaemia are 
proposed to cause increased angiotensin II expression that activates RAAS, which result in 
increased BP via increased sodium resorption and cardiac output, and ultimately 
vasoconstriction (Horita et al., 2011; O’Neill & O’Driscoll, 2015; Soleimani, 2015). Glucose and 
insulin levels were both significantly higher in the MetS group of the current study (Table 3.1), 
suggesting that glucose intolerance/IR may have played a role in the prevalence of 
hypertension. 
 
4.4 DESCRIPTIVE PROFILE OF THE STUDY POPULATION ACCORDING TO 
METABOLIC STATUS AND BODY MASS INDEX 
Although BMI is not routinely used by the IDF to assess adiposity, a large body of scientific 
evidence indicate that an increased BMI is associated with a worsening metabolic profile, since 
BMI was positively correlated with hypertension, IR, dyslipidaemia, and an increased risk of the 
MetS and CVD (Wildman et al., 2008; Jeon et al., 2011; Peer et al., 2013; Abu-Farha et al., 
2014; Helelo et al., 2014). Various studies indicated that individuals with the MetS had 
significantly higher BMIs, which suggest a definite link between the MetS and obesity (Nigam et 
al., 2009; Bremer et al.; 2011; Esteghamati et al., 2011; Atanassova et al., 2014). It is suggested 
that obesity and its associated metabolic alterations contributes to alterations in glucose 
homeostasis, increased hepatic glycogenesis, and IR that leads to a greater risk of other co-
morbidities (Aballay et al., 2013). These studies, as well as several others established that 
obesity is a dominant risk factor for the MetS, and it is exactly for that reason that BMI was also 
used in the current study to try to determine the effect of the metabolic status together with BMI 
on different physiologically relevant parameters. 
 
4.4.1 Body mass index classification 
Studies found that approximately 2.1 billion adults were either overweight or obese, with an 
increasing prevalence of female obesity in low- to middle-income countries (Garrido et al., 2009; 
Stellenbosch University  https://scholar.sun.ac.za
  
 
102 
 
Alkerwi et al., 2011; Crowther & Norris, 2012; Erasmus et al., 2012; Peer et al., 2013; Ng et al., 
2014; Senekal et al., 2015). In South Africa, 69.3 % of women were overweight, while 42.0 % 
were obese (Ng et al., 2014). This trend of more individuals being overweight was also observed 
in the current study population, with only 20.0 % of the women showing normal body weight 
(Figure 3.5A). The MetS group of the present study included equal numbers of overweight 
(n=17, 50.0 %) and obese (n=17, 50.0 %) participants, while the non-MetS group included 
normal weight (n=16, 34.8 %), overweight (n=17, 37.0 %), and obese (n=13, 28.3 %) women 
(Figure 3.5B & 3.5C). This could have accounted for the significantly higher mean BMI evident in 
the MetS group.  
 
The current study also observed that when BMI was used to categorise individuals, the BMIs in 
all the respective groups were significantly higher compared to the NMetS- group, and the BMI 
of both obese groups were significantly higher than their overweight counterparts (Figure 3.7A). 
These findings differ from that found by Senekal et al. (2015), who reported that obesity was 
more common than being overweight (55.0 % vs 27.0 %), in women in the Western Cape. The 
present study and the study by Senekal et al. (2015) included participants with a low socio-
economic status; however, the study by Senekal et al. (2015) included women from urban and 
rural areas, and level of urbanisation have been shown to be positively correlated with the 
prevalence of obesity.  
 
Urbanisation is often associated with lifestyle changes, including tobacco use, unhealthy diet, 
excessive alcohol consumption, and physical inactivity, and these factors contribute to the 
development of obesity (Erasmus et al., 2012; Hoebel et al., 2013). The majority of women in 
both the MetS (50.0 %) and non-MetS (45.7 %) groups in the current study were non-smokers, 
while fewer women in the MetS group (35.3 %) were current smokers than in the non-MetS 
group (43.5 %) (Appendix I.1). This makes it unlikely that smoking contributed to obesity in this 
population. Dietary intake in the current study did not reveal a healthy diet plan, since large 
quantities of SFA, red meat, and refined carbohydrates were consumed, while intake of fruit, 
vegetables and dietary fibre were low (Table 3.5), and this may have contributed to the 
prevalence of overweight and obesity in these women. Additionally, although the majority of 
participants in the current study were current alcohol consumers, current drinking was less 
common among the MetS (55.9 %) than non-MetS (71.7 %) women (Appendix I.1). Alcohol 
intake is known to increase obesity, due to increased energy intake (Hoebel et al., 2011; Strand 
et al., 2015), and this may have played a role in the current study. Physical inactivity could also 
have contributed to the prevalence of obesity in this population, since fewer participants in the 
MetS group (50.0 % for the MetS and 55.6 % for the non-MetS) participated in moderate-
intensity work (Appendix I.2), compared to a greater proportion participating in moderate-
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intensity recreational activities (76.5 % vs 69.6 %). Only a small proportion of women in both the 
MetS (5.9 %) and non-MetS (10.9 %) groups did vigorous-intensity recreational activities. 
  
4.4.2 Metabolic-associated blood parameters 
The MetS consists of several individual risk factors, including abdominal obesity, hypertension, 
IR/hyperinsulinaemia and impaired glucose homeostasis, and dyslipidaemia (Alberti et al., 2006; 
Alberti et al., 2009; Jeon et al., 2011; Crowther & Norris, 2012). Although the exact 
pathophysiology of each of these components and the sum of the individual risk factors remain 
elusive, studies agree on the individual components of the MetS (Erasmus et al., 2012; Klug et 
al., 2012; Camargo et al., 2014). Each of these components (WC, SBP, DBP, and glucose and 
TG levels) were significantly higher, while HDL-c levels were significantly lower in the MetS 
compared to the non-MetS women in the current study (Table 3.1). Our findings therefore 
confirm the data obtained from other studies (Nigam et al., 2009; Bremer et al.; 2011; 
Esteghamati et al., 2011; Atanassova et al., 2014). This cluster of metabolic abnormalities 
increases the risk of CVD, T2DM, lifestyle-associated cancers, and mortality through its effects 
on hormonal, inflammatory, and growth factor pathways (Kuchiba et al., 2012; Reeves et al., 
2012; Peer et al., 2015).  
 
4.4.2.1 Waist circumference 
Waist circumference is known to contribute to the increased prevalence of the MetS, including 
obesity, and in agreement, the current study noted that WC was significantly higher in all groups 
compared to the NMetS- group (Figure 3.6A). This finding was similar to that observed by 
Gómez-Ambrosi et al. (2012) and Motie et al. (2014). Waist circumference was significantly 
greater in the obese compared to the overweight groups with and without the MetS (Figure 
3.6A), which is not an unexpected finding, since obesity is characterised by excessive lipid 
storage, adipocyte hypertrophy, and weight gain (Donohoe et al., 2010; Blüher & Mantzoros, 
2015; Mendonça et al., 2015).  
 
The current study also noted a statistical trend between the WC measurements of the OWMetS- 
and OWMetS+ groups. The WC is used as a proxy measure of VAT, and in agreement, we 
reported significantly strong positive associations between WC and VAT %, and VAT:SAT in 
both obese groups (Appendix J, Table J.1). Furthermore, a significantly strong negative 
relationship was observed between WC and SAT % in these groups. Increasing VAT leads to an 
increased risk of the MetS, since increased abdominal fat is associated with increased lipolysis, 
and therefore increased FFAs in the bloodstream (Evans et al., 2011; Aballay et al., 2013). This 
reduces insulin sensitivity and impairs insulin signalling, while also increasing insulin synthesis 
and -secretion (Aballay et al., 2013). Although insulin levels were significantly higher in the MetS 
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compared to the non-MetS group of the current study, no other significant differences were 
observed for insulin levels of the obese subgroups (Table 3.1 & Appendix K).  
 
4.4.2.2 Systolic- and diastolic blood pressure  
The MetS is associated with arterial hypertension, possibly due to the association between 
abdominal obesity and IR (Jennings et al., 2009; Jeon et al., 2011; Peer et al., 2013, Helelo et 
al., 2014; Kaur, 2014). An earlier study by Al-Daghri et al. (2013) observed positive relationships 
between BP, BMI, and WC. Studies by Marques-Vidal et al. (2010) and Gómez-Ambrosi et al. 
(2012) noted that SBP and DBP were significantly higher in obese than in normal weight 
individuals, while Motie et al. (2014) found no significant differences for SBP or DBP with 
increasing BMI. Similar to the findings of Motie et al. (2014), the current study did not observe 
any significant difference for SBP or DBP with increasing BMIs (Figure 3.6B & 3.6C). Increasing 
body weight is often associated with increased BP, for which several mechanisms have been 
proposed to explain this association (Wildman et al., 2008; Jeon et al., 2011; Peer et al., 2013; 
Abu-Farha et al., 2014). One such mechanism suggests that obesity causes microvascular 
dysfunction and abnormal vascular tone, which leads to improved vasoconstriction and reduced 
vasodilation, and ultimately increased BP (de Boer et al., 2011; Peer et al., 2013; Helelo et al., 
2014; Kaur, 2014).  
 
Hyperinsulinaemia might also be responsible for the high prevalence of hypertension observed 
in our population, since the study by Al-Daghri et al. (2013) noted a significant positive 
association between BP and HOMA-IR. This is possible, since hyperinsulinaemia increases 
sodium resorption, leads to vasodilation and volume expansion, and ultimately increases BP 
(Kirk & Klein, 2009). Insulin levels, and SBP and DBP were all higher than the IDF cut-off values 
for all the respective groups in the current study (except SBP for the OBMetS-) and this may 
explain why no significant differences were observed for either SBP, DBP, insulin, and glucose 
levels with increasing BMI (Appendix K). 
 
One also has to consider the sympathetic nervous activity that is associated with obesity, and 
which often leads to hyperinsulinaemia and counteracts vasodilation (Aballay et al., 2013; 
Canale et al., 2013). Alterations in the sympathetic nervous system is part of the 
pathophysiology of the MetS, and considering its effect on cardiac output, peripheral vascular 
resistance and renal sodium handling, these factors have been thought to contribute to 
hypertension via its downstream effects (Canale et al., 2013). The current study found SBP to 
be significantly higher in the OBMetS+ compared to the OBMetS- group (Figure 3.6B), which is 
in line with the mechanism proposed by Canale et al. (2013). Considering that adipocytes 
produce small quantities of angiotensin, thereby affecting the RAAS that contribute to 
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hypertension (Aballay et al., 2013), the fact that WC and BMI were significantly higher in all the 
respective groups compared to the NMetS- group (Figure 3.6A & 3.7A) might explain the overall 
high SBP and DBP in the current study population. 
 
4.4.2.3 Blood glucose and insulin levels 
Studies by Marques-Vidal et al. (2010) and Gómez-Ambrosi et al. (2012) found exponentially 
higher glucose and fasting insulin levels with increasing BMI. However, Motie et al. (2014) and 
the current study did not observe significant differences for glucose with increasing BMI (Figure 
3.6D), while insulin levels were only significant higher in the OWMetS+ compared with the 
OWMetS- group (Appendix K). The individual components of the MetS may have played a role, 
since a positive relationship exists between IR and abdominal obesity (Jennings et al., 2009; de 
Boer et al., 2011). The proposed mechanism highlights the association between obesity and 
adipose tissue dysfunction, including its ability to increase the secretion of pro-inflammatory 
adipokines, which contribute to IR (Shah et al., 2012; Shah et al., 2014; Yeoh et al., 2015). The 
current study observed several significant differences for WC between the respective groups 
(Figure 3.6A), which makes it possible that abdominal obesity may have affected glucose and 
insulin levels.  
 
Literature suggests that IGF-1 plays a role in glucose homeostasis, since increased insulin 
levels decrease IGFBP levels that could increase IGF-1 bioavailability (Donohoe et al., 2012; 
Doyle et al., 2012; Rajpathak et al., 2012; Sierra-Johnson et al., 2015). The IGF-1 concentration 
in the current study was only significantly higher in the OBMetS+ women compared with the 
NMetS- women, which suggests that IGF-1 may have played a role (Figure 3.15A). Adipokines 
(such as leptin) function to regulate energy balance and glucose homeostasis; however, obesity 
and the MetS are associated with dysregulation of adipokines (Yun et al., 2011; Motie et al., 
2014). In agreement, Al-Daghri et al. (2013) also reported a significant positive association 
between the HOMA-IR and leptin levels. Dysregulation of leptin synthesis affects insulin 
signalling and glucose homeostasis, which may lead to hyperglycaemia (Deng & Scherer, 2010; 
García-Jiménez et al., 2015). Albeit so, the current study did however not observe any 
significant differences for either glucose or leptin levels in the respective groups (Figure 3.15B).  
 
4.4.2.4 Lipid profile 
Another distinctive component of the MetS is dyslipidaemia, which may contribute to 
atherosclerotic lesions and CVD (Shapira, 2009). Studies by Jeon et al. (2011) and Gómez-
Ambrosi et al. (2012) noted a more atherogenic lipid profile (significantly higher total cholesterol, 
LDL-c and TGs levels, and lower HDL-c levels) in obese compared to normal weight persons. 
Stellenbosch University  https://scholar.sun.ac.za
  
 
106 
 
This especially places the obese group at an increased risk of dyslipidaemia, the MetS, and 
CVD (Jeon et al., 2011; Gómez-Ambrosi et al., 2012).  
 
Insulin resistance may also contribute to atherogenic dyslipidaemia, since IR results in 
increased lipolysis, which in turn elevates TG levels by increasing VLDL production and -
secretion, as well as by increasing HDL-c catabolism (Sumner et al., 2005; Ginsberg & 
Karmally, 2009; Kirk & Klein, 2009; Jeon et al., 2011). Studies also found that low HDL-c levels 
were significantly associated with an increased risk of IR in women (Jennings et al., 2009; 
Delisle et al., 2013). This might explain why HDL-c levels were significantly higher in the 
OWMetS- compared to the OWMetS+ group, since the only significant difference for insulin 
levels was also observed between these two groups (Figure 3.6E & Appendix K). Triglyceride 
levels were also significantly higher in the OWMetS+ compared with the OWMetS- women 
(Figure 3.6F). 
 
The results of the present study did not indicate significant differences in the lipid profiles of the 
normal and obese groups; however, both HDL-c and TG levels were significantly lower and 
higher in the OWMetS+ compared to the NMetS- group, respectively (Figure 3.6E & 3.6F). 
These findings were similar to that reported by Gómez-Ambrosi et al. (2012) in persons without 
the MetS. However, the study by Gómez-Ambrosi et al. (2012) also found a significant increase 
in total cholesterol and LDL-c levels with increasing BMI. In contrast, the study by Motie et al. 
(2014) did not corroborate these findings, findings that were also not evident in our study. 
Delisle et al. (2013) noted that overweight and obesity, as measured by WC, is associated with 
low HDL-c levels; therefore, obesity may have played a role in the lipid profiles of the women of 
the current study, since increasing BMI was associated with increasing WC (Figure 3.6A).  
 
4.4.2.5 Confounding factors for the metabolic syndrome components 
Gender, ethnicity, age, medical history, lifestyle choices, stress, and level of urbanisation 
(Umscheid et al., 2010; Jeon et al., 2011; Delisle et al., 2013; Peer et al., 2013) were all 
confounding factors in the current study and may explain why our findings for some of the 
individual components of the MetS differ from that observed in previous studies. 
 
Gender  
Several studies have reported that the MetS prevalence is much higher in women compared to 
men (Garrido et al., 2009; Motala et al., 2011; Gyakobo et al., 2012; Shah et al., 2014). A 
possible explanation is that women have higher body fat, total adiposity, and insulin sensitivity 
compared to men, and this may be due to hormonal and adipose tissue distribution differences 
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(Rochlani et al., 2015). The current study only included female participants, which may have 
influenced the findings.  
 
Ethnicity  
The prevalence of the components of the MetS has also been found to differ between ethnic 
groups. For example, hyperglycaemia was more common among Black than Caucasian women 
(Evans et al., 2011). Ethnic background, reported by Jennings et al. (2009) and Evans et al. 
(2011), was associated with elevated TG levels among Caucasian women compared to Black 
women. Jennings et al. (2009) also suggested that genetic differences between different ethnic 
groups were partially related to the different lipid profiles. Caucasian, Coloured, and Black 
women were included in the current study, and cultural influences may have played a role in the 
prevalence of overweight and obesity in this population. Overweight and obesity are related to 
all the individual components of the MetS, and ethnicity may have affected these parameters. 
Moreover, cultural influences are associated with a larger body size in Black women, since it 
reflects happiness and health (Holdsworth et al., 2004; Kaduka et al., 2012; Peer et al., 2015), 
and this may contribute to the significantly higher prevalence of obesity among women.  
 
Age  
Prevalence of the MetS components also increase with ageing, which was demonstrated in a 
study by Peer et al. (2013), where a higher prevalence for hypertension was noted in the older 
group (25-34 years vs 65-74 years). Ageing is associated with hypertension due to age-
associated arterial thickening and increased arterial resistance (Helelo et al., 2014). Another 
factor to consider is oestrogen and its beneficial effects on BP; however, the age-related decline 
in oestrogen contributes to hypertension (Hilliard et al., 2013; Rochlani et al., 2015). The 
ageing-associated decline in oestrogen is also associated with adipose tissue redistribution 
(Alkerwi et al., 2011; Camhi et al., 2011), and in agreement Senekal et al. (2015) also reported 
that abdominal obesity was associated with ageing. The effects of ageing must also be 
considered in the current study population, since the MetS group (mean age 40.2 years) was 
significantly older than their non-MetS counterparts (mean age 35.0 years) (Table 3.1). 
 
Diet  
The unhealthy Westernised diet, which mainly includes red and processed meat, saturated and 
trans-fat, and low intake of dietary fibre, fruit and vegetables, is associated with the MetS, and 
its individual components (de Oliveira et al., 2012; Shab-Bidar et al., 2014; Grosso et al., 2015; 
Senekal et al., 2015). Poor lifestyle choices, including increased salt intake, contribute to the 
increased prevalence of hypertension, since sodium homeostasis is disturbed (Sheng, 2009; 
Helelo et al., 2014). Dietary fat intake such as SFA and trans-fats causes lower HDL-c and 
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higher TG levels via its effect on insulin levels, which lead to increased lipolysis (Hosseinpour-
Niazi et al., 2016). The women of the current study consumed several food products that 
contain SFAs and trans-fats and this may have influenced the different components of the MetS 
(Figure 3.16).  
 
Smoking  
Smoking may have unfavourable effects on the components of the MetS. For example, smoking 
affects BP, since it is associated with endothelial injury, increased sympathetic activity induced 
by nicotine, increased inflammation, increased arterial stiffness, and changes in lipid profile 
(Malekzadeh et al., 2013). Although the majority of women in the current study in both the MetS 
and non-MetS groups were non-smokers (Appendix I.1), factors such as under-reporting and 
the lack of information on smoking duration, number of cigarettes smoked, and the effects of 
previous smoking may be confounding factors. 
 
Physical activity  
Physical activity is another lifestyle factor that is associated with the MetS. Studies suggest that 
physical activity is protective against hypertension (Malekzadeh et al., 2013; Peer et al., 2013), 
possibly due to its ability to induce weight loss, increase metabolic rate and fat metabolism, and 
reduce IR, plasma renin, and vascular tone (Golbidi et al., 2012; Malekzadeh et al., 2013). A 
smaller proportion of MetS (50.0 % for moderate-intensity and 17.7 % for vigorous-intensity) 
women in the current study participated in moderate- and vigorous-intensity activities at work 
compared to their non-MetS counterparts (55.6 % for moderate-intensity and 20.0 % for 
vigorous-intensity) (Appendix I.2). More women in the MetS group (76.5 % vs 69.6 %) 
participated in moderate-intensity recreational activities, which may indicate over-reporting of 
physical activity in the women of the MetS group.  
 
4.4.3 Anthropometric parameters 
For the present study, all anthropometric indices of adiposity (BMI) and abdominal adiposity 
(WC, W:H, W:Ht, and SAD) were significantly higher in the MetS group (Table 3.1). Studies by 
both Bremer et al. (2011) and Atanssova et al. (2014) showed BMI and WC to be significantly 
higher, while Cheong et al. (2015) and Peer et al. (2015) found not only BMI and WC, but also 
W:H to be significantly higher in MetS participants. Despite the lack of statistical significance 
between the HC measurements of the MetS and non-MetS groups, significant differences were 
noted between the NMetS- group and all the subgroups, as well as the overweight and obese 
groups (Figure 3.7B). These findings are in agreement with that of Gómez-Ambrosi et al. (2012), 
who found that WC and HC measurements, and the W:H were significantly greater in obese- 
compared with normal weight persons. The W:H was only significantly higher in the OBMetS+ 
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compared to the NMetS- group, while a statistical trend was noted between the OWMetS+ and 
NMetS- groups (Figure 3.7C).  
 
The WC, HC and W:H are surrogate measures of adipose tissue distribution, particularly the 
more pathogenic visceral compartment (Willet & Hu, 2013; Anunciaçao et al., 2014; Cheong et 
al., 2015). Yim et al. (2010) also found that the SAD is indicative of visceral obesity, regardless 
of age, gender, degree of obesity or other metabolic parameters. This is in agreement with the 
current study where both obese groups presented with a significantly greater SAD compared to 
their overweight counterparts (Figure 3.7D). The SAD of the OWMetS+, OBMetS+ and OBMetS- 
was also significantly greater compared to the NMetS- group. Furthermore, a strong positive 
relationship was established between the SAD and VAT % in both obese groups (Appendix J, 
Table J.2), which confirms the findings reported by Yim et al. (2010).  
 
Although the IDF definition do not include the SAD and W:Ht, these anthropometric parameters 
have been shown to correlate with the components of the MetS, including TGs, glucose levels, 
and BP (Schneider et al., 2011; Ware et al., 2014). Visceral adiposity is also associated with 
several adverse metabolic alterations and lifestyle-associated cancers through its effects on 
inflammatory cytokine production that promotes carcinogenesis (Kang et al., 2010; Yamamoto et 
al., 2010; Yim et al., 2010; Donohoe et al., 2011; Doyle et al., 2012; Anunciaçao et al., 2014; 
Carlsson et al., 2014; Vasques et al., 2015). Adipose tissue metabolism is closely related to the 
complications of obesity preceding the MetS, and NCDs such as T2DM, CVD, and certain 
lifestyle-associated cancers (Evans et al., 2011; Jeon et al., 2011, Gómez-Ambrosi et al., 2012; 
Peer et al., 2013, Abu-Farha et al., 2014; Helelo et al., 2014; Almquist et al., 2015; Miglani et al., 
2015).  
 
Under normal physiological conditions, adipose tissue will neutralise and store nutritional 
overload to protect the body from IR (Esteves & Dias-Peixoto, 2015). In contrast, the obese 
state is associated with adipose tissue dysfunction and its associated effect in altering 
adipokine- and cytokine secretion (Kranendonk et al., 2015). This causes a state of low-grade 
chronic inflammation, and macrophage mobilisation and infiltration, which lead to 
hyperinsulinaemia, IR, dyslipidaemia, and hypertension that ultimately contribute to the 
development of the MetS (Bremer et al., 2011; Esteves & Dias-Peixoto, 2015; Kranendonk et 
al., 2015). Thus, since the MetS group presented with increased BP, and TG and insulin levels 
(Table 3.1, Figure 3.6 & Appendix K), we cannot rule out the involvement of the inflammatory 
and immune systems that accompanies the obese state, which may also have contributed here. 
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Age might be considered a possible confounding factor in the associations between the MetS 
and WC, HC, and W:H, since Al-Daghri et al. (2013) observed positive relationships between 
age and the W:H in non-MetS normal weight persons between the ages of 22 and 67 years. 
Cheong et al. (2015) proposed that this was due to the age-associated changes in total- and 
regional adipose tissue distribution. In agreement, the current study observed a positive 
statistical trend between age and W:H for the NMetS- group (Appendix K, Table J.3). Although 
the MetS group (mean age 40.2 years) of the current study was also significantly older than the 
non-MetS group (mean age 35.0 years) (Table 3.1), no other significant positive relationships 
were observed between age and W:H.  
 
A limitation of using WC, HC, and SAD is that measurements may be inaccurate and 
overestimated due to the standing position of the participant and/or the looseness of the 
abdominal- and gluteal muscles (Willet & Hu, 2013; Anunciaçao et al., 2014). Different studies 
have also used different anatomical locations to measure the WC, HC, and SAD, and different 
cut-off values may have been used, which complicates the comparison of studies (Anunciaçao 
et al., 2014; Hoebel et al., 2014). In obese participants, it may be especially difficult to locate the 
anatomical landmarks to take the measurements due to the accumulation of adipose tissue 
around this site (Steward & Sutton, 2012).  
 
4.4.4 Bioelectrical impedance analysis characteristics 
The MetS group showed significantly greater VAT area, VAT %, and VAT:SAT, while SAT % 
was significantly lower (Table 3.2). These findings are similar to studies by Fox et al. (2007), 
Kim et al. (2011), and Yeoh et al. (2015) who also showed that in women, an increasing 
VAT:SAT was significantly associated not only with the MetS, but also with all of the individual 
components of the MetS. In agreement, the current study noted significant positive associations 
between VAT:SAT and WC for both obese groups, while a positive correlation was also noted 
between VAT:SAT and SBP for the OBMetS+ group (Appendix J, Table J.1 & Table J.4). 
Statistical trends were also observed for VAT:SAT and HDL-c, and VAT:SAT and LDL-c for 
OWMetS- women. The VAT and SAT differ in anatomical location, LPL activity, and cytokine 
secretion profiles, and therefore its association with cardiometabolic diseases (Liu et al., 2010b), 
and this may explain why the MetS group also presented with significantly greater VAT area, 
VAT % and VAT:SAT. 
 
Although studies on the role of SAT in the pathogenesis of the MetS are mostly inconsistent, it 
was suggested that increased SAT might lead to hepatic- and skeletal muscle fat accumulation 
with associated IR that contributes to the pathogenesis of the MetS (Pou et al., 2009; Liu et al., 
2010b; Bremer et al., 2011). Others found that the SAT depot is the least active adipose tissue 
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depot with lower macrophage infiltration, and adipokine secretion (Pou et al., 2009; Kranendonk 
et al., 2015), since the visceral compartment is more metabolically active, thereby secreting 
larger quantities of pro-inflammatory adipokines, which is directly associated with IR (Shah et 
al., 2014; Mendonça et al., 2015; Yeoh et al., 2015). Moreover, VAT is regarded as more 
lipolytically active, promoting the release of FFAs into the portal circulation and increasing 
hepatosteatosis (Esteves & Dias-Peixoto, 2015; Kranendonk et al., 2015). This directly affects 
hepatic glucose- and lipid metabolism, because increased visceral adiposity is associated with 
impaired β-cell function, and subsequent reduced insulin sensitivity and IR (Jennings et al., 
2009; Gletsu-Miller et al., 2013). This is also evident in the current study where significantly 
higher insulin levels were observed in the MetS compared with the non-MetS group, and the 
OWMetS+ group presented with significantly higher insulin levels compared to the OWMetS- 
group (Table 3.1 & Appendix K). 
 
In a state of positive energy balance, excess FFAs are stored in the SAT; however, during a 
state of caloric excess, remodelling of the adipose tissue takes place via adipocyte hypertrophy 
and -hyperplasia (Yeoh et al., 2015). In the obese state, adipose tissue remodelling becomes 
pathologic, since the lack of adequate adipocytes and the limited capacity to store adipose 
tissue subcutaneously, results in spill over into the ectopic (visceral) fat compartment (Pou et al., 
2009; Yeoh et al., 2015). This state is characterised by hypoxia, angiogenesis, inflammation, 
and concomitant IR (Bremer et al., 2011; Vykoukal & Davies, 2011), a mechanism supported by 
the findings of several studies that indicated that increasing BMI is associated with increasing 
VAT- and SAT areas (Camhi et al., 2011; Motala et al., 2011; Motie et al., 2014; Shah et al., 
2014; Vasques et al., 2015). Our results also showed that the SAT areas were significantly 
greater in the OWMetS+, OBMetS+ and OBMetS- groups compared with the NMetS- group, 
while the VAT area was also significantly greater in the OWMetS- compared with the NMetS- 
group (Figure 3.8). Additionally, VAT and SAT areas were also greater in the OBMetS- 
compared to the OWMetS- groups, while a statistical trend was observed for the OBMetS+ and 
OWMetS+ groups. The SAT % was significantly higher in the NMetS- compared with all the 
respective subgroups, while both overweight groups presented with significantly higher SAT % 
than their obese counterparts (Figure 3.9A). The opposite was true for VAT % and VAT:SAT 
(Figure 3.9B & 3.9C).  
 
The area of adipose tissue distribution is related to metabolic dysfunction, because it was shown 
that visceral adiposity is more pathogenic than subcutaneous adiposity (Liu et al., 2010b; Shah 
et al., 2014; Kranendonk et al., 2015). The distribution of adipose tissue is also a key factor in 
the pathophysiology of the MetS (Jeon et al., 2011; Camargo et al., 2014; Alberti et al., 2006; 
Crowther & Norris, 2012). Adipose tissue is either stored in the subcutaneous- or visceral 
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compartments to participate in metabolic pathways such as lipid- and glucose metabolism 
(Kranendonk et al., 2015). If one assumes that anthropometric measures are correlated with 
more direct measures of obesity, such as SAT and VAT (Camhi et al., 2011), BMI might be 
considered a useful surrogate to describe obesity status. This is possible, since VAT and SAT 
have been related to metabolic dysfunction, and both are associated with BMI and WC (Pou et 
al., 2009; Yim et al., 2010; Camhi et al., 2011; Kaess et al., 2012; Yeoh et al., 2015). In 
agreement, the present study also found positive associations between BMI and VAT:SAT, and 
BMI and VAT % in the obese subgroups (Figure 3.17C & 3.17F). Additionally, positive 
relationships were also revealed for WC and VAT:SAT, WC and VAT %, SAD and VAT:SAT, 
and SAD and VAT % in the obese subgroups (Appendix J, Table J.1 & J.2). Opposing results 
were obtained for SAT % (Figure 3.17I and Appendix J, Table J.1 & J.2). This is in agreement 
with the findings of Yeoh et al. (2015), who reported that during caloric excess, the cellular 
characteristics of SAT changes reduce its ability to expand, and excess calories are stored in 
the visceral compartment. These findings also confirm that increasing BMI is associated with 
increasing VAT, which is associated with an increasing risk of CVD, and several lifestyle-
associated cancers (Kuchiba et al., 2012; Wiedman et al., 2013; Lindkvist et al., 2014; Kawai et 
al.,2013; Yeoh et al., 2015).  
 
The metabolic changes associated with obesity, such as IR, hypertension, and dyslipidaemia 
can also contribute to increased cancer risk (Jeon et al., 2011; Peer et al., 2013; Helelo et al., 
2014). Abdominal obesity can specifically increase the risk of cancer, since adipose tissue can 
act in an autocrine or paracrine manner to alter the insulin/IGF-1 pathway, and increase 
inflammatory markers and the production of adipokines such as leptin that promote 
carcinogenesis (Donohoe et al., 2011; Donohoe et al., 2012; Doyle et al., 2012). The current 
study also noted that several measures of abdominal obesity, and IGF-1 and leptin levels were 
significantly higher in the MetS group (Table 3.1 & 3.4). 
 
The degree of obesity is not the only factor responsible for the association between obesity and 
IR, but the site of adipose tissue accumulation may also play a role (Vasques et al., 2015). Liu et 
al. (2010b) found that the VAT compartment is a much stronger correlate of the components of 
the MetS compared to the SAT compartment. In agreement, Evans et al. (2011) found that VAT 
is associated with increased sympathetic activity and increased angiotensin expression, which 
contributes to increased BP. Visceral adipose tissue accumulation may also have contributed to 
hypertension in the current population, since MetS women presented with significantly higher 
VAT area and -%, VAT:SAT, SBP and DBP (Table 3.1 & 3.4). Kaess et al. (2012) also reported 
significant positive associations between the VAT:SAT and several cardiometabolic risk factors, 
including the MetS components.  
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The current study found statistical trends between TG levels and VAT %, and VAT:SAT in the 
NMetS- group (Appendix J, Table J.5). Additionally, a strong negative trend was observed 
between SAT % and TG levels. This is in agreement with earlier findings by Fox et al. (2007), 
where obesity and the obesity-associated chronic inflammation alters lipoprotein metabolism, 
and IR in the liver, thereby reducing VLDL and TG catabolism and increasing HDL-c catabolism.  
 
Several confounding factors may influence adipose tissue distribution. For example, Shah et al. 
(2012) reported that women have significantly higher SAT and lower VAT compared to men. 
The current study only included women, and these findings may therefore not be applicable to 
men. Although the principles underlying the association between VAT and SAT, and gender is 
unclear, this association may be related to the regulatory effects of oestrogen on metabolism, 
and lipogenesis (Kaess et al., 2012). Ethnicity is another factor that may influence adipose 
tissue distribution, since Black women presented with lower VAT compared to their Caucasian 
counterparts for the same WC measurement (Jennings et al., 2009; Camhi et al., 2011). Age 
may also influence adipose tissue distribution, since ageing is associated with the loss of SAT 
and gain of VAT. Yim et al. (2010) demonstrated this mechanism by reporting significantly 
higher VAT and lower SAT in older women (75-84 years) compared to younger counterparts 
(35-44 years). Although all of these factors mentioned above may have influenced the BIA 
findings of the current study, we did not specifically assess the association between these 
factors and the different measures of adipose tissue distribution.  
 
4.4.5 Red blood cell membrane fatty acid profile 
Comparison of the FA profiles of healthy individuals to those diagnosed with the MetS indicated 
a possible link between the MetS and specific FAs (Kabagambe et al., 2008; Novgorodtseva et 
al., 2011; Zong et al., 2013). Body mass index has a modifying effect on the relationship 
between the individual components of the MetS and FA composition. This was demonstrated by 
Klein-Platat et al. (2005), who reported that FA levels are directly associated with weight status, 
since SFAs were significantly higher, and PUFA levels were significantly lower in overweight 
individuals respectively. Fatty acids are also regarded as the major link between obesity, IR, and 
cancer, since increasing body weight is associated with hyperinsulinaemia/IR, and increased 
IGF-1 levels that creates a pro-tumorigenic environment (Boden, 2009; Doyle et al., 2012). 
 
4.4.5.1 Saturated fatty acids  
Evidence suggest that the MetS is positively correlated with SFAs, since MetS groups presented 
with significantly higher SA levels compared to healthy controls (Nigam et al., 2009; 
Novgorodtseva et al., 2011; Žák et al., 2014). The results of the current study did not report any 
significant differences in PA or SA levels in the MetS and non-MetS groups, or any of the 
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respective subgroups (Table 3.3, Figure 3.13A & 3.14A). Factors such as IR, obesity, and 
dyslipidaemia are positively correlated with FA levels, which may explain the discrepant findings 
– various studies reported even higher HOMA-IR, insulin, TG and LDL-c levels, and WC 
measurements (Nigam et al., 2009; Novgorodtseva et al., 2011; Žák et al., 2014) compared to 
the present study. Women in the MetS group of the current study did however present with 
significantly higher glucose and insulin levels compared to the non-MetS group (Table 3.1, 
Figure 3.6 & Appendix K).  
 
Saturated fatty acids and insulin resistance  
Insulin resistance may have played a role in the non-significant findings for the SFAs, SA and 
PA, in the current study (Table 3.1, Figure 3.13A & 3.14A). This is possible since the MetS is 
characterised by elevated glucose and insulin levels, and this state is associated with enhanced 
hepatic de novo lipogenesis and reduced FA oxidation (Sethom et al., 2011). Although various 
studies reported positive relationships between glucose levels and SFAs (Kabagambe et al., 
2008; Patel et al., 2010), the current study did not observe any significant difference in SFA or 
glucose levels between the subgroups (Figure 3.6, 3.13 & 3.14). Dietary fat quality may 
influence glucose metabolism and the development of IR, since the consumption of SFAs is 
associated with reduced insulin sensitivity (Nigam et al., 2009; Astrup et al., 2011; Patel et al., 
2010). One of the proposed mechanisms for this association is that SFAs have adverse effects 
on cell membrane function due to alterations in membrane fluidity, ion permeability, and insulin 
receptor binding and -affinity (Patel et al., 2010). The current study has shown this to be true, 
since here, relatively large quantities of SFA fat were consumed, and insulin levels were also 
elevated (Table 3.5 & Appendix K). 
 
Saturated fatty acids and obesity 
A study by Kawashima et al. (2009) did not find any significant differences between the SFA 
levels of normal and obese persons, similar to the results for SFAs observed in the present 
study (Figure 3.13A & 3.14A). However, a recent study by Tremblay-Franco et al. (2015) found 
that the MetS obese group presented with higher SA levels and decreased Δ-9 SCD 2 activity 
compared to the non-MetS normal weight participants. Pickens et al. (2015) corroborated these 
findings; however, the current study did not observe any statistically significant differences for Δ-
9 SCD 2 enzyme activity or n-9 SI between the respective groups (Figure 3.14C & 3.14D). 
Different factors could account for the discrepant results, such as the specific MetS definition 
used, and the fact that Tremblay-Franco et al. (2015) matched participants for age and gender. 
Furthermore, geographical region may have played a role, and the large variability in sample 
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sizes used in Tremblay-Franco et al.’s (2015) study compared to the current one (n=75 vs n=13 
for the MetS obese group, and n=210 vs n=16 for the non-MetS normal weight) (Figure 3.5).  
 
A dairy intervention study by Abdullah et al. (2015) found that although SFAs are predominant in 
dairy products, SA levels were not significantly different between the control and intervention 
groups. In agreement, women of the current study consumed relatively large quantities of SFA-
containing foods, including red meat, lamb, pork, chicken, and whole milk products, although 
SFA levels did not differ significantly between the groups (Figure 3.16). 
 
Saturated fatty acids and dyslipidaemia 
Some studies have also reported on the association between SFAs and dyslipidaemia; however, 
results have been conflicting, possibly due to the diverse effects of specific SFA on the lipid 
profile (Mayneris-Perxachs et al., 2014; Hlavaty et al., 2015; Ruiz-Núñez et al., 2016). The 
mechanism proposes that changes in lipoprotein synthesis leads to increased LDL-c and TG 
levels, glucose metabolism enzyme activity, and inflammation (Patel et al., 2010; Astrup et al., 
2011; Abdullah et al., 2015). Kim et al. (2015) supported this mechanism by reporting a positive 
association between PA and TG levels. Although TG levels were significantly higher in the 
OWMetS+ group compared to the OWMetS- and NMetS- groups, no significant differences were 
noted for PA levels in any of the subgroups in the current study (Figure 3.6 & 3.16). 
 
4.4.5.2 Monounsaturated fatty acids  
We did not report any significant differences for the MUFAs (PLA and OA) between the MetS 
and non-MetS groups, or any of the subgroups in this study (Table 3.3, Figure 3.13B & 3.14B). 
Although Novgorodtseva et al. (2011) reported significantly lower PLA in the MetS group 
compared to healthy controls, studies by Nigam et al. (2009), Sethom et al. (2011), and Žák et 
al. (2014) found the opposite to be true. Nigram et al. (2009) and Žák et al. (2014) also noted 
that OA levels did not differ between groups with and without the MetS; whereas, Sethom et al. 
(2011) found OA levels to be significantly higher in the MetS group, possibly due to the 
compensatory upregulation of the Δ-9 SCD enzymes in response to persistently higher SFA 
levels here. We reported no significant difference in Δ-9 SCD 1 or -2 activities, the n-9 SI, or any 
of the individual FAs used to calculate these ratios (Table 3.3, Figure 3.13 & 3.14). Since the 
activities of the Δ-9 SCD desaturase enzymes are under hormonal- and nutritional control 
(Mikirova et al., 2004), elevated MUFA levels may therefore suggest an increased insulin-
induced upregulation of Δ-9 SCD activity to convert SFAs to MUFAs (Sethom et al., 2011). 
Although insulin levels in the MetS group were significantly higher than the non-MetS group 
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(Table 3.1), a finding also evident in the overweight subgroups, no significant differences in 
MUFA levels were observed (Figure 3.13 & 3.14).  
 
Monounsaturated fatty acids and insulin resistance  
Increased FFAs are associated with reduced insulin sensitivity and inhibition of glucose uptake 
that ultimately lead to IR (Boden, 2009; Mendonça et al., 2015). Levels of MUFAs are also 
positively associated with insulin levels and IR, because insulin stimulates hepatic de novo 
lipogenesis and reduces FA oxidation (Nigam et al., 2009; Sethom et al., 2011; Kurotani et al., 
2012; Sertoglu et al., 2014). The only significant difference noted for insulin levels in the current 
study, were significantly higher insulin levels in the OWMetS+ group compared to the OWMetS- 
group, and yet MUFA levels did not indicate any significance (Figure 3.13 & Appendix K). 
Palmitoleic acid is normally not present in the diet and dietary intake may therefore not have 
played a role; therefore, PLA levels reflect the conversion of PA to PLA via the Δ-9 SCD 1 
enzyme (Kurotani et al., 2012).  
 
Even though the women in the current study consumed several OA-containing food products, 
including olive- and sunflower oil, and potatoes (Ginsberg & Karmally, 2009), OA levels still did 
not differ between any of the groups or subgroups (Table 3.3, Figure 3.14B & 3.16). A possible 
explanation may involve the use of the three-day food diary, which only collected information on 
dietary habits three days following the initial visit to the research group, and which is not really 
comparable to FA levels in the RBC membranes, since it shows medium-term intake instead (± 
120 days). The Westernised diet also obtains OA from animal products, which contains large 
quantities of SFAs, and this makes it likely that SFA intake confounded the OA findings. Women 
in the current study consumed relatively large quantities of foods containing SFAs, including 
dairy products (full cream milk and cheese), sunflower oil, and meat products (Figure 3.16).  
 
Monounsaturated fatty acids and obesity 
Obesity may also affect MUFA levels (Sethom et al., 2011; Žák et al., 2014), which was evident 
in a study by Tremblay-Franco et al. (2015), where PLA levels were significantly higher in obese 
women with the MetS. More recently, BMI was positively associated with PLA levels in a study 
by Dugas et al. (2016). This is possible since obesity is associated with reduced FA oxidation 
and increased lipogenesis (Sethom et al., 2011; Tremblay-Franco et al., 2015). However, the 
current study did not show any significant differences in PLA levels or any significant 
associations between PLA levels and W:H in any of the different groups (Figure 3.13B & 
Appendix J, Table J.6).  
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Distinct differences in the activity of the Δ-9 SCD 1 enzyme has been reported between normal 
weight and obese groups, with Δ-9 SCD 1 enzyme activity being significantly elevated in the 
obese group (Kawashima et al., 2009). In contrast, the present study did not find any significant 
differences in the Δ-9 SCD 1 enzyme with increasing BMI (Figure 3.13C). While the current 
study used BMI to define obesity (normal weight: BMI=18.5-24.9 kg/m2 and obese: BMI≥30.0 
kg/m2), Kawashima et al. (2009) defined the normal and obese groups according to WC 
(normal: WC<85 cm and obese: WC≥85 cm). The WC is a surrogate measure of abdominal 
obesity, while BMI reflects level of adiposity (Willet & Hu, 2013), and this may explain why 
Kawashima et al. (2009) reported significant findings. These findings may therefore suggest a 
much stronger association between Δ-9 SCD 1 activity and abdominal obesity, rather than BMI.  
 
Monounsaturated fatty acids and dyslipidaemia 
Obesity is associated with increased lipolysis and subsequent increased FFA release, and 
increased synthesis of glucose, TGs, and VLDL particles that lead to dyslipidaemia (Kawashima 
et al., 2009; Kurotani et al., 2012; Tremblay-Franco et al., 2015). In agreement, Kim et al. (2015) 
reported strong positive associations between TG levels and PLA, OA, and Δ-9 SCD, which is 
possible since Δ-9 SCD overexpression is associated with elevated TG production. However, 
although metabolic parameters of dyslipidaemia (TG and LDL-c levels) and glucose metabolism 
(glucose and insulin levels) were significantly higher in the MetS groups of the current study, no 
significant differences in MUFAs were observed (Table 3.1, Figure 3.13 & 3.14). It should 
however also be noted that the desaturase indices are calculated as product-to-precursor ratios, 
and this is only an indirect measure of desaturase activity.  
 
4.4.5.3 Omega-3 polyunsaturated fatty acids  
Nigam et al. (2009) found that MetS participants presented with significantly lower EPA and 
DHA levels compared to healthy controls. Similar to that reported by Sethom et al. (2011), the 
current study found no significant difference in the EPA or DHA levels in the MetS and non-
MetS participants (Table 3.3). The study population of Nigam et al. (2009) included individuals 
with history of acute myocardial infarction, and this disease and its medication may be the 
reason for the contrasting results, since the use of fibrates have been shown to decrease DHA 
levels. Nigram et al. (2009) further showed that alterations in the Ω-3 FA levels in individuals 
with the MetS caused a significantly lower Ω-3 index compared to healthy controls. In contrast, 
the present study did not find a significant difference in the Ω-3 index between the MetS and 
non-MetS groups (Table 3.3). Considering the association between the MetS and the different 
classes of Ω-3 FAs (Nigam et al., 2009), it is believed that the individual components of the 
MetS will also have different effects on the Ω-3 FAs. Insulin resistance may explain the 
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contrasting findings, since Nigam et al. (2009) used the ATP III definition to diagnose the MetS, 
while the current study used the IDF definition. These definitions differ regarding the cut-off 
value for impaired glucose regulation (≥6.1 mmol/L for ATP III and ≥5.6 mmol/L for IDF), and 
therefore the study by Nigam et al. (2009) investigated participants with a higher degree of IR. 
The IR state is associated with enhanced hepatic de novo lipogenesis, and reduced FA 
oxidation, which may be responsible for the negative relationship between IR and Ω-3 FAs 
(Sethom et al., 2011). 
 
Omega-3 fatty acids and insulin resistance 
Positive associations have been reported between the components of the MetS and α-LA levels. 
For example, Cespedes et al. (2015) found lower glucose levels among persons with higher α-
LA levels, suggesting that α-LA may have beneficial effects on glucose metabolism. The 
glucose levels of the current study population did not reach statistical significance for any of the 
respective groups and this might have played a role in the non-significant findings for α-LA 
levels (Figure 3.6D).  
 
Alpha-linolenic acid, one of the major Ω-3 FAs found in nuts, seeds and some vegetable oils, 
can be converted to EPA and DHA via the desaturase enzymes (DeFilippis & Sperling, 2006). 
Factors such as LA levels and competitive inhibition of the desaturase enzymes by EPA and 
DHA may also influence the conversion of α-LA to EPA, and then DHA (DeFilippis & Sperling, 
2006). Astorg et al. (2008) found that α-LA levels did not correspond with its dietary intake, and 
therefore reflects the de novo biosynthesis of α-LA, which could suggest that the dietary intake 
of the current study may also not have contributed to the non-significant findings for α-LA 
between the MetS and non-MetS groups (Table 3.3).  
 
Omega-3 fatty acids and blood pressure 
Omega-3 FAs also have favourable effects on BP due to the modulation of membrane fluidity, 
activities of membrane enzymes and -receptors, and the production of anti-inflammatory 
eicosanoids (DeFilippis & Sperling, 2006; Nagao & Yanagita, 2008). However, the MetS women 
in the current study had significantly higher SBP and DBP compared to non-MetS women, 
which may possibly be due to the low Ω-3 FA levels (Table 3.1). Several mechanisms have 
been proposed for this association, including changes to the cell membrane, activation of a pro-
inflammatory state, and increased vasoconstriction (Novgordtseva et al., 2011). Omega-3 FAs 
were shown to have beneficial effects on SBP by improving endothelial function, suppressing 
aldosterone secretion, alterations in plasma viscosity, and by regulating blood fluid volume 
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through the RAAS (Kabagambe et al., 2008; Cabo et al., 2012; Vanhala et al., 2012). 
Additionally, DHA can modulate the RAAS to promote apoptosis of vascular smooth muscle 
(Cabo et al., 2012).  
 
Literature indicates that Ω-3 FAs (specifically EPA and DHA) are precursors of lipoxins, 
resolvins and protectins, which function to regulate vascular tone, mediate vasoconstriction, and 
regulate BP (Cabo et al., 2012; Kim et al., 2013). It is therefore not surprising that participants in 
the highest DHA quartile had a significantly lower risk of developing hypertension (Zhang et al., 
2012a). In agreement, correlation analyses of the present study revealed negative relationships 
between SBP and DHA, DPA, the Ω-3 index, and the Ω-3:Ω-6 for the NMetS- group, although 
none of these reached statistical significance (Figure 3.18). The relationship between Ω-3 FAs 
and BP remain controversial, since some studies reported negative associations, while 
Cespedes et al. (2015) did not observe any association between Ω-3 FAs and blood pressure. 
In contrast, strong positive statistical trends were revealed between SBP and EPA, DHA, the Ω-
3 index, and the Ω-3:Ω-6 for the OWMetS+ group in the present study. These findings may be 
attributed to impaired FA metabolism associated with the MetS, which may accelerate arterial 
stiffness and cause hypertension (Kim et al., 2013). 
 
Omega-3 fatty acids and obesity 
Obesity may also influence the Ω-3 index, although limited scientific evidence exists on the 
beneficial effects of Ω-3 FAs on obesity (von Schacky, 2011). Some reported a negative 
associated between Ω-3 FAs and abdominal obesity (Kabagambe et al., 2008; Nagao & 
Yanagita, 2008), while Tremblay-Franco et al. (2015) and the current study did not observe any 
significant difference in the Ω-3 FA levels of normal and obese persons, regardless of their MetS 
status (Figure 3.10 & 3.11).  
 
The suggested mechanism for the beneficial effects of Ω-3 FAs on abdominal obesity is that 
elevated Ω-3 FA levels improve FA β-oxidation, which reduces fat mass and body weight 
(Clarke et al., 2001; Klein-Platat et al., 2005; Kabagambe et al., 2008). This is in agreement with 
findings by Kawashima et al. (2009), who noted lower Ω-3 FA levels in obese compared to 
normal weight counterparts, albeit in men (mean age 49.3 years for the normal weight group 
and 51.0 years for the obese group). The study by Kawashima et al. (2009) differed from the 
current study, since male participants in their study were allocated to the control (without any 
MetS risk factors), abdominal obese (WC≥85 cm) or MetS groups (IDF definition). Female 
participants in the current study were allocated to the MetS (IDF definition, WC≥80 cm) or non-
MetS groups, although participants in the latter group also presented with some of the MetS risk 
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factors that may have influenced our findings (Figure 3.2 & 3.3). Women of the current study 
were further categorised according to BMI and not WC like the study by Kawashima et al. 
(2009). These are surrogate measures of obesity and abdominal obesity, respectively, and this 
may have influenced our findings. 
 
Confounding factors such as age, diet, and Ω-6 FAs may influence Ω-3 FA levels (von Schaky, 
2011). Ageing needs to be considered, since it is associated with increased prevalence of 
obesity, which is associated with abnormal lipid metabolism and this may affect FA levels (Jeon 
et al., 2011). Although the MetS group of the current study was significantly older (40.2 years vs 
35.0 years), no significant differences were observed for the Ω-3 FAs (Table 3.1 & 3.4). Eating 
frequency, fat intake, and meat- and snack consumption are just some of the dietary factors that 
may play a role in the development of obesity, and obesity-associated changes to the FA profile 
(Jeon et al., 2011). A dairy intervention study by Abdullah et al. (2015) found that the 
intervention group presented with significantly higher plasma DPA levels compared to the 
control group. Dietary intake of the women in the current study revealed three dairy products in 
the top ten food products consumed, which may have influenced our findings (Figure 3.16). 
However, dietary intake questionnaires are susceptible to self-reported errors resulting in either 
over- or underestimation of dietary consumption.  
 
Body mass index is inversely associated with Ω-3 FAs, and moreover, it is also inversely 
associated with SAT (Pou et al., 2009; Yim et al., 2010; Camhi et al., 2011; Doyle et al., 2012; 
Shah et al., 2014; Yeoh et al., 2015). In addition, a positive relationship was reported between 
SAT and Ω-3 FAs (Fekete et al., 2015). Heemskerk et al. (2015) recently showed that SAT of 
obese women contained significantly higher EPA, DPA, and DHA levels to reduce obesity-
associated inflammation, since Ω-3 FAs have anti-inflammatory properties. Accordingly, the 
present study also observed significant positive correlations between the SAT area and the Ω-3 
index in OWMetS+ and OBMetS- women, and also between SAT and the Ω-3:Ω-6 in the 
OWMetS+ and OBMetS+ women (Figure 3.19). Regardless of the relatively low Ω-3 FA levels in 
adipose tissue, adipose-specific beneficial effects include prevention of adipose tissue 
hyperplasia and hypertrophy, and the improvement of adipose tissue inflammation (Cespedes et 
al., 2015). This is in direct contrast to the pro-inflammatory effects of the Ω-6 FAs (DeFilippis & 
Sperling, 2006; Odegaard, 2009). 
 
4.4.5.4 Omega-6 polyunsaturated fatty acids  
Arachidonic acid, commonly found in animal meat, is one of the most prominent Ω-6 FAs in the 
human diet (DeFilippis & Sperling, 2006). Despite this, the link between the MetS and AA still 
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remains unclear, since the current study (Table 3.3), as well as others (Nigam et al., 2009; Žák 
et al., 2014) report no difference in AA levels. However, the studies by Sethom et al. (2011) and 
Novgorodtseva et al. (2011) observed significantly lower AA levels in the MetS compared to the 
non-MetS group. Nigam et al. (2009) (ATP III definition), Žák et al. (2014) and the current study 
(both used the IDF definition) reported similar findings, yet different definitions of the MetS were 
used. Interestingly, Sethom et al. (2011) also used the IDF definition, yet different results were 
obtained. Novgorodtseva et al. (2011) used the AHA/NHLBI definition of the MetS, which only 
differ from the IDF regarding WC cut-off values (females WC≥88 cm for AHA, and WC≥80 cm 
for IDF). The contrasting findings between the current study and that of Novgorodtseva et al. 
(2011) may also be a result of the group allocation of participants, since Novgorodtseva et al. 
(2011) characterised participants with MetS and normal insulin levels, or controls. The current 
study on the other hand, identified participants with the MetS (WC≥80 cm, and any two or more 
MetS risk factors) or without the MetS (WC<80 cm, regardless of the presence of any MetS risk 
factors), and participants with elevated insulin levels were present in both groups. The inverse 
association between insulin and AA levels may explain the contrasting results, since insulin 
levels were much higher in the current population (34.4 and 15.6 mIU/L, Table 3.1) compared to 
the population used in the study by Novgorodtseva et al. (2011) (18.5 and 8.1 mIU/L). Studies 
have reported significant inverse relationships between insulin and Ω-6 FAs (Kabagambe et al., 
2008; Novgorodtseva et al., 2011). Elevated insulin levels and the degree of IR in the current 
study population may consequently have contributed to the low Ω-6 levels and the non-
significant findings, since the Ω-6 FAs are precursors of pro-inflammatory eicosanoids, and this 
increases the risk of IR through inflammatory processes (Spector, 2000; Strandvik, 2011; Shah 
et al., 2012; Hussein, 2013; Suburu et al., 2013).  
 
Omega-6 fatty acids and insulin resistance  
Insulin and AA levels are inversely associated due to the reduced desaturation-elongation 
cascade in IR, which worsens as IR increases (Nigam et al., 2009; Kim et al., 2013). Degree of 
obesity and distribution of adipose tissue may also play a role in the levels of different Ω-6 FAs 
(Kabagambe et al., 2008; Kim et al., 2013). Visceral obesity is associated with IR and therefore, 
AA levels are negatively associated with VAT % (Kim et al., 2013; Vasques et al., 2015). 
However, the present study did not observe any significant associations between AA levels and 
VAT % (Appendix J, Table J.7). Insulin levels were also significantly higher in the OWMetS+ 
compared with the OWMetS- group (Appendix K). 
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Omega-6 fatty acids and obesity 
Comparing AA levels of normal weight persons with and without the MetS indicated significantly 
lower AA levels in the latter group (Tremblay-Franco et al., 2015). Additionally, the obese non-
MetS group presented with significantly higher AA levels compared to the obese MetS group 
(Tremblay-Franco et al., 2015). The AA results of the current study were not statistically 
significant in any of the other subgroups (Figure 3.12B). Studies on the association between AA 
and body weight are inconsistent, since some studies observed unfavourable effects, while 
others did not detect any significant differences (Dunbar et al., 2014, Fekete et al., 2015; 
Tremblay-Franco et al., 2015). The lack of significant differences may be attributed to the 
increased synthesis of pro-inflammatory eicosanoids, because obesity is associated with 
chronic low-grade inflammation, and increased utilisation of AA (Fekete et al., 2015; Dugas et 
al., 2016). Additionally, the association between endogenous FA synthesis and dietary FA 
intake may also have played a role (Spector, 2000; DeFilippis & Sperling, 2006; Fekete et al., 
2015).  
 
4.4.5.5 The omega-3 to omega-6 ratio 
An earlier study by Nigam et al. (2009) found that the MetS group presented with a significantly 
lower Ω-3:Ω-6 compared to their non-MetS counterparts. Contrary to these findings, Vanhala et 
al. (2012) found a significantly higher Ω-3:Ω-6 in the MetS group. Although these two 
aforementioned studies show contrasting results, the results of the current study, as well as that 
of Sethom et al. (2011) did not find any statistically significant difference in Ω-3:Ω-6 of the MetS 
and non-MetS groups (Table 3.3). Several reasons may account for these discrepant findings. 
Firstly, the choice of FAs to include in the calculation of the total Ω-3 FAs, since different studies 
included different combinations of Ω-3 FAs (Murff et al., 2011). Examples of the different 
combinations include: (i) α-LA, EPA, DPA, and DHA; (ii) EPA, DPA, and DHA; (iii) α-LA, EPA, 
and DHA or (iv) only EPA and DHA. Some studies omitted α-LA in the calculation because it is 
poorly converted to EPA in humans, while others, and the present study, only included EPA and 
DHA, since these Ω-3 FAs have been shown to have anti-tumour promoting properties (Bagga 
et al., 2002; Murff et al., 2011; Pouchieu et al., 2014). Secondly, differences in dietary intake of 
the study populations of the abovementioned studies may also account for contrasting findings 
(Vanhala et al., 2012). The findings for Ω-3:Ω-6 in the current study may be due to the low 
intake of fatty fish and fish oils with concomitant high intake of Ω-6 vegetable oils in both the 
MetS and non-MetS groups (Table 3.5). Thirdly, IR may also play a role because insulin-
resistant individuals do not respond to insulin-stimulated LPL-mediated hydrolysis of TGs 
(Vanhala et al., 2012). Kabagambe et al. (2008) reported positive associations between insulin, 
HOMA-IR index and Ω-6 FAs. In the current study, the MetS group presented with significantly 
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higher insulin levels, which may have influenced Ω-6 FA levels, and it is possible that this played 
a role in the findings for the Ω-3:Ω-6 (Table 3.1 & Appendix K). The Ω-6 and -3 FAs have pro- 
and anti-inflammatory effects, which makes the Ω-3:Ω-6 clinically important, since its 
constituents compete for the same elongase and desaturase enzymes in different metabolic 
pathways (DeFilippis & Sperling, 2006; Odegaard, 2009; Murff et al., 2011; Strandvik, 2011; 
Cottet et al., 2015).  
 
Sethom et al. (2011) found that obesity is associated with reduced FA oxidation that cause 
reduced PUFA levels. Since no significant differences were evident for LA and AA levels, the 
current study also did not observe significant differences for the Ω-3:Ω-6 of the respective 
groups (Figure 3.12C). No significant correlations were also noted between the Ω-3:Ω-6 and 
BMI for any of the groups (Appendix J, Table J.6). Arachidonic acid competes with EPA and 
DHA for enzymes and space in the cell membrane (Hussein, 2013) and this interaction between 
these FAs may explain the findings of the current study. 
 
4.4.5.6 Additional factors influencing fatty acid levels  
Fatty acid assessment method 
Different studies used different methods to detect FAs in biological samples, and this 
complicates the comparison of the current results to that obtained from other studies, since the 
different tissues reflect different metabolic changes that influence FA levels (Baylin et al., 2005). 
Fatty acid levels in plasma or serum reflect dietary intake of the past few days, and may be 
compared with dietary assessment, since both reflect short-term dietary intake. The RBC 
membrane FAs reflect medium-term dietary intake changes that accumulate during the lifetime 
of the RBCs (± 120 days) (Jackson et al., 1997; Vessby et al., 2002; Hodson et al., 2008; Patel 
et al., 2010; Serra-Majem et al., 2012). The current study used the RBC membrane FA method 
to study FA composition, and this may have contributed to our findings.  
 
Studies by Nigam et al. (2009) and Žák et al. (2014) illustrates the effect of FA assessment 
methods and reported no significant differences in the plasma α-LA in the MetS and non-MetS 
groups, which is in agreement with the results of the current study (Table 3.3). Even though the 
studies by Nigam et al. (2009) and Žák et al. (2014) used plasma samples, which reflect short-
term FA levels and the present study used the RBC membrane FA method, which is indicative 
of medium-term FA levels (Jackson et al., 1997; Patel et al., 2010; Serra-Majem et al., 2012) 
similar results were obtained. This could therefore suggest that plasma FA levels are 
comparable to RBC membrane FA composition. 
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Gender  
Mayneris-Perxachs et al. (2014) reported that higher levels of PA and desaturase activities were 
more strongly related to an increased risk of the MetS in women, thereby suggesting that the 
MetS has a greater impact in women. Oestrogen upregulates desaturase activities, which 
explains these gender-related differences in FA levels (Hodson et al., 2008; Mayneris-Perxachs 
et al., 2014). Sexual dimorphism in lipid metabolism may explain the significantly higher Ω-3 FA 
levels and higher Ω-3 index, since studies observed that women have higher proportions of 
DHA, since oestrogen upregulates the conversion of α-LA to DHA via the Δ-6 desaturase, 
thereby increasing DHA biosynthesis (Hodson et al., 2008; von Schaky, 2010; Harris et al., 
2012). Although studies suggest that FA levels are higher in women, and the current study only 
included women, these participants were selected regardless of menopausal status, and the 
age-associated decline in oestrogen may have affected the findings. 
 
Physical activity  
Lower physical activity and adiposity are reportedly associated with higher PLA levels, 
suggesting that energy imbalance affects FA levels (Mozaffarian et al., 2010). Warensjӧ et al. 
(2005, 2006) found no associations between physical activity and FAs, or SCD activity. In 
contrast, Vinknes et al. (2013) reported weak associations between physical activity and SCD 
activity, and suggested that physical activity has tissue-specific effects on SCD activity. These 
findings suggest that physical activity may have led to the non-significant findings of the current 
study, since fewer MetS women participated in moderate- (50.0 % vs 55.6 %), and vigorous-
intensity (17.7 % vs 20.0 %) work compared to the non-MetS women (Appendix I.2). This was 
also the case for vigorous-intensity recreational activities (5.9 % of MetS and 10.9 % of non-
MetS women), while a greater proportion of MetS women (76.5 % for MetS and 69.6 % for non-
MetS) participated in moderate-intensity recreational activities. 
 
Smoking status 
Findings also suggest that smoking may have significant effects on the FA composition, since 
smokers presented with higher MUFA levels compared to non-smokers, possibly due to 
alterations in Δ-9 SCD activity or MUFA catabolism (Warensjӧ et al., 2005; Hodson et al., 2008). 
Likewise, Warensjӧ et al. (2006) also reported positive associations between smoking and PLA, 
OA, and desaturase activity. Smoking remains a prominent risk factor for obesity, IR, and CVD, 
since nicotine has unfavourable effects on glucose metabolism, and these metabolic alterations 
may affect FA composition (Warensjӧ et al., 2006). The majority of women in the current study 
in both the MetS (50.0 %) and non-MetS (45.7 %) groups were non-smokers, and no significant 
associations were observed between MUFAs (PA and OA levels) and smoking status in this 
population (Appendix I & L). A smaller proportion of women in the MetS group (35.3 %) were 
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current smokers compared to the non-MetS group (43.5 %). This suggests that smoking did not 
contribute to the findings for the different FAs and FA ratios of the current study; however, 
factors such as under-reporting and the lack of information on smoking duration, number of 
cigarettes smoked, and the effects of previous smoking may be confounding factors. 
 
4.4.6 Biochemical blood analyses 
4.4.6.1 Insulin-like growth factor-1  
Although the link between elevated IGF-1 and cancer risk is well established, the association 
between IGF-1 and metabolic diseases is still questioned, since limited and contradictory data 
exists on the relationship between IGF-1 and the MetS (Boden, 2009; Doyle et al., 2012; Ren & 
Anversa, 2015). The insulin/IGF-1 pathways have been associated with the MetS, since these 
pathways play a role in metabolic alterations.  
 
Insulin-like growth factor-1 and obesity 
Several studies reported significantly lower IGF-1 concentrations in women with the MetS 
(Parekh et al., 2010; Friedrich et al., 2013; Ren & Anversa, 2015), although the current study 
found significantly higher IGF-1 concentrations in the MetS women (Table 3.4). A possible 
explanation for this occurrence is that obesity is associated with IGF-1 concentration, since it 
stimulates adipocyte differentiation, which leads to increased adipocyte IGF-1 production and 
elevated free IGF-1 levels (Sierra-Johnson et al., 2008; Faupel-Badger et al., 2009; Donohoe et 
al., 2012; Doyle et al., 2012; Rajpathak et al., 2012; Westley & May, 2013; Ren & Anversa, 
2015).  
 
The BMI of the MetS women of the current study was significantly higher than their non-MetS 
counterparts, suggesting that obesity may be responsible for their significantly higher IGF-1 
concentration (Table 3.1). When BMI and the metabolic status were considered, the OBMetS+ 
group presented with a two and a half times higher IGF-1 concentration compared to OBMetS- 
women (Figure 3.15A). In addition, the OBMetS+ group also had significantly higher IGF-1 
concentrations compared to the NMetS-. This was also apparent in the study by Rajpathak et al. 
(2012), where a positive association was established between free IGF-1 levels and BMI, and 
IGF-1 levels and WC. This is consistent with the findings of the current study where several 
measures of obesity (including BMI, WC, W:H, W:Ht, and SAD) and IGF-1 concentration were 
all significantly higher in the MetS compared to the non-MetS group (Table 3.1, 3.4 & Figure 
3.7).  
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The current study also observed a significant strong positive association between IGF-1 and 
W:H for the OWMetS+ group (Appendix J, Table J.8). However, some studies found an inverse 
association between IGF-1 levels, BMI, and WC, and proposed that obesity is associated with 
weight-related changes in insulin and GH levels, and this causes the inverse relationship 
between IGF-1 levels and measures of adiposity (Parekh et al., 2010). In agreement, the current 
study observed significant strong negative associations between IGF-1 concentrations and HC, 
and IGF-1 concentration and BMI for OWMetS+ women (Appendix J, Table J.8). 
 
Insulin-like growth factor-1 and insulin resistance 
Insulin resistance and elevated insulin levels promote GH receptor resistance, and this leads to 
decreased IGF-1 levels (Oh et al., 2012). However, others suggest that IGF-1 also play a role in 
glucose homeostasis, since increased insulin levels are associated with the MetS. This can lead 
to decreased IGFBPs, thereby increasing the bioavailability of IGF-1 that could lead to elevated 
free IGF-1 levels (Sierra-Johnson et al., 2008; Jeon et al., 2011; Erasmus et al., 2012; Klug et 
al., 2012; Camargo et al., 2014). Our findings are in agreement with the latter studies, since the 
MetS group presented with significantly higher insulin and IGF-1 concentrations (Table 3.1 & 
3.4). However, insulin levels were only significantly higher in the OWMetS+ compared with the 
OWMetS- group of the current study (Appendix K). A proposed mechanism here is that 
hyperinsulinaemia and obesity increase GH expression, which stimulates IGF-1 production to 
increase IGF-1 levels (Westley & May, 2013). A second proposed mechanism is that the 
production of IGFBPs is downregulated to increase the bioavailability of IGF-1 (Westley & May, 
2013; Ren & Anversa, 2015). 
 
Confounding factors 
A number of confounding factors may contribute to the contrasting results for IGF-1, including 
age, and ethnicity. Ageing was associated with reduced IGF-1 levels. Here, IGF-1 is involved in 
growth, and concentrations generally peak during puberty and decline progressively with ageing 
(Parekh et al., 2010). Additionally, the association between age and IGF-1 is also related to the 
age-related decrease in GH, since GH stimulates IGF-1 production (Westley & May, 2013). 
However, the opposite was true for the current study – MetS women were significantly older 
(40.2 years vs 35.0 years), and yet MetS women presented with significantly higher IGF-1 
concentrations than non-MetS women.  
 
Ethnicity is another possible confounding factor, since previous studies have described ethnic 
differences in adipose tissue distribution, and prevalence of obesity (Faupel-Badger et al., 2013; 
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Evans et al., 2011). Obesity is associated with IGF-1 levels, which makes it possible that 
ethnicity may affect IGF-1 levels. In the same way, ethnicity may also have contributed to our 
findings, since women of different ethnic backgrounds were included.  
 
In the current study, IGF-1 concentrations of some participants (n=5 for the MetS group and 
n=13 for the non-Mets group) were excluded, since values were either below the detection limit 
or extremely high, thus reducing the sample size, and this may have affected the statistical 
power of the results obtained. Possible reasons for the discrepant findings may also be the 
specificity of the ELISA kit used, the fact that different studies used different sample types to 
assess IGF-1 concentrations, and that different components of the IGF-1 axis were assessed 
(for example binding proteins and receptors) (Rajpathak et al., 2012; Friedrich et al., 2013; 
Levine & Levine, 2013; Westley & May, 2013).  
 
4.4.6.2 Leptin 
Leptin, the most abundant adipokine, has several functions relating to energy expenditure and -
balance, satiety, and body weight (Braun et al., 2011; Levine & Levine, 2013). Individuals with 
the MetS presented with significantly higher leptin concentrations compared to controls 
(Kawashima et al., 2009; Esteghamati et al., 2011; Chiu et al., 2012; Abu-Farha et al., 2014; 
Shah et al., 2014; García-Jiménez et al., 2015), which is in direct contrast to the findings of the 
current study (Table 3.4).  
 
Leptin and the metabolic syndrome risk factors 
Studies by Yun et al. (2011) and Esteghamati et al. (2011) suggested that leptin could be a 
significant predictor of the MetS, independent of BMI class. While leptin levels predicted MetS 
status and correlated with the number of individual MetS risk factors in women, these 
associations became insignificant after adjustment for BMI (Yun et al.; 2011; Esteghamati et al.; 
2011). This is in agreement with the findings of the present study, since a significant difference 
was observed between leptin concentrations of the MetS and non-MetS groups, but not between 
the subgroups categorised according to MetS status and BMI (Table 3.4 & Figure 3.15B).  
 
Several studies have also reported associations between leptin levels and BP, glucose and 
insulin levels, and HOMA-IR in persons with the MetS (Ganji et al., 2009; Yun et al., 2011; Chiu 
et al., 2012; Cohen et al., 2012; Shah et al., 2012; Atanassova et al., 2014; Abu-Farha et al., 
2014). Elevated leptin levels are associated with hypertension, since leptin increases arterial BP 
by stimulating the sympathetic nervous system, enhancing renal sodium resorption and by 
stimulating endothelin production, a vasoconstrictor (de Castro et al., 2015). Several studies 
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suggested that the other individual components of the MetS might also contribute to the pro-
inflammatory and IR state, including glucose, insulin and HOMA-IR (Ganji et al., 2009; Lee et 
al., 2009b; Bremer et al., 2011). The association between leptin and glucose metabolism is 
explained by the leptin receptors located on the pancreatic β-cells to suppress insulin secretion 
(Chiu et al., 2012). In the leptin-resistant state, leptin does not suppress glucose-stimulated 
insulin secretion and this leads to IR (Deng & Scherer, 2010; Esteghamati et al., 2011; Chiu et 
al., 2012). Leptin and obesity ultimately lead to a state of leptin resistance that increase the risk 
of several components of the MetS (Doyle et al., 2012; García-Jiménez et al., 2015; Mendonça 
et al., 2015). All of these metabolic-associated parameters (SBP, DBP, and glucose and insulin 
levels) were significantly higher in the MetS women of the current study, but leptin levels were 
significantly lower (Table 3.1 & 3.4). 
 
Leptin and obesity 
Several MetS-associated factors influence leptin concentrations, including abdominal obesity, 
and insulin and glucose levels (Donohoe et al., 2011; Doyle et al., 2012). Obesity disrupts 
normal adipose tissue function, including the secretion of adipokines, such as leptin (Abu-Farha 
et al., 2014). Leptin levels were also significantly higher in overweight compared to normal 
weight women without the MetS (Gómez-Ambrosi et al., 2012). Increased adipose tissue mass, 
increased WC, W:H and/or BMI, and regional adiposity may influence circulating leptin levels, 
since leptin plays a role in appetite regulation, energy expenditure, and body weight (Li et al., 
2011b;Yun et al., 2011; Chiu et al., 2012; Shah et al., 2014). Increased leptin levels in obese 
individuals is the result of both increased fat mass, and adipocyte hypertrophy that cause 
increased leptin secretion (Howard et al., 2010). All measures of obesity were significantly 
higher in the MetS group of the current study, yet leptin concentrations were significantly lower 
(Table 3.1).  
 
While many studies investigated the association between increased BMI and leptin levels, few 
have focused on the relationship between the MetS and leptin levels stratified according to BMI. 
Increasing leptin levels were associated with increasing BMI in participants with the MetS, 
because leptin levels are positively associated with body weight, and its levels were related to 
several measures of obesity, including increased WC, total adipose tissue mass, body fat, and 
regional adiposity (Yun et al., 2011; Chiu et al., 2012; Shah et al., 2012; Abu-Farha et al., 2014). 
Waist circumference is closely associated with the VAT (including abdominal fat), which is also 
regarded more pathogenic than SAT, because adipokine secretion is greater in the VAT 
compartment (Crowther & Norris, 2012; Willett & Hu, 2013). Despite increasing visceral 
adiposity (WC, W:H, SAD, and VAT:SAT) across groups categorised according to the MetS 
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status and BMI, no significant differences were observed for leptin concentration in the present 
study (Figure 3.15B).  
 
Although we anticipated a positive relationship between WC and leptin concentrations, it was 
not observed (Appendix J, Table J.9). However, there was a very strong significant positive 
correlation between the SAD and leptin concentrations in the OBMetS- group (Appendix J, 
Table J.9), which is possible since the SAD reflects abdominal fat distribution, and visceral 
adiposity (Stewart & Sutton, 2012). We propose, as others did, that obesity might be associated 
with leptin resistance, which leads to impaired leptin- and insulin signalling (Esteghamati et al., 
2011; Pan et al., 2014; Garcia-Jiménez et al., 2015). This leads to a leptin deficient state, 
characterised by failed appetite regulation and energy expenditure, and increased body weight. 
In agreement, the current study observed that the participants in the OBMetS- subgroup had 
approximately two times higher leptin concentrations than those in the OBMetS+ subgroup 
(Figure 3.15B).  
 
Leptin and obesity have also been implicated in the pathogenesis of lifestyle-associated cancers 
(Doyle et al., 2012; García-Jiménez et al., 2015; Mendonça et al., 2015). The proposed 
mechanism is that the leptin-resistant state is associated with impaired leptin- and insulin 
signalling, and increased inflammation that contributes to IR and increased cancer risk, since 
obesity leads to macrophage activation, and this triggers cytokine overproduction that enhances 
inflammation (Chiu et al., 2012; Doyle et al., 2012; Barazzoni et al., 2014; Atannasova et al., 
2014; Garcia-Jiménez et al., 2015). It is proposed that the effect of leptin on intracellular 
pathways that control cell growth, apoptosis, and angiogenesis are involved in the pathogenesis 
of cancer (Rodríguez et al., 2013; Mendonça et al., 2015).  
 
Confounding factors  
Age, ethnicity, and lifestyle choices, were all confounding factors in the current study and may 
explain why our findings for leptin levels differ from previous studies. It is well known that with 
ageing, there is redistribution of adipose tissue from peripheral- to abdominal areas, and this 
may explain the association between decreasing leptin levels and ageing (Schautz et al., 2012). 
This was also evident in the current study, where the significantly older MetS group also 
presented with significantly lower leptin levels (Table 3.1 & 3.4). Additionally, the age-related 
decline in oestrogen levels have also been implicated as responsible for the decrease in leptin 
levels that is associated with ageing (Marques-Vidal et al., 2010; Schautz et al., 2012). The 
current study did not classify participants according to menopausal status, and both pre- and 
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postmenopausal women were included, which could possibly explain the lack of significant 
findings.  
 
Ethnicity may also have played a role, since Cohen et al. (2012) found that Black women 
presented with significantly higher leptin levels compared to their Caucasian counterparts, 
possibly due to differences in body fat distribution, and subsequent leptin production. The 
current study population included Caucasian, Coloured, and Black women, and although ethnic 
differences in leptin levels were not assessed, it might have played a role.  
 
Zuo et al. (2013) found that leptin levels were mostly associated with a Westernised diet, while 
Jafari-Vayghan et al. (2015) failed to identify a relationship between major dietary patterns 
(including Western, healthy, and traditional), and leptin levels. Participants of the current study 
mainly consumed a Westernised diet, which may have affected leptin concentrations (Table 3.5 
& Figure 3.16). Fasting state may also play a role in leptin levels, because short-term energy 
balance affects leptin release by adipocytes (de Castro et al., 2015). Although most women of 
the current study were fasted, others were not, and this may have influenced the findings.  
 
Smoking has also been shown to decrease leptin levels, and although the exact mechanism is 
still unclear, it is speculated that tobacco decreases basal metabolic rate, which is negatively 
associated with leptin levels (Marques-Vidal et al., 2010; Cohen et al., 2012). Lower leptin levels 
reported in smokers may also be due to increased leptin sensitivity among smokers, which also 
leads to lower body weight, and subsequent lower leptin release from adipocytes (Ganji et al., 
2009; Cohen et al., 2012). The majority of women in both the MetS (50.0 %) and non-MetS 
(45.7 %) groups were non-smokers, followed by current smokers (35.3 % for the MetS group 
and 43.5 % for the non-MetS), which makes it unlikely that smoking played a role (Appendix I.1). 
However, smoking is a lifestyle factor that is often under-reported, which may have been the 
case here.  
 
The specificity and sensitivity of the ELISA kit used to determine leptin concentrations might also 
explain the large variation in leptin concentrations of the present study. Additionally, the data for 
leptin concentration of several participants were excluded (n=six for the MetS group and n=14 
for the non-MetS group) due to levels below the detection limit of the kit or levels that were too 
high (outliers) and this may have influenced the statistical power. 
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CHAPTER 5: CONCLUSION 
 
5.1 INTRODUCTION 
This chapter contains the main findings and conclusions of the current study, followed by the 
strengths and limitations of the data collection procedures. The chapter concludes with future 
recommendations. 
 
The current study observed a MetS prevalence of 42.5 %, which is somewhat higher than 
prevalence rates reported for South-African populations. The majority of women in the MetS 
group presented with three MetS risk factors (58.8 %), while the majority of non-MetS women 
presented with two risk factors (54.3 %). It is also somewhat disturbing that only six women 
(13.0 %) in this population presented with no risk factors. Even more important is the fact that 
20.6 % of women presented with four and five MetS risk factors, respectively. Although the 
predominant risk factors were similar in the MetS and non-MetS groups, the order in which they 
appeared differed for the two groups. Abdominal obesity was most predominant (100 %) in the 
MetS group, followed by hypertension (82.4 %), and low HDL-c (76.5 %). For the non-MetS 
group, hypertension was most prevalent (47.8 %), followed by abdominal obesity (39.1 %), and 
low HDL-c levels (34.8 %). The high prevalence of the MetS and its individual risk factors in 
women of this study are distubing, because the MetS is associated with an increased risk of 
developing T2DM, CVD, and lifestyle-associated cancers. Consequently, it is important for these 
women to be aware of these risks, and to make lifestyle changes to reduce their risk of 
developing these diseases later in life. 
 
5.1.1 The influence of metabolic status 
Our findings revealed the adverse effects of the MetS on physiological- and biochemical 
parameters, anthropometric measurements, and body composition. These findings suggest that 
obesity contributes to leptin resistance, and this leads to impaired leptin- and insulin signalling. 
Categorisation according to metabolic status did not indicate any significant differences for the 
individual FAs or FA ratios, which makes it difficult to draw an accurate conclusion linking the 
individual FAs or FA ratios to the MetS, and future studies are therefore needed to clarify this 
relationship. Metabolic status predicted changes in IGF-1 levels, thereby linking the MetS to 
increased cancer risk. This study also noted characteristic differences in the lifestyle behaviours 
of women with and without the MetS, and this may have played a role in our findings. 
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5.1.2 The combined influence of metabolic status and body mass index 
The combined effect of the metabolic status and BMI only had an effect on some of the MetS 
risk factors (WC, SBP, DBP, and HDL-c levels), as well as IGF-1 levels. Although it also affected 
anthropometric (BMI, HC, W:H, and SAD) and BIA parameters (VAT and SAT areas, VAT % 
and SAT %, and VAT:SAT), it did not influence DBP, glucose, insulin, LDL-c, total cholesterol 
and leptin levels, or any of the individual FAs or FA ratios. The majority of women in the current 
study were either overweight or obese, and these findings confirm that adipose tissue 
dysfunction associated with these states contribute to the MetS. As a result, the classification of 
individuals according to metabolic status and BMI predicted various physiological-, 
anthropometric-, and body composition parameters, and indicated a possible effect on the 
parameters linking the MetS to cancer risk.  
 
Strong significant associations were also evident between IGF-1 levels and the different 
measures of obesity, suggesting that obesity stimulates adipocyte IGF-1 production that leads to 
increased free IGF-1 levels. The current study showed significant correlations between 
measures of abdominal obesity (WC and SAD) and body composition (VAT %, SAT %, and 
VAT:SAT). Furthermore, VAT:SAT correlated with some metabolic parameters, including SBP, 
and TG and LDL-c levels, thereby supporting the notion that increasing VAT and abdominal 
obesity is associated with increased lipolysis, reduced insulin sensitivity, and impaired insulin 
signalling, which all increases the risk of the MetS, CVD, and lifestyle-associated cancers.  
 
5.1.3 Correlation analyses 
Correlation analyses indicated that obesity is a key determinant in the pathophysiology of the 
MetS, which was evident from significant associations between BMI and body composition (VAT 
%, SAT %, and VAT:SAT). These findings also confirm that anthropometric measures correlate 
with more direct measures of obesity. We also showed significant positive associations between 
SAT area and the Ω-3 index, and the Ω-3:Ω-6, possibly highlighting the anti-inflammatory 
properties of Ω-3 FAs on the obesity-associated chronic low-grade inflammation. However, the 
current study did not include inflammatory markers, thus no accurate conclusion could be drawn 
here. 
 
5.2 STRENGTHS OF THE STUDY 
A major strength of this study was that individuals without the MetS, and categorised according 
to BMI, were compared with individuals with the MetS, also categorised into the same BMI 
classes. The sample was ethnically diverse (Caucasian, Coloured, and Black participants) with a 
wide age range (18 to 60 years), BMI (18.6 to 53.8 kg/m2), and WC (63.0 to 120.0 cm), enabling 
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comparisons with other study populations that made use of the same specifications. The current 
study investigated the pathophysiology of the MetS by including several factors, such as 
metabolic- and growth factors, additional measures of body fat distribution, and anthropometric 
measurements to assess body fat.  
 
Students were trained in new techniques using standardised procedures and -measurements 
prior to starting the research project. According to our knowledge, this is a novel study, as it is 
the first time that the FA profile of farm workers in the Western Cape was investigated. 
Furthermore, the present study did not only determine individual FAs, but FA ratios and –
metabolism were also investigated. Information regarding participant medication use and 
chronic diseases, lifestyle behaviours (including smoking and alcohol use), nutritional intake, 
and physical activity were available to the study, which enabled a more accurate and thorough 
interpretation of the results. While many other studies relied on a 24-hour recall or the lengthy 
FFQ, the present study obtained dietary intake data for three days, which could be used to 
estimate the usual dietary intake of participants. 
 
5.3 LIMITATIONS OF THE CURRENT STUDY 
This study made use of a cross-sectional study design, which is limited by the fact that causality 
cannot be established. Participants were conveniently recruited in the farming areas around 
Stellenbosch. Only female participants were included in the study, and the results obtained here 
can therefore not be generalised to the general farm worker population from this region. It is not 
unusual to encounter measurement errors during anthropometrical assessment such as 
positioning of the body, locating body landmarks in obese participants, and errors in reading 
measurements off equipment and recording it. Certain anthropometric measurements, including 
WC and HC, are dependent on the time of day, postural deviations, environmental 
temperatures, and lung function (depth of inspiration). Anthropometric measurements could not 
be validated and assessed using the gold standard, such as magnetic resonance imaging (MRI) 
and computed tomography (CT). The procedure to assess FA metabolism directly is complex, 
and therefore we could only use product-to-precursor ratios. Definitive conclusions about SCD 
enzyme activity could not be made here, although estimated enzyme activity is useful to 
interpret FA metabolism and desaturation patterns. Subjectivity and recall- and information bias 
are common problems when participants are asked to complete a three-day food record. Dietary 
intake may vary due to seasonality of certain products, and under- and over-reporting are 
significant limitations of this dietary assessment tool. 
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5.4 FUTURE RESEARCH AND RECOMMENDATIONS 
Future research should use a randomised control study group consisting of men and women of 
different age- and ethnic groups in order to evaluate the gender-, age- and ethnic differences in 
the epidemiology of the MetS in the Western Cape. Additional surrogate measures for 
abdominal obesity (including the W:H and SAD) and fat distribution (VAT and SAT) may be 
useful in future MetS studies, since abdominal obesity is a critical component of the MetS. 
Inflammatory markers, such as IL-6, may be useful in future research, since obesity is 
associated with chronic low-grade inflammation.  
 
It may also be useful to assess adiponectin levels, since this is an insulin sensitising adipokine 
associated with the MetS. Inclusion of these additional markers may improve our understanding 
of the effects of lifestyle factors and urbanisation on body composition, the constituents of the 
MetS, and the associated cancer risk. Future studies may also benefit from methods that are 
more sensitive to measure leptin and IGF-1 levels, since levels of some participants in the 
current study were excluded, as values were either too high or too low.  
 
Findings for the RBC membrane FA analysis in the current study did not indicate any significant 
differences. Future studies may benefit from using plasma samples to determine FA levels 
complementary to dietary assessment, since both these methods reflect short-term intake and 
may be comparable (Vessby et al., 2002; Hodson et al., 2008; Patel et al., 2010; Serra-Majem et 
al., 2012). Intervention studies may also be useful to aid in our understanding of the FA profile of 
MetS participants. For example, Ω-3 FAs have beneficial effects on the components of the 
MetS, and for that reason, it may be useful to compare the metabolic-, inflammatory-, and FA 
profiles of non-MetS and MetS groups with and without Ω-3 supplementation.  
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Appendix B: Consent form 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
Cancer risk during urbanisation: metabolic syndrome and cancer 
REFERENCE NUMBER: N13/04/052 
PRINCIPAL INVESTIGATOR: Dr Theo A. Nell 
ADDRESS: 
Department of Physiological Sciences 
Mike de Vries Building 
Room 2007  
Stellenbosch University 
CONTACT NUMBER: 021 8083147 
 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand. It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved. Also, your participation is entirely voluntary and you are free to 
decline to participate. If you say no, this will not affect you negatively in any way whatsoever. 
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
This study will only be done in Western Cape Health districts. We will need approximately 1000 
patients. We are trying to gather information on laboratory tests, body composition and patient 
questionnaires profiles of people undergoing migration. By getting this information we would be 
able to assess the prevalence of the metabolic syndrome in different regions in the Western 
Cape and how this might increase risk of developing cancer. 
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More people are relocating to larger cities and with this, their traditional habits change. One 
factor that plays an important role is nutritional changes. There are also changes in your body 
where some might become overweight. Your participation will help us look at the markers that 
tell researchers what factors are important to look at. Blood will be taken by a registered medical 
nurse. It will then be sent away to PathCare (Stellenbosch) where metabolic-associated 
parameters will be measured. Other biochemical tests that will be done by PathCare include 
insulin, glucose, lipids, and hormone measurements. The remainder of your blood samples will 
be used to analyse omega-3 fats. The blood pressure and anthropometric evaluation, and life 
style questionnaire will be done at the clinic. 
 
Why have you been invited to participate? 
We are trying to gather information on people that live in certain areas in the Western Cape 
provincial health districts. Your participation will help us understand what factors could lead to 
the development of certain cancers if people migrate from rural to urban areas. There will also 
be questions asked about your diet at home and how active you are during the week. By 
donating blood to our study, you will be helping us to determine these profiles and how we can 
relate them to the current diagnostic tests to investigate the metabolic syndrome and 
development of cancer. 
 
What will your responsibilities be? 
We will need to examine you as one of the selected patients. A blood sample will then be taken 
for laboratory tests. There will be a lifestyle questionnaire that you need to complete with the 
help of the researcher. A registered anthropometrist, Dr Theo Nell, will also perform 
anthropometric measurements to measure your waist circumference, hip circumference, and 
arm circumference, the back of your arm’s skin fold, height and weight. You will also be asked to 
lie on the examination bed where Dr Nell will use a special machine that will tell us how much fat 
is in your body. This will only take a few minutes and does not hurt you. 
 
Will you benefit from taking part in this research? 
Although there may not be any direct benefits to me/the participant by participating at this stage, 
future generations may benefit if the researchers succeed in finding out more about how 
migration could lead to increased number of people developing cancer. If you choose to know 
the results of your blood tests, we will make these available. However, you would have to 
discuss this information with your usual/personal doctor, in order to assess your medical status. 
 
Are there any risks involved in your taking part in this research? 
There are no more than minimal medical or physiological risks associated with this study. 
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I/the participant may feel some pain associated with having blood drawn from a vein in my arm, 
and may experience some discomfort, bruising and/or slight bleeding at the site. The 
anthropometrical test will require you to take some of your clothes and shoes off, but there is no 
pain involved during this procedure. All measurements will be done in private and confidentiality 
is very important. The machine that will be used to determine the fat in the body uses a very 
small electrical current that you will not feel. 
 
If you do not agree to take part, what alternatives do you have? 
It is your decision to participate or not and nothing will be done from the researchers’ part or 
medical staff at the clinic/hospital to in any way to persuade you to take part. 
 
Who will have access to your medical records? 
Only the principal researcher (Dr Theo Nell and other collaborators) will have access to your 
data and records. All information will be treated with respect and utmost confidentiality. Under 
no circumstances will your name or any form of identification be used in any publication, poster, 
lecture or thesis that results from this study. Dr Theo Nell will be the only authorised personnel 
who will have access to all your results from this study as well as the lifestyle questionnaire and 
anthropometric measurements. 
 
What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
There are no risks involved that could lead to injury. Not applicable here. 
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in the study. There will be no costs involved for you, if you 
do take part. 
 
Would you like to know the results of your blood tests? 
Please indicate by marking the correct box with an X 
YES 
NO 
 
Is there anything else that you should know or do? 
You can contact Dr Theo Nell on 021 808 3147 if you have any further queries or encounter any 
problems. You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study doctor. You 
will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled (Cancer risk during urbanisation: metabolic syndrome and cancer). 
I declare that: 
 
I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
    
 ...................................................................   ............................................................  
Signature of interpreter Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
I explained the information in this document to ………………………………….. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the 
declaration below). 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
    
 ...................................................................   ............................................................  
Signature of interpreter Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………………………………………. to explain 
the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa/Zulu/English. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) …………....……2015 
 
 ...................................................................   ............................................................  
Signature of interpreter Signature of witness 
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Appendix C: Fatty acid analysis protocol 
 
SAMPLE COLLECTION AND PRE-TEST PREPARATION 
• Blood samples for the FA profile were collected in two EDTA tubes, and spun down 
immediately (10 minutes @ 4000 rpm) to separate RBCs from plasma. 
• The supernatant (plasma) was then drawn off and an equal volume of sterile 0.9 % saline 
solution at room temperature was added and mixed with the RBCs. 
• The sample was centrifuged for four minutes @ 2500 rpm. 
• The supernatant, as well as the WBCs were drawn off and discarded. 
• This step was repeated three times until the supernatant was colourless, and clear and free 
of all WBCs. 
• Following the final wash and complete removal of saline, the RBCs in the EDTA tubes were 
rapidly frozen on dry ice and stored at -80 °C until analysis. 
 
FATTY ACID EXTRACTION 
• Red blood cell samples in EDTA tubes were thawed at 4 °C overnight before the analysis. 
• One mL methanol (CH3OH) and 500 µL of RBC were placed in extraction tubes, and 
vortexed for 10 seconds. 
• Two mL chloroform (CCl3) was then added to each tube, and vortexed for 1 minute. 
• After thorough extraction, 1.5 mL saline was added and the tube vortexed for 10 seconds. 
• Tubes were then centrifuged for four minutes at 2000 rpm. 
• The bottom chloroform phase with lipids were then transferred to transmethylation tubes. 
• Tubes were then dried under a nitrogen stream (99.9 % nitrogen) in a waterbath set at 50-60 
°C. 
 
TRANSMETHYLATION OF FATTY ACIDS TO FATTY ACID METHYL ESTERS 
• One hundred µL toluene and 2.0 mL methanol sulphuric acid (MeOH 5 % H2SO4) were 
added to each tube, vortexed briefly, and then incubated for two hours in a waterbath set at 
70 °C. 
• Two mL dH2O and 2.0 mL hexane were added, and the tube vortexed for 20 seconds to 
extract FAMEs. 
• The upper hexane layer was then transferred to a new transmethylation tube containing a 
small amount of sodium bicarbonate (NaHCO3). 
• Tubes were then dried under a nitrogen stream (99.9 % nitrogen) in a waterbath set at 50-60 
°C. 
• One hundred µL hexane was placed in each tube, and vortexed briefly. 
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• The contents of each tube were then placed in a GLC vial for FA analysis. 
 
QUALITATIVE ANALYSIS 
• Analysis was done by automated GLC (GLC, Thermo, Focus) equipped with flame ionisation 
detector. 
• The peaks on the chromatograph were identified based on the retention time for each FA. 
• Calculation of total FA and each FA expressed as a percentage of the total FAs. 
 
Figure C.1: Example of a gas chromatograph used to identify the different fatty acids based on retention 
times. 
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Table C.1. Retention times of different long chain fatty acids. 
FATTY ACID REFERENCE RANGE 
14:0 5.070 
14:1 5.400 
16:0 6.728 
16:1 7.242 
18:0 9.020 
18:1 n-9 9.568 
18:1 n-11 9.683 
18:2 n-6 10.510 
18:3 n-6 11.163 
18:3 n-3 11.695 
20:0 11.812 
20:1 n-9 12.437 
20:2 n-6 13.517 
20:3 n-6 14.237 
20:4 n-6 14.742 
20:3 n-3 14.815 
22:0 14.905 
22:1 n-9 15.577 
20:5 n-3 16.105 
22:2 n-6 16.718 
24:0 18.137 
22:4 n-6 18.545 
24:1 18.797 
22:5 n-3 19.523 
22:6 n-3 19.967 
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Appendix D: Enzyme-linked immunosorbent assay (ELISAs) 
 
Appendix D.1: Insulin-like growth factor-1 ELISA 
 
SAMPLE PREPARATION: 
BODY MASS INDEX 
CLASS 
DILUTION VOLUME OF 
SAMPLE  
(µL) 
VOLUME OF 
SAMPLE DILUENT  
(µL) 
TOTAL VOLUME  
(µL) 
Normal, overweight 
and obese 
20x 12.50 237.50 250.00 
(Adopted from: Yee et al., 2010; Bogin et al., 2015; Koeglenberg et al., 2015). 
 
PLATE PREPARATION: 
Each microplate contained the eight standards (columns 1 and 2) and eight samples of each of 
the different study groups (columns 3 to 12), as illustrated below. All samples were assayed in 
duplicate.  
 
  
Standards NMetS- OWMetS- OBMetS- OWMetS+ OBMetS+ 
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ASSAY PROCEDURE: 
 
 
Table D.1. Method of measurements, detection limits, measureable concentration range and concentration of 
deficiency for haematology for insulin-like growth factor-1 levels of adults. 
 IGF-1 
Significance Cancer risk through growth-promoting properties 
Test used Sandwich (quantitative) ELISA 
Detection method Colorimetric 
Sample type Serum/plasma 
Storage of kit -20 °C 
Label or dye HRP 
Sensitivity <0.20 ng/mL 
Measureable concentration range 0.10-30.00 ng/mL 
Dilution 20x 
Assay duration Multiple steps standard assay 
Absorbance measured at 450 nm 
 
  
Read OD at 450 nm (endpoint reading) immediately 
Add 50 µL of Stop Solution to each well 
Add 100 µL of TMB one-step substrate reagent to each well, and incubate at RT in the dark for 30 minutes with 
gentle shaking 
Discard solution and wash four times with Wash solution  
Add 100 µL of HRP-Streptavidin solution to each well, and incubate at RT for 45 min with gentle shaking 
Discard solution and wash four times with Wash solution  
Add 100 µL of biotinylated IGF-1 detection antibody to each well and incubate at RT for 1 hr with gentle shaking 
Remove any remaining liquid by apirating or decanting from wells, invert plate, and blot against clean paper towels 
Discard solution and wash four times with Wash solution  
Add 100 µL of either sample or standard to wells, cover, and incubate at RT for 2.5 hr with gentle shaking 
Prepare reagents (Wash solution, biotinylated IGF-1 detection antibody and HRP-Streptavidin solution), standards, 
samples, and plate 
Equilibrate all materials and reagents to be used at RT 
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Appendix D.2: Leptin ELISA 
 
SAMPLE PREPARATION: 
BODY MASS INDEX 
CLASS 
DILUTION VOLUME OF 
SAMPLE  
(µL) 
VOLUME OF 
SAMPLE DILUENT  
(µL) 
TOTAL VOLUME 
(µL) 
Normal and overweight 40x 5.00 195.00 200.00 
Obese 90x 4.40 395.00 399.40 
(Adopted from: de Castro et al., 2015; García-Jiménez et al., 2015; Jafari-Vayghan et al., 2015). 
 
PLATE PREPARATION: 
Each microplate contained the eight standards and eight samples of each of the different study 
groups. All samples were assayed in duplicate as illustrated below. 
 
  
Standards NMetS- OWMetS- OBMetS- OWMetS+ OBMetS+ 
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ASSAY PROCEDURE: 
 
 
Table D.2. Method of measurements, detection limits, measureable concentration range and concentration of 
deficiency for haematology for leptin of adults. 
 LEPTIN 
Significance Adipose tissue biomarker 
Test used Sandwich (quantitative) ELISA 
Detection method Colorimetric 
Sample type Serum/plasma 
Storage of kit 4 °C 
Label or dye HRP 
Sensitivity 5.30 pg/mL 
Measureable concentration range 11.70-750.00 pg/mL 
Dilution 20x for BMI = 18.50-29.99 kg/m
2
 
90x for BMI ≥30.00 kg/m
2
 
Assay duration One step assay 
Absorbance measured at 450 nm 
  
Read OD at 450 nm (endpoint reading) immediately 
Add 100 µL of Stop Solution to each well, shake plate on plate shaker for 1 minute to mix 
Add 100 µL of TMB Substrate to each well and incubate in the dark  
(Recommended time: 10 minutes @ RT on a plate shaker at 400 rpm, however timing can differ) 
After the final wash, remove remaining liquid, invert plate, and blot on clean paper towels 
Wash wells with 3x 350 µL Wash Buffer PT by apirating or decanting from wells followed by dispensing 350 µL Wash 
Buffer PT into each well 
Add 50 µL of Antibody Cocktail to each well , seal plate, and incubate  
(1 hr @ RT on a plate shaker at 400 rpm) 
Add 50 µL of either sample orstandard to wells 
Prepare reagents (Wash buffer PT and antibody cocktail), standards, samples, and plate 
Equilibrate all materials and reagents to be used at RT 
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Appendix E: Anthropometry data sheet 
 
 
 
CANSA Study: Data Collection Sheet 
 
Age  
Body Mass (kg)  
Height (m)  
BMI (kg/m2)  
BP (mmHg)  
Heart Rate (b/m)  
WC (cm)  
HC (cm)  
W:H  
W:Ht  
SAD (cm)  
VAT   
Impedance (Ohms)  
Phase Angle   
SAT  
Impedance (Ohms)  
Phase Angle   
  
Id Code: __________________ 
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Appendix F: Bioelectrical impedance analysis protocol 
(Maltron BioScan 920II, 2015b). 
 
PRE-TEST PROTOCOL 
 Start by showing the participant the BioScan920-II multi-frequency analyser (Maltron 
BioScan 920II, United Kingdom) testing device and explain clearly, where you will place 
the electrodes and what you will be doing. 
 Instruct the participant to remove any jewellery, metal objects, cell phones or other 
electronic equipment before the analysis started, since these may interfere with the 
conductivity and ultimately the readings on the machine. 
 Participants were also asked to empty their bladders prior to testing because a full 
bladder may affect values for total body water. 
 Participant stands in the upright position with feet apart. 
 Areas on the abdomen where the electrodes will be placed are cleaned with alcohol 
swabs. 
 The participant should refrain from alcohol intake for 12 hours prior to the procedure. 
 The participant should not be diaphoretic (covered with sweat) or soaked in urine since 
the analyser measures this fluid as fat-free mass. 
 The participant should not have exercised or taken a sauna within 8 hours of the 
procedure. 
 Make sure analyser battery is relatively new and well charged. 
 Regularly check analyser calibration and patient cables using a standard protocol. 
 Turn the analyser on and make sure the subject refrains from movement. 
 To ensure consistency and repeatability, electrodes should be placed exactly as shown 
in the illustrations. Variation in the placement of these electrodes will result in errors in 
the data. 
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ABDOMINAL SUBCUTANEOUS MEASUREMENT 
 
The recorded values should then be entered in the Maltron BioScan 920 v1.1 software programme 
The test results will then be displayed and the impedance and phase angle should be recorded 
Select “Visceral” and press “Enter” 
Select “Abdominal” and “Proceed” after the electrodes have been placed correctly 
On the “Main Menu” of the BioScan920-II multi-frequency analyser select “Test” followed by “Segmental” 
Four electrodes are placed horizontally across the anterior surface of the abdomen at the level of the umbilicus 
Electrode 2: place 7.00 cm to the 
left side of the umbilicus  
Electrode 1: place 12.00 cm to 
the left side of the umbilicus  
Electrode 4: place 7.00 cm to the 
right side of the umbilicus  
Electrode 3: place 12.00 cm to 
the right side of the umbilicus 
The waist circumference (in cm) is measured and used as the level for placement of the electrodes on the trunk 
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ABDOMINAL VISCERAL MEASUREMENT 
 
The recorded values should then be entered in the Maltron BioScan 920 v1.1 software programme 
The test results will then be displayed and the impedance and phase angle should be recorded 
Select “Visceral” and press “Enter” 
Select “Abdominal” and “Proceed” after the electrodes have been placed correctly 
On the “Main Menu” of the BioScan920-II multi-frequency analyser select “Test” followed by “Segmental” 
On the line of this measurement place the electrodes and stickers in the following manner: 
Place electrode 1 as close as 
possible to the umbilicus 
Place electrode 3 in the middle of 
the back at the level of the 
umbilicus 
Using electrode 1 as a reference point, 
measure “d” to the left of the participant 
and place electrode 2 here the 
umbilicus 
Using electrode 3 as a reference 
point, measure “d” to the left of the 
participant and place electrode 4 
here at the umbilicus 
To calculate “d”, divide the waist circumference measurement by eight 
Measure the waist circumference (in cm) using a tape measure 
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Appendix G: Three-day food record 
 
RECORD KEEPING PERIOD 
PERIOD TIME 
FRAME 
RECORD KEEPING 
WEEKS 
RECORD KEEPING DAYS* - 3 CONSECUTIVE 
DAYS 
    
* Day: Starts midnight and ends following midnight 
 
Record keeping instructions 
Record: 
 Everything consumed – eat and drink 
 Immediately – ensures nothing is forgotten/Less work 
 Each day separate page – 2 pages per day (+ extra) 
 Each food item new line 
 Each food item detailed and accurately as possible 
 
Information: 
 Column 1: Time you ate/drank something, e.g. 13:00 (or 1 pm) 
 Column 2: What you consumed, e.g. green beans, Rooibos tea 
 Column 3: How the food was prepared, e.g. boiled, fried, sweetened 
 Column 4: How much you consumed, e.g. ½ cup; 1 H tablespoon 
 
HOW MUCH YOU CONSUMED 
Last column: Quantity recordings 
 Ruler 
- Measure size of food about to eat 
- Length + Width + Height (Thickness) – Bread slice; Meat portion/Cold cut 
(Edible portion/Bone); Wedge/Slice 
- Height + Diameter – Fruit 
 Measuring cup  
- 500 mL capacity – Larger amount: 
- Measure volume about to eat/drink – Vegetable portions; Fluids 
 Measuring spoons  
- Teaspoon = 5 mL; Tablespoon = 15 mL; Also: Dessertspoon = 12.5 mL)  
- Smaller amount: Measure volume about to eat – Margarine/Butter as 
spread/Portions “dished up” 
 NOTE: Indicate heaped (H) or level (L) 
 Volume/Weight: 
- If known can be recorded – 175 mL yoghurt (container) 
DO NOT ESTIMATE OR GUESS 
Weighed with reliable scale 
Similar/Standard amount consumed from day-to-day: 
Measure precisely on first use (once) and record thereafter 
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WHAT YOU CONSUMED AND HOW IT WAS PREPARED 
 Columns 2 and 3: 
Describe extensively – Brand names/Attach recipes (mixed ingredients/dishes ≈ mixed 
vegetables; mixed herbs) 
 
Cooking methods: 
Boiling  Cooking (rapidly) in boiling water 
Steaming Cooking over boiling water in steam from water or in steam from food without 
added liquid 
Frying  Cooking in oil (specify shallow-fried or deep-fried) 
Baking  Cooking in oven 
Roasting  Cooking in oven with small amount of fat or oil 
 
FOOD 
DESCRIPTION – 
Type/Kind 
PREPARATION –  
Recipe descriptions 
Bread/rolls 
 
Brown; White; Whole wheat 
Hotdog; Hamburger 
Additions/Accompaniments: 
Spreads: Butter; Margarine (type 
– hard, soft, light); Peanut butter; 
Jam (type – smooth, pieces); 
Cheese (type) 
NOTE: Sandwich (2 bread slices) 
Porridge 
(cooked) 
Cereals 
(ready-to-eat breakfast) 
Maize meal; Oats – traditional, 
instant 
Brand names – Flavour 
Maize meal – soft cooked / stiff 
Additions / Accompaniments: 
Milk (type – full cream, low fat (2 
%), fat-free 
(skim)) 
Sugar (type – white, brown) 
Honey; Sweetener (type) 
Butter; Margarine (type) 
Rice Brown; White Cooked; Fried; Savoury 
Pasta Macaroni; Spaghetti Sauce 
Legumes Lentils; Dried beans – Broad 
beans, 
Kidney beans, etc. 
 
Meat Beef; Mutton; Pork 
Minced meat – Hamburger 
patties; 
Meatballs 
Cold cuts – Ham; Polony 
(French; Garlic), Sausages – 
Boerewors; Pork; Viennas; 
Frankfurters, Biltong; Dried 
sausage – Beef; Ostrich; 
Game 
- Lean / Fatty (visible fat) cuts 
Fried (fat/oil and shallow-
fried/deep-fried); 
Grilled; Roasted 
Stews; Casseroles 
Additions such as potatoes and 
other vegetables 
Boerewors – thick, medium or 
thin 
 
Additions / Accompaniments: 
Sauces (gravy) 
Chicken 
 
Drumstick; Thigh 
– With / Without skin 
Batter; Crumbs 
Fried; Grilled; Roasted stews; 
Casseroles 
Additions such as potatoes and 
other vegetables 
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FOOD 
DESCRIPTION – 
Type/Kind 
PREPARATION –  
Recipe descriptions 
Fish: Fresh / frozen 
Fish: Tinned 
Hake; Snoek 
Sardines; Tuna; Pilchards (in 
tomato sauce); Mackerel 
Batter; Crumbs; Grilled; Fried 
Fish cakes; Fish fingers 
Eggs  Boiled; Fried 
Scrambled; Omelette 
Additions / Accompaniments: 
Milk; Vegetables; Cheese 
Milk Fresh; Reconstituted milk 
powder - full cream, low fat (2 
%), fat-free (skim) 
Creamers (Brand names) 
 
Cheese Cheddar; Gouda; Cottage – 
smooth, chunky, flavoured 
 
Soup Type - Vegetable; Legume; 
Meat addition 
Thin (watery) / Thick 
Additions / Accompaniments: 
Croutons; Parsley 
Vegetables Type – Fresh; Frozen; Canned 
- Side dish / Main ingredient 
- Ingredient in mixed dishes 
Peeled / Unpeeled 
Whole; Sliced; Diced 
Steamed; Boiled; Stir-fried; 
Baked; Mashed (potatoes) 
Additions / Accompaniments: 
Butter/Margarine; Sugar; Salad 
dressings; Mayonnaise - Types 
Fruit Type – Fresh; Canned; Dried Fresh – With / Without peel 
Canned – Syrup / Juice packed 
Coffee Pure; Blend; Filter; Instant Additions: Milk; Sugar; Honey; 
Sweetener 
– Specify 
OR black, no sugar 
Tea English; Rooibos; Green; 
Herbal (Specify) 
Milk drinks Brand (Milo; Horlicks; 
Nesquick, etc.) 
Fruit juices 
Dairy mixes 
Cold drinks 
 
Flavours; Pure; Blends; 
Brand 
Flavours – Brand (Tropica; 
Fiesta, etc.) 
Fizzy drinks; Cordials (Brand: 
Oros; Lecol, etc.) 
Sweetened / Unsweetened 
 
Alcoholic drinks Wine – Red; White; Rosé 
Brandy; Whisky, Beer; Sherry 
 
Cake; 
Biscuits 
(Cookies); 
Rusks; 
Tarts 
Chocolate, Lemon Creams; 
Romany Creams; Tennis 
biscuits, Buttermilk, Apple; Milk 
With / Without filling / icing 
(butter) 
Homemade / Commercial 
 
Additions / Accompaniments: 
Cream; Ice cream (Full cream; 
Sorbet); Custard (Milk type) 
Pudding; 
Ice cream 
Instant – Butterscotch; Banana 
Baked – Bread; Malva 
Ingredients – Recipes 
Additions / Accompaniments: 
Cream; Ice cream (Full cream; 
Sorbet); Custard (Milk 
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FOOD 
DESCRIPTION – 
Type/Kind 
PREPARATION –  
Recipe descriptions 
type); Sauces (Chocolate) 
Sweets Chocolate: Slab – Milk; White; 
Dark; 
Bars; Assorted centres 
Hard / Soft jelly type 
Dried fruit squares, sticks, rolls 
Marshmallow – Plain / 
Coconut covered 
Peanut brittle 
Toffees 
Fudge 
 
Salty snacks 
 
Potato chips (crisps) 
NikNaks; Cheese curls 
Pretzels 
Nuts – Peanuts 
Salty biscuits – Brands: 
Salticrax; Tuc; 
Cream crackers; Provita 
Baked; Fried 
 
 
 
Additions / Accompaniments: 
Margarine; Spread; Dip; Cheese 
Condiments 
 
Tomato sauce; Chutney; 
Mustard 
Mayonnaise 
Other sauces 
Less oil – Trim 
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EXAMPLE OF A DIETARY RECORD 
 
TIME WHAT DID YOU EAT/DRINK? HOW WAS IT 
PREPARED? 
HOW MUCH? 
Example    
7:00 ProNutro Thick (with milk and 
sugar) 
1 cup 
 2 % low fat milk  ½ cup 
 Sugar  2 heaped 
teaspoons 
 Banana Fresh 1 large  
    
11:30 Sandwich prepared from:   
 Whole wheat bread Toasted 2 slices (thick; 
15x2x10 cm) 
 Margarine Flora light 2 teaspoons 
(thinly spread) 
 Cheddar cheese Grated  ¼ cup 
 Tomato  Raw 1 small 
 Lettuce Fresh 1 leaf 
 Ham Cooked  2 sandwich slices  
    
13:00 Cooked meal:   
 Pumpkin Cooked, sweetened 
and with margarine 
½ cup 
 Beans  Cooked with potato 
and margarine 
¾ cup 
 Fish (hake) Battered  2 fillets (60 g 
each) 
 Green salad (lettuce, tomato, 
cucumber and onion) 
Salad dressing, 
regular  
1 cup + 1 
tablespoon 
dressing 
 Coffee With milk and sugar 1 mug (300 mL) 
 Full cream milk   30 mL 
 Sugar  2 teaspoons  
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DIETARY RECORD: DAY 1-3 
Date:             
Day of the week:            
 
TIME WHAT DID YOU EAT/DRINK? 
HOW WAS IT 
PREPARED? 
HOW MUCH? 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
Id Code: _________________ 
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Appendix H: Questionnaires 
 
Appendix H.1: Familial cancer history 
 
  FAMILY CANCER HISTORY 
 
Id Code:_____ 
 
Immediate family cancer 
diagnosis? 
Mother Father Brother Sister 
What type of cancer:  
When diagnosed:  
Current status of cancer: 
Newly 
diagnosed 
Living with 
cancer 
Remission Deceased 
Treatment: Chemotherapy Radiotherapy Combination No treatment 
 
 
Appendix H.2: Smoking/tobacco use and alcohol consumption 
 
SMOKING/TOBACCO USE 
 
Id Code: _____ 
 
Smoking or tobacco use: Non-smoker Previous smoker Current smoker 
ALCOHOL CONSUMPTION 
 
Alchol consumption: Non-drinker Previous drinker Current drinker 
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Appendix H.3: Global physical activity questionnaire (GPAQ) 
 
 
GLOBAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(GPAQ) 
 
Id Code: _____ 
 
Next, I am going to ask you about the time you spend doing different types of physical activity in a 
typical week. Please answer these questions even if you do not consider yourself to be a physically 
active person. 
 
Activity at work: 
Think first about the time you spend doing work. Think of work as the things you have to do such as 
paid or unpaid word, study/training, household chores, harvesting food/crops, fishing or hunting for 
food, seeking employment. In answering the following questions ‘vigorous-intensity activities’ are 
activities that require hard physical effect and cause large increases in breathing or heart rate, 
‘moderate-intensity activities’ are activities that require moderate effort and cause small increases in 
breathing and heart rate. 
Questions Response Code 
1. Does your work involve vigorous-
intensity activity that causes large 
increases in breathing and heart rate 
for at least 10 minutes 
continuously? 
 
Yes        1 
 
No          2            If No, go to P4 
 
P1 
2. In a typical week, on how many days 
do you do vigorous-intensity 
activities as part of your work? 
 
Number of days: _____ 
 
 
P2 
3. How much time do you spend doing 
vigorous-intensity activities at work 
on a typical day? 
 
______hours: _______ minutes 
 
P3 
(a-b) 
4. Does your work involve moderate-
intensity activity that causes large 
increases in breathing and heart rate 
for at least 10 minutes 
continuously? 
 
Yes        1 
 
No          2            If No, go to P7 
 
P4 
5. In a typical week, on how many days 
do you do moderate-intensity 
activities as part of your work? 
 
Number of days: _____ 
 
 
P5 
6. How much time do you spend doing 
moderate-intensity activities at work 
on a typical day? 
 
______hours: _______ minutes 
 
P6 
(a-b) 
 
Travel to and from places: 
The next questions exclude the physical activities at work that you have already mentioned. Now I 
would like to ask you about the usual way you travel to and from places. For example to work, for 
shopping, to market, to places of worship. 
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7. Do you walk or use a bicycle for at 
least 10 minutes continuously to get 
to and from places? 
 
Yes        1 
 
No          2        If No, go to P10 
 
P7 
8. In a typical week, on how many days 
do you walk or bicycle for at least 10 
minutes to get to and from places? 
 
Number of days: _____ 
 
 
P8 
9. How much time do you spend walking 
or bicycling for travel on a typical 
day? 
 
______hours: _______minutes 
 
P9 
(a-b) 
 
Recreational activities: 
The next questions exclude the work and transport activities that you have already mentioned. Now I 
would like to ask you about sports, fitness and recreational activities (leisure). 
10. Do you do any vigorous-intensity 
sports, fitness or recreational (leisure) 
activities that cause large increases in 
breathing and heart rate for at least 10 
minutes continuously? 
 
Yes        1 
 
No          2        If No, go to P13 
 
P10 
11. In a typical week, on how many days 
do you do vigorous-intensity sports, 
fitness or recreational (leisure) 
activities? 
 
Number of days: _____ 
 
 
P11 
12. How much time do you spend doing 
vigorous-intensity sports, fitness or 
recreational (leisure) activities on a 
typical day? 
 
______hours: ______minutes 
 
P12 
(a-b) 
13. Do you do any moderate-intensity 
sport, fitness or recreational (leisure) 
activities that cause large increases in 
breathing and heart rate for at least 10 
minutes continuously? 
 
Yes        1 
 
No          2        If No, go to P16 
 
P13 
14. In a typical week, on how many days 
do you do moderate-intensity sports, 
fitness or recreational (leisure) 
activities? 
 
Number of days: _____ 
 
 
P14 
15. How much time do you spend doing 
moderate-intensity sports, fitness or 
recreational (leisure) activities on a 
typical day? 
 
______hours: _______minutes 
 
P15 
(a-b) 
 
Sedentary behaviour: 
The following question is about siting or reclining at work, at home, getting to and from places, or with 
friends including time spent sitting at a desk, sitting with friends, travelling in car, bus or train, reading, 
playing cards or watching television. This does not include time spent sleeping. 
16. How much time do you usually spent 
sitting or reclining on a typical day? 
 
______hours: _______minutes 
P16 
(a-b) 
(Adopted from: WHO, 2004b).  
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Appendix I: Lifestyle factors 
 
Appendix I.1: Smoking/tobacco use and alcohol consumption 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.1: The percentage of participants who are non-, previous- or current smokers and drinkers in the 
MetS (n=34) (A, C) and non-MetS (n=46) (B, D) groups.  
  
45.65 % 
10.87 % 
43.48 % 
Non-smokers
Previous smokers
Current smokers
B 
n=20 
n=21 
n=5 
50.00 % 
14.71 % 
35.29 % 
Non-smokers
Previous smokers
Current smokers
A 
n=12 n=17 
n=5 
26.47 % 
17.65 % 
55.88 % 
Non-drinkers
Previous drinkers
Current drinkers
C 
n=9 
n=6 
n=19 
23.91 % 
4.35 % 
71.74 % Non-drinkers
Previous drinkers
Current drinkers
D 
n=33 
n=11 
n=2 
MetS: Non-MetS: 
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Appendix I.2: Physical activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.2: The percentage of participants who partake in vigorous- and moderate-intensity physical activity 
at work in the MetS (n=34) (A, C) and non-MetS (n=46) (B, D) groups.  
  
MetS: Non-MetS: 
17.65 % 
82.35 % Vigorous-intensity
activity at work: Yes
Vigorous-intensity
activity at work: No
A 
n=6 
n=28 
20.00 % 
80.00 % Vigorous-intensity
activity at work: Yes
Vigorous-intensity
activity at work: No
B 
n=9 
n=36 
50.00 % 50.00 % 
Moderate-intensity
activity at work: Yes
Moderate-intensity
activity at work: No
C 
n=17 n=17 
55.56 % 
46.67 % 
Moderate-intensity
activity at work: Yes
Moderate-intensity
activity at work: No
D 
n=25 n=21 
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Figure I.3: The percentage of participants who partake in vigorous- and moderate-intensity physical activity 
during leisure in the MetS (n=34) (A, C) and non-MetS (n=46) (B, D) groups.  
  
MetS: Non-MetS: 
5.88 % 
94.12 % 
Vigorous-intensity
activity at leisure: Yes
Vigorous-intensity
activity at leisure: No
A 
n=2 
n=32 
10.87 % 
89.13 % 
Vigorous-intensity
activity at leisure: Yes
Vigorous-intensity
activity at leisure: No
B 
n=5 
n=41 
76.47 % 
23.53 % 
Moderate-intensity
activity at leisure: Yes
Moderate-intensity
activity at leisure: No
C 
n=8 
n=26 
69.57 % 
30.43 % 
Moderate-intensity
activity at leisure: Yes
Moderate-intensity
activity at leisure: No
D 
n=14 
n=32 
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Appendix J: Supplementary correlation analyses 
 
Table J.1: Relationship between waist circumference and the percentage visceral- and subcutaneous adipose 
tissue, and the VAT:SAT for the respective groups. 
 WC & VAT % WC & SAT % WC & VAT:SAT 
 r-value p-value r-value p-value r-value p-value 
NMetS- 0.38 0.15 -0.38 0.15 0.42 0.11 
OWMetS+ 0.39 0.12 -0.39 0.12 0.34 0.18 
OWMetS- 0.40 0.11 -0.40 0.11 0.41 0.10 
OBMetS+ 0.72 0.00 -0.72 0.00 0.74 0.00 
OBMetS- 0.84 0.00 -0.84 0.00 0.84 0.00 
 
Table J.2: Relationship between sagittal abdominal diameter and the percentage visceral- and subcutaneous 
adipose tissue, and the VAT:SAT for the respective groups. 
 SAD & VAT % SAD & SAT % SAD & VAT:SAT 
 r-value p-value r-value p-value r-value p-value 
NMetS- 0.30 0.25 -0.30 0.25 0.27 0.31 
OWMetS+ -0.07 0.79 0.07 0.79 -0.03 0.92 
OWMetS- -0.01 0.98 0.01 0.98 -0.02 0.93 
OBMetS+ 0.62 0.01 -0.62 0.01 0.63 0.01 
OBMetS- 0.85 0.00 -0.85 0.00 0.81 0.00 
 
Table J.3: Relationship between age and W:H for the respective groups. 
 Age & W:H 
 r-value p-value 
NMetS- 0.50 0.05 
OWMetS+ 0.13 0.62 
OWMetS- 0.28 0.28 
OBMetS+ 0.22 0.40 
OBMetS- -0.51 0.08 
 
Table J.4: Relationship between VAT:SAT and some of the individual components of the metabolic syndrome 
for the respective groups. 
 VAT:SAT & SBP VAT:SAT & HDL-c VAT:SAT & LDL-c 
 r-value p-value r-value p-value r-value p-value 
NMetS- -0.14 0.61 -0.02 0.93 0.55 0.03 
OWMetS+ -0.18 0.50 -0.00 1.00 0.48 0.05 
OWMetS- -0.10 0.71 0.49 0.048 0.47 0.06 
OBMetS+ 0.64 0.01 -0.25 0.34 -0.21 0.41 
OBMetS- 0.11 0.72 0.43 0.14 0.06 0.84 
 
Table J.5: Relationship between triglyceride levels and the percentage visceral- and subcutaneous adipose 
tissue, and the VAT:SAT for the respective groups. 
 TG & VAT % TG & SAT % TG & VAT:SAT 
 r-value p-value r-value p-value r-value p-value 
NMetS- 0.47 0.07 -0.47 0.07 0.47 0.06 
OWMetS+ 0.27 0.29 0.27 0.29 0.21 0.42 
OWMetS- -0.13 0.63 0.13 0.63 -0.11 0.69 
OBMetS+ 0.18 0.49 -0.18 0.49 0.16 0.53 
OBMetS- 0.03 0.93 -0.03 0.93 0.03 0.93 
 
Table J.6: Relationship between W:H and palmitoleic acid levels, and body mass index and the omega-
3:omega-6 for the respective groups. 
 W:H & PLA BMI & Ω-3:Ω-6 
 r-value p-value r-value p-value 
NMetS- -0.02 0.95 -0.28 0.29 
OWMetS+ -0.14 0.58 0.17 0.51 
OWMetS- 0.27 0.29 0.00 0.99 
OBMetS+ -0.13 0.63 -0.05 0.85 
OBMetS- -0.25 0.42 0.46 0.11 
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Table J.7: Relationship between percentage visceral adipose tissue and oleic- and arachidonic acid levels, 
the n-9 saturation index, and the delta-9 SCD 2 for the respective groups. 
 VAT % & OA VAT % & AA VAT % & n-9 SI VAT % & Δ-9 SCD 2 
 r-value p-value r-value p-value r-value p-value r-value p-value 
NMetS- 0.14 0.59 0.03 0.92 -0.31 0.24 0.26 0.33 
OWMetS+ 0.14 0.60 -0.03 0.92 -0.18 0.48 0.27 0.30 
OWMetS- 0.18 0.49 -0.31 0.23 -0.23 0.37 0.42 0.09 
OBMetS+ 0.29 0.26 0.12 0.65 -0.20 0.45 -0.04 0.88 
OBMetS- -0.23 0.46 -0.17 0.57  -0.00 1.00 -0.07 0.83 
 
Table J.8: Relationship between insulin-like growth factor-1 concentration and measures of obesity for the 
respective groups. 
 IGF-1 & W:H IGF-1 & HC IGF-1 & BMI 
 r-value p-value r-value p-value r-value p-value 
NMetS- -0.23 0.43 -0.12 0.69 -0.22 0.45 
OWMetS+ 0.80 0.00 -0.69 0.00 -0.55 0.03 
OWMetS- 0.35 0.27 -0.13 0.68 -0.07 0.83 
OBMetS+ 0.11 0.70 0.06 0.84 0.15 0.60 
OBMetS- 0.31 0.45 -0.32 0.44 -0.17 0.70 
 
Table J.9: Relationship between leptin concentration and waist circumference, and sagittal abdominal 
diameter for the respective groups. 
 Leptin & WC Leptin & SAD 
 r-value p-value r-value p-value 
NMetS- 0.23 0.55 0.14 0.72 
OWMetS+ -0.17 0.54 -0.07 0.82 
OWMetS- 0.05 0.86 0.10 0.76 
OBMetS+ 0.06 0.83 0.08 0.78 
OBMetS- 0.49 0.15 0.74 0.01 
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Appendix K: Additional components of the metabolic syndrome 
 
            
            
            
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure K.1: Additional metabolic risk factors, (A) insulin, (B) low-density lipoprotein cholesterol, and (C) total 
cholesterol levels. Solid lines represent normal cut-off values. 
(IDF, 2006; Klug et al., 2015). 
* p<0.05, ** p<0.01, *** p<0.001. 
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Appendix L: Association between some individual monounsaturated fatty acids 
and smoking status for participants with and without the MetS   
   
 
 
 
 
 
 
 
 
 
 
 
Figure L.1: Association between palmitoleic acid levels and smoking status for participants with (n=34
•
) and 
without (n=46
‡
) the MetS. 
* p<0.05, ** p<0.01, *** p<0.001. 
• 
Non-smokers (n= 17, 50.0 %), previous smokers (n= 5, 14.7 %) and current smokers (n=12, 35.3 %) for the MetS group. 
‡ 
Non-smokers (n= 21, 45.7 %), previous smokers (n=5, 10.9 %) and current smokers (n=20, 43.5 %) for the non-MetS group. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure L.2: Association between oleic acid levels and smoking status for participants with (n=34
•
) and 
without (n=46
‡
) the MetS. 
* p<0.05, ** p<0.01, *** p<0.001. 
• 
Non-smokers (n= 17, 50.0 %), previous smokers (n= 5, 14.7 %) and current smokers (n=12, 35.3 %) for the MetS group. 
‡ 
Non-smokers (n= 21, 45.7 %), previous smokers (n=5, 10.9 %) and current smokers (n=20, 43.5 %) for the non-MetS group. 
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